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Abstract
MECHANISMS AND TREATMENT OF PAIN-DEPRESSED BEHAVIORS IN MALE AND
FEMALE MICE
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University, 2021
Advisor: S. Stevens Negus, PhD
One of the largest discrepancies between preclinical and clinical assessment of pain and
analgesia is the type of behavioral endpoint used. Although most preclinical research has
historically focused on drug effectiveness to block reflexive withdrawal behaviors stimulated by
a noxious stimulus, increasing evidence shows that drug-induced restoration of pain-depressed
behaviors provides increased clinical translation with decreased susceptibility to false-positives.
Accordingly, the first portion of this dissertation designed a behavioral battery that featured paindepressed behaviors as well as more conventional pain-stimulated behaviors for testing candidate
analgesics in male and female mice. The main findings are as follows. (1) Intraperitoneal
injection of dilute lactic acid (IP acid) served as an effective visceral chemical noxious stimulus
to produce concentration-dependent stimulation of two behaviors (stretching and facial grimace;
pain-stimulated behaviors) and depression of two behaviors (rearing and nesting; pain-depressed
behaviors). (2) Pharmacological characterization with two positive control analgesics
(ketoprofen, oxycodone) and two active negative controls (diazepam, amphetamine) validated a
strategy for distinguishing analgesics from nonanalgesics by profiling drug effects in this battery
of complementary pain-stimulated and pain-depressed behaviors along with two additional painindependent behaviors (nesting and locomotor activity in the absence of the IP acid noxious
stimulus). (3) A National Institutes of Health mandate for consideration of Sex as a Biological

ix

Variable (SABV) was published at the start of this dissertation research. Accordingly, we
developed an experimental design for considering SABV when sex differences are not the
principle independent variable, with emphases on exploratory power analyses (effect size, power,
predicted N) and segregation of data by sex to allow transparent analysis of SABV and help
guide future study designs.
The second portion of this dissertation applied this behavioral battery and SABV dataanalysis strategy to evaluate a spectrum of endocannabinoid (eCB) catabolic enzyme inhibitors
ranging in selectivity for the eCB catabolic enzymes monoacylglycerol lipase (MAGL) and fatty
acid amide hydrolase (FAAH), which have received increasing interest for development of
candidate analgesics. The main findings are as follows: (1) antinociceptive effectiveness
decreased as MAGL-selectivity decreased, with the most MAGL-selective inhibitor MJN110
producing the most effective antinociceptive profile, (2) time course and antagonism studies for
MJN110 showed a long duration of antinociceptive action (40min – 6hrs), mediation by CB1R
but not CB2R, a tendency for greater effects in females, and (3) repeated administration of
MJN110 produced partial but sustained attenuation of IP acid-induced depression of nesting,
with segregation of data by sex demonstrating sustained but weak antinociception in males and
variable effects following repeated dosing in females.
Overall, these data provide a framework for predicting the analgesic potential of test
drugs in preclinical pain models in male and female mice, and suggest that MJN110 may have
only partial effectiveness as a candidate analgesic for treatment of visceral episodic pain.

x

Chapter I: Introduction
I. Core Pain-Related Measures in Preclinical and Clinical Research: Discrepancies
Highlight Roadmap for Improved Preclinical Assessments
Pain is a leading global health problem (Goldberg, 2011) and major reason for healthcare
utilization in the United States (St. Sauver et al., 2013). Almost 40 million people undergo
surgery that often produces acute pain, and more than 100 million Americans suffer from chronic
pain each year, costing the United States over $600 billion annually (Institute of Medicine, 2011;
Chapman and Vierck, 2017; Pogatzki-Zahn, 2021). For the first time since 1979, the
International Association for the Study of Pain (IASP) updated their definition of pain,
describing it as, “an unpleasant sensory and emotional experience associated with, or resembling
that associated with, actual or potential tissue damage.” Despite decades of research, the most
commonly used analgesics continue to be non-steroidal anti-inflammatory drugs (NSAIDs) and
𝜇-opioid receptor (MOR) agonists that were introduced over a century ago (Kissin, 2010; Obeng
et al., 2021). Use of these compounds is constrained by limited clinical efficacy for some pain
indications (Finnerup et al., 2015) and by side effects that include gastric ulceration for NSAIDs
and abuse liability and potentially lethal respiratory depression for MOR agonists that have
contributed in part to the current public health crisis. The opioid crisis in particular has
invigorated efforts to discover new, effective, and safe medications for pain treatment (Skolnick
and Volkow, 2016; Volkow and Collins, 2017).
Preclinical testing in laboratory animals will likely play an important role in this drugdiscovery effort, but preclinical-to-clinical translation has been poor in analgesic drug
development, with numerous candidate analgesic compounds (e.g. NK-1 antagonists) appearing
highly effective preclinically and failing in clinical trials (Mogil, 2009; Yezierski and Hansson,
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2018; Negus, 2019; Tappe-Theodor et al., 2019; Gonzalez-Cano et al., 2020; Kandasamy and
Morgan, 2020). Experimental evaluation of pain inherently involves delivery of a noxious
stimulus with the intent of producing a pain state (primary independent variable) followed by
measurement of different behaviors interpreted as evidence of that pain state (dependent
variable). In preclinical research, noxious stimuli are often classified as either acute,
inflammatory ± evocation with an acute stimulus, neuropathic ± evocation with an acute
stimulus, or a disease state (e.g. bone cancer) ± evocation with an acute stimulus (Negus, 2019).
While large strides have been made in preclinical development of noxious stimuli to model
clinically-relevant pain indications (Le Bars et al., 2001; Mogil, 2009; Deuis et al., 2017; Munro
et al., 2017), less progress has been made regarding pain-related behaviors, with one of the
largest discrepancies between preclinical and clinical pain assessment being the type of
behavioral endpoint used to indicate the presence of a pain state and impact of a drug treatment.
Clinical pain in human medicine is primarily measured via verbal reporting, whereas
preclinical pain research has focused almost exclusively on reflexive withdrawal behaviors
stimulated by noxious stimuli. This creates a major discrepancy for translational research
because verbal behavior cannot be measured in animals, and suppression of nocifensive
withdrawal reflexes is not a priority for analgesic administration in humans. For example, 2016
CDC guidelines recommend the primary goal in clinical pain treatment to be decreasing painrelated functional impairments rather than solely decreasing pain intensity (Ballantyne and
Sullivan, 2015; Dowell et al., 2016; Negus, 2019; Tappe-Theodor et al., 2019; Kandasamy and
Morgan, 2020). Moreover, pain is a multi-faceted experience comprised of sensory and affective
dimensions that manifests as a constellation of unconditioned and learned behaviors in both
humans and animals, with adequate assessment likely requiring evaluation of multiple behaviors
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relative to different pain indications that are mediated by different neural circuits (Garcia-Larrea
and Peyron, 2013; Negus, 2019).
Pain-related behaviors can be classified into the two following categories: (1) painstimulated behaviors, which increase in rate, frequency, duration, or intensity following delivery
of a noxious stimulus, and (2) pain-depressed behaviors, which decrease in rate, frequency,
duration, or intensity following delivery of a noxious stimulus. While pain-stimulated behaviors
possess clinical face validity for reflexive pain-related behaviors (e.g., removing your hand from
a hot surface), they are highly susceptible to false positives such as general motor sedatives and
do not model the primary clinical goal for functional restoration of behavior. Accordingly, our
lab and others have argued for the inclusion of pain-depressed behaviors, which are not
susceptible to false positives from general motor sedatives, are one of the main endpoints used in
veterinary medicine for diagnosis and treatment of pain, and possess increased clinical
translation by modeling the primary treatment goal for restoring pain-related functional
impairment (e.g. pain decreasing ability to sleep, move, work, eat) (Stevenson et al., 2009; de la
Puente et al., 2017; Negus, 2019; Tappe-Theodor et al., 2019; Kandasamy and Morgan, 2020).
Figure I.I illustrates the key differences in drug effects on pain-stimulated vs pain-depressed
behaviors, with particular emphasis placed on susceptibility to false positives.

II. Design and Pharmacological Characterization of a Behavioral Battery for Testing
Candidate Analgesics in Male and Female Mice
The goal of Chapter III was to validate a battery of pain-stimulated and pain-depressed
behaviors for use in mice to test candidate analgesics, as complementary assessment of both
pain-stimulated and pain-depressed behaviors not only broadens the scope and translational
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relevance of preclinical behavioral testing, but also protects against false-positive effects from
drugs that produce sedation or motor impairment (Figure I.I) (Negus, 2019). Intraperitoneal
injection of dilute lactic acid (IP acid) served as an acute visceral noxious stimulus that models
inflammation-associated tissue acidosis as one contributor to inflammatory pain from various
pain indications, including post-surgical inflammation (Koster et al., 1959; Holzer, 2009;
Stevenson et al., 2009; Cobos et al., 2012; McMahon et al., 2013; de la Puente et al., 2017;
Spahn et al., 2017). IP acid has the experimental advantage of providing fine-tuned control of
noxious stimulus intensity and the transient nature allows replicable effects with repeated
administration in within-subject experimental designs (Le Bars et al., 2001; Stevenson et al.,
2009; Negus, 2018).
Additionally, care was taken to include behavioral endpoints reflecting sensory and
affective dimensions of pain that are likely mediated by different neural circuits (Garcia-Larrea
and Peyron, 2013). One feature of behaviors interpreted as evidence of the “sensory” dimension
of pain is their focus on the body part affected by the putative noxious stimulus. For example,
delivery of a noxious thermal stimulus to a rodent’s hind paw may elicit both a reflexive pawwithdrawal response and more complicated paw-licking/grooming responses. In contrast,
behaviors interpreted as evidence of the “affective” dimensions of pain involve more general
changes in behavior not specifically directed to the site of noxious stimulus delivery. For
example, noxious stimuli can elicit common facial grimacing behaviors and signs of general
behavioral depression regardless of the site where the noxious stimulus is delivered. These
different sensory and affective pain behaviors appear to involve overlapping but dissociable CNS
pathways. Additionally, local spinal cord circuits have been shown to be sufficient to mediate
simple reflexive pain behaviors in spinalized subjects, whereas higher order somatotopically
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organized pathways (e.g., spinothalamocortical pathway) appear to be involved in coordinating
more complex behaviors such as licking/grooming of a pain state (Grossman et al., 1982; Le
Bars et al., 2001). Conversely, affective behaviors are thought to involve spinal-bulbar-limbic
circuits that have a lower level of somatotopic organization (Price, 2003; Almeida et al., 2004).
Drug effects in this dissertation were examined on four different IP acid-induced painrelated behaviors: (1) stimulation of a stretching (or writhing) response as a conventional painstimulated behavior somatotopically directed to the site of noxious stimulus delivery and
potentially relying on spinal circuits (Collier et al., 1968; Clement et al., 2000; Le Bars et al.,
2001), (2) stimulation of facial grimace as a pain-stimulated behavior directed to a remote site
away from the noxious stimulus and hence requiring supraspinal circuits and potentially
reflecting affective pain behaviors (Langford et al., 2010; Matsumiya et al., 2012), (3) depression
of rearing as an unconditioned and high-frequency vertical locomotor behavior (Cho et al., 2013;
Cobos and Portillo-Salido, 2013), and (4) depression of nesting as a robust and adaptive
ethological behavior (Jirkof, 2014; Negus et al., 2015). Drug effects were also evaluated on two
additional pain-independent behaviors in the absence of the IP acid noxious stimulus: (1) nesting
to assess drug-induced disruption of an adaptive ethological behavior and (2) horizontal
locomotor activity that could be either increased or decreased by test drugs.
To validate this behavioral battery for both clinically effective and ineffective drugs as
recommended for translational research (Ferreira et al., 2019), effects were compared for two
mechanistically distinct but clinically effective positive-control analgesics (ketoprofen and
oxycodone) and two negative-control drugs that are not clinically indicated for use as analgesics
but do produce robust behavioral effects in mice (diazepam and amphetamine). Ketoprofen is a
cyclooxygenase1/2 (COX) inhibitor representative of NSAID analgesics, whereas oxycodone is
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an MOR agonist representative of opioid analgesics (Kantor, 1986; Kalso, 2005; McMahon et
al., 2013; Brunton et al., 2018). Diazepam is a GABA type A (GABAA)-receptor positive
allosteric modulator that produces general motor suppression, and amphetamine is a substrate at
dopamine and norepinephrine transporters that produces dopamine and norepinephrine release
and subsequent psychomotor-stimulant behavioral effects (Calcaterra and Barrow, 2014; Hutson
et al., 2014; Brunton et al., 2018). We hypothesized that ketoprofen and morphine would
alleviate both IP acid–stimulated and IP acid–depressed behaviors at doses that did not alter
pain-independent behaviors, whereas diazepam and amphetamine would not. Results of this
work were then used in Chapter IV as an empirical framework to interpret effects produced by a
series of candidate analgesic targeting the endocannabinoid system.

III. Responding to the NIH Mandate for Consideration of Sex as a Biological Variable in
Preclinical Research
At the time this dissertation research began, the National Institutes of Health (NIH) issued a
policy promoting the inclusion of male and female subjects in preclinical biomedical research
(Miller et al., 2017). This policy acknowledged that sex differences are not the primary variable
of interest in much preclinical research, but that absent an explicit scientific rationale to exclude
either males or females, both sexes should be included and the data-analysis plan should address
the role of sex as a biological variable (SABV). As further guidance for addressing this new
mandate, the policy articulated “The Four C’s of Studying Sex to Strengthen Science”
(https://orwh.od.nih.gov/sex-gender/nih- policy-sex-biological-variable)(NIH, 2015): (1)
Consider (design studies that take sex into account, or explain why it is not incorporated), (2)
Collect (tabulate sex-based data), (3) Characterize (analyze sex-based data), and (4)
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Communicate (report and publish sex-based data). As sex differences were not the primary aim
for the present studies and sample sizes required to detect sex differences were unknown, we
designed an experimental framework in Chapter II to address “The Four C’s of Studying Sex to
Strengthen Science” when sex is not the primary variable of interest. In this framework, the
“Consider” mandate for experimental design that takes sex into account is addressed through
inclusion of both males and females, the “Collect” mandate for tabulating sex-based data is
addressed through segregation of data by sex following analysis of primary variable(s) in data
pooled across sex, the “Characterize” mandate is addressed by using ANOVAs to analyze sexbased differences with existing sample sizes and power analyses to guide both interpretation of
the ANOVA results and design of any future studies that might focus on sex differences, and the
“Communicate” mandate for reporting and publishing sex-based data is addressed through
reporting results of ANOVAs (F statistics) and power analyses (effect size, power, predicted Ns)
as a useful array of statistical outcome measures.
Ultimately, three categories of sex differences have been described: Type 1 (“sexual
dimorphism”; qualitatively different phenotypes between sexes), Type 2 (“sex differences”;
quantitatively different phenotypes), and Type 3 (“sex convergence and divergence”; similar
phenotypes with different biological mechanisms) (McCarthy et al., 2012). The analysis
proposed in Chapter II will be more sensitive to Type 1 than Type 2 differences, but in either
case, it can provide preliminary information on the existence of phenotypic sex differences. In
contrast, this approach will not detect Type 3 differences. As a result, even if adequately
powered statistical analysis indicates that a phenotypic sex difference is absent, it remains
possible that the convergent phenotypes could have sexually divergent underlying mechanisms.
It is also important to note that all experiments contain multiple secondary variables, many of
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which have been shown to significantly impact experimental outcomes and clinical translation
(e.g. importance for utility of outbred strains compared to inbred rodent strains (Tuttle et al.,
2018b)). The experimental design and analysis framework described in Chapter II can be applied
for analysis of a variety of secondary variables (not just sex), with inclusion of these additional
secondary analyses dependent upon the research group and experimental question.
With these caveats in mind, we utilized the strategy detailed in Chapter II for preliminary
analysis of sex effects in studies that include both sexes but do not aim to focus on sex as a
primary variable of interest. In those instances, we suggest that priority of analyses should follow
standard statistical assessment with priority placed on adequately powered primary variables
based on initial study design, followed by segregation of data by sex when underpowered for
direct sex comparisons to avoid potential masking of effects (Miller et al., 2017; Tannenbaum et
al., 2019; Galea et al., 2020) and inclusion of power analyses (effect size, power, predicted N) to
help guide both interpretation of current results and design of any future studies targeting
possible sex differences.

IV. Targeting the Endocannabinoid System Main Degradative Enzymes for Assessment of
Candidate Analgesics
Neurons communicate nociceptive information from the periphery to the CNS through
excitatory transmission, with clinical pain states often involving hyperactivity of these pathways
(Basbaum et al., 2009; Dostrovsky and Craig, 2013; Heinricher and Fields, 2013). Current
clinically used analgesics have receptor targets throughout these neural pathways that mediate
the sensory and affective dimensions of pain. For example, the spinal cord, spinal-thalamiccortical and spinal-bulbar-limbic circuits are rich in MORs (Mansour et al., 1987; Mansour et al.,
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1995; Stein, 2016), which are the primary target for opioid analgesics like oxycodone. These
main pain-processing pathways are also rich in cannabinoid 1 and 2 receptors (CB1/2Rs) that
mediate a form of feedback inhibition (Herkenham et al., 1991; Tsou et al., 1998; Reggio, 2010;
Blankman and Cravatt, 2013; Ohno-Shosaku and Kano, 2014). More specifically, CB1/2Rs are
Gi/o G-protein coupled receptors (GPCRs) that can be activated by exogenous orthosteric
agonists (e.g. ∆9-tetrahydrocannabinol (THC)) or by endogenous lipids, with the two main
endocannabinoid (eCB) lipids being 2-arachidonyl glycerol (2-AG) and anandamide (AEA)
(Devane et al., 1992; Mechoulam et al., 1995). CB1Rs are widely expressed throughout the
central and peripheral nervous system, and CB2Rs are predominately expressed on peripheral
immune cells.
Unlike neurotransmitters that are released from presynaptic vesicles to produce effects on
postsynaptic terminals, excitatory anterograde transmission within pain-processing pathways will
elicit post-synaptic synthesis of 2-AG and AEA. As illustrated in Figure I.II, these highly
lipophilic molecules activate presynaptic CB1Rs through retrograde signaling, leading to
inhibition of adenylyl cyclase, enhancement of inwardly rectifying potassium channels, and
inhibition of calcium channels, effectively dampening further anterograde neurotransmitter
release (Reggio, 2010; Lu and Mackie, 2016). 2-AG and AEA signaling is terminated primarily
via the enzymes monoacylglycerol lipase (MAGL), which hydrolyzes 2-AG into arachidonic
acid (AA) and glycerol in the presynaptic nerve terminal, and fatty-acid amide hydrolase
(FAAH), which hydrolyzes AEA into AA and ethanolamine in the postsynaptic terminal. Both
pharmacological inhibition and genetic knock-out of these enzymes produce dramatic increases
in their respective eCB brain lipid levels, indicating these enzymes as key regulators for 2-AG
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and AEA signaling in vivo (Cravatt et al., 2001; Long et al., 2009a; Chanda et al., 2010;
Niphakis et al., 2013).
Previous studies have shown that the eCB system acts as an on-demand feedbackinhibition mechanism to dampen the hyperactive excitatory signaling seen in both acute and
chronic pain states (Meng, 1998; Guindon and Hohmann, 2009; Reggio, 2010; Woodhams et al.,
2017). More specifically, delivery of a noxious stimulus recruits the eCB system in the periphery
(Hohmann, 2002; Guindon and Beaulieu, 2009; Kaczocha et al., 2018), dorsal horn of the spinal
cord (Richardson et al., 1998; Nyilas et al., 2009; Woodhams et al., 2017), and neural circuits
associated with both acute and chronic pain states (Sagar et al., 2009; Woodhams et al., 2017).
Accordingly, great interest has been placed on targeting the eCB system for development of
candidate analgesics. Multiple studies have shown poor clinical efficacy alongside unwanted
psychomimetic and motor-impairing effects with CB1/2R agonists as analgesics (Raft et al., 1977;
Greenwald and Stitzer, 2000; Wallace et al., 2007; Kraft et al., 2008; Babalonis et al., 2019; Mun
et al., 2020). This year, the IASP released a statement that they “…do not endorse the general
use of cannabinoids to treat pain” due to a lack of evidence following a systematic review of
current clinical evidence for cannabinoids as analgesics by the Presidential Task Force on
Cannabis and Cannabinoid Analgesia (Rice et al., 2021).
Instead of globally activating all CB1/2Rs throughout the CNS and periphery via
exogenous agonists, increasing evidence suggests analgesic potential for enhanced signaling of
the eCB system through inhibition of the main degradative catabolic enzymes MAGL and FAAH
(Schlosburg et al., 2009; Fowler, 2012; Donvito et al., 2018). Compared to exogenous agonists,
development of MAGL- and FAAH-selective inhibitors allows researchers increased temporal
and spatial selectivity as enhanced inhibitory signaling of CB1/2Rs will only be produced where
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2-AG and/or AEA is being synthesized. Additionally, MAGL and FAAH inhibitors possess dual
inhibitory capacity for neuronal signaling and proinflammatory mediators through decreased
production of AA, suggesting potential antinociceptive effectiveness in pain states involving
inflammatory mechanisms, especially for MAGL-selective inhibitors as 2-AG has been shown as
a major source of AA in the brain (Ahn et al., 2009; Long et al., 2009a; Nomura et al., 2011;
Kinsey et al., 2013; Ignatowska-Jankowska et al., 2015a; Thompson et al., 2020).
Pharmacological inhibition of MAGL and FAAH elicits antinociceptive effects in
neuropathic, inflammatory, and thermal preclinical pain models (Long et al., 2009a; Schlosburg
et al., 2009; Nomura et al., 2011; Booker et al., 2012; Fowler, 2012; Kwilasz et al., 2014;
Dalmann et al., 2015; Burston et al., 2016; Wilkerson et al., 2018; Habib et al., 2019; Thompson
et al., 2020). Moreover, inhibitors selective for MAGL and FAAH did not produce classic
cannabimimetic effects in mice, suggesting an increased safety profile compared to orthosteric
CB1/2R agonists (Ignatowska-Jankowska et al., 2015a). Despite these promising preclinical
reports, failure of a FAAH inhibitor in a clinical trial for pain due to osteoarthritis of the knee,
and neurological effects by the FAAH inhibitor BIA 10-2474 case doubts on the clinical utility
of FAAH inhibitors as candidate analgesics (Huggins et al., 2012; von Schaper, 2016; Weber et
al., 2020). However, the discovery a microdeletion in a FAAH pseudogene in a patient with pain
insensitivity and elevated AEA levels has reinvigorated these efforts (Habib et al., 2019).
Clinical results have not yet been published with MAGL-selective or dual MAGL/FAAH
inhibitors for pain indications; however, the MAGL-selective inhibitor Lu AG06466 (formerly
ABX-1431) successfully completed a phase 1b study in Tourette Syndome with no serious
adverse effects and is currently in clinical trials for multiple diseases, including fibromyalgia
(Abide Therapeutics, 2017; Cisar et al., 2018; Muller-Vahl et al., 2021).
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eCB catabolic enzyme inhibitors have been evaluated in a limited range of preclinical
pain assays predominantly focused on sensory pain-stimulated behaviors and have not been
extensively evaluated in preclinical studies that include assays of pain-depressed behaviors. The
existing data for pain-depressed behaviors suggest that MAGL inhibitors may be more effective
than FAAH inhibitors (Kwilasz et al., 2014; Wilkerson et al., 2018). Accordingly, Chapter IV
utilized the battery of pain-stimulated, pain-depressed, and pain-independent mouse behaviors
validated and pharmacologically characterized in Chapter III to compare the direct CB1/2R
agonist THC to the following spectrum of eCB catabolic enzyme inhibitors: the MAGL-selective
inhibitors MJN110 and JZL184, the dual MAGL/FAAH inhibitors JZL195 and SA57, and the
FAAH-selective inhibitors URB597 and PF3845 (see Figure IV.I). We predicted a more
favorable profile of antinociceptive effects without motor impairment for MAGL-selective
inhibitors than for dual or FAAH-selective inhibitors or THC. Additionally, previous work has
shown the antinociceptive effects of MAGL and FAAH to be CB1/2R-mediated in neuropathic
and inflammatory pain models, with some inconsistencies for the involvement of CB2R in
MAGL effects (Kinsey et al., 2009; Naidu et al., 2010; Booker et al., 2012; IgnatowskaJankowska et al., 2015b; Burston et al., 2016; Thompson et al., 2020). Accordingly, the time
course and CB1/2R antagonism were assessed for the most effective eCB catabolic enzyme
inhibitor.
Additionally, there is increasing evidence for sex differences in cannabinoid
antinociception (Cooper and Craft, 2018; Blanton et al., 2021), along with evidence for sex
differences in pain processing (Greenspan et al., 2007; Sorge et al., 2011; Fullerton et al., 2018).
As this study was designed for primary analysis of eCB candidate analgesic effects and not for
detection of sex differences, we included equal numbers of male and female mice and analyzed
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results for sex differences using the stepwise strategy developed in Chapter II and utilized in
Chapter III.
The data in Chapter IV demonstrate that MJN110, the most MAGL-selective inhibitor,
produced the most effective antinociceptive profile among the eCB catabolic enzyme inhibitors,
with significant antinociception without motor disruption on three of the four IP acid-induced
behaviors at a dose of 1.0 mg/kg (Figure IV.VII). While the interaction between sex and
treatment was not significant, a main effect of sex in IP acid-depressed nesting suggests an
increased effect in females compared to males, especially at 1.0 mg/kg (Supp. Figure IV.I D).
While these acute antinociceptive effects support further consideration of MAGL-inhibitors
(especially MJN110) as candidate analgesics, other groups evaluating the effects of repeated
administration of MAGL inhibitors suggest tolerance may develop to these acute antinociceptive
effects. Previous studies evaluating repeated administration of MJN110 in chronic models of
cancer-induced bone pain (CIBP) and osteoarthritic pain report sustained antinociceptive effects
following repeated MJN110 administration (Burston et al., 2016; Thompson et al., 2020), with
Burston et al. showing development of antinociceptive tolerance to be dose-dependent, with
higher doses (5 mg/kg) producing tolerance to antinociceptive effects on monosodium
iodoacetate-stimulated behaviors.
Studies investigating the MAGL inhibitor JZL184 also demonstrate antinociceptive
tolerance following persistent pharmacological inhibition or genetic disruption of MAGL to be
dose-dependent. More specifically, repeated administration of 4 mg/kg JZL184 did not produce
tolerance in a variety of behavioral and neurochemical measures, while 40 mg/kg JZL184
produced functional tolerance of antinociceptive effects on pain-stimulated behaviors in
inflammatory and neuropathic pain models (Schlosburg et al., 2010; Ghosh et al., 2013; Kinsey
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et al., 2013). Mechanisms underlying this development of tolerance were shown to be mediated
through CB1Rs as repeated dosing of 40 mg/kg JZL184 produced cross-tolerance to CB1R
agonists, reduced CB1R function (assessed via agonist-stimulated [35S]GTP𝛾S binding), reduced
CB1R density (assessed via saturation binding with the CB1R-selective antagonist
[3H]SR141716A) in mouse brain, and increased expression of off-target eCB lipids, such as
AEA, palmitoylethanolamine, and N-oleoylethanolamine (Schlosburg et al., 2010; Ghosh et al.,
2013; Kinsey et al., 2013).
Accordingly, Chapter V of this dissertation focused on evaluating the antinociceptive
effectiveness of repeated administration of MJN110 on pain-depressed behavior. For this study, a
pain-depressed behavior must be selected that allows the following: (1) stable and reproducible
effects in the absence of the noxious stimulus across 7-days, and (2) consistent noxious stimulusinduced depression of the behavior across 7-days. The primary dependent variable in Chapter V
for evaluation of noxious stimulus and drug treatment effects was nestlet consolidation, as
previous work from our laboratory has demonstrated stable and high rates of nesting across
multiple days (Negus et al., 2015). Additionally, IP acid was used as the repeated noxious
stimulus as our lab has previously shown that daily administration of IP acid produces reliable
depression of operant responding in rats that can be reversed by repeated treatment with
clinically-effective analgesics (Altarifi et al., 2015; Lazenka et al., 2018; Legakis et al., 2020).
Studies in Chapter V aim to extend the utility of daily administration of IP acid to mice as a
model of repeated episodic visceral pain suitable for evaluating effects of repeated test-drug
administration. As the temporal pattern of the underlying pain state is often presumed to be
relatively constant for periods of weeks to months in most chronic pain research, this repeated

14

daily IP acid model provides an important tool for repeatable expression of a transient pain state
for episodic chronic pain.

V. Nociceptive Circuitry and its Modulation of the Mesolimbic System
As described in Chapter I.II, pain is a multi-faceted experience with both sensory and
affective dimensions likely mediated by different neuronal circuits (Garcia-Larrea and Peyron,
2013). The spinothalamocortical tract has been shown as a crucial pathway for mediation of
sensory-related neuronal signaling. Following delivery of a noxious chemical, thermal, or
mechanical stimulus to the periphery, primary A𝛿 and C fibers (nociceptors) with cell bodies in
the DRG are activated, as illustrated in Figure I.III. These synapse to secondary neurons in the
dorsal horn of the spinal cord that decussate and ascend via the spinothalamic tract to synapse in
the thalamus. Tertiary thalamic neurons then project to cortical regions, including the
somatosensory and motor cortexes, that inform behavioral responses localized to the site of the
noxious stimulus. Sensory pain-related behaviors can also be mediated via reflex arcs within the
spinal cord, where secondary neurons in the dorsal horn project to cell bodies in the ventral horn
of the spinal cord to elicit nocifensive withdrawal responses (see Fig. I.III). In this dissertation,
IP acid-induced stimulation of stretching is interpreted as evidence of the “sensory” dimension of
pain that may be mediated through signaling in the spinothalamocortical pathway.
The neuronal circuits involved in affective behaviors are less understood. Preclinical pain
research utilizes the term “affective” to capture emotional aspects of pain; however, as emotions
in preclinical models are inferred from behavioral interpretation of animal subjects, this
classification may be more similar to “non-sensory” components of pain-related behaviors that
involve more general changes not specifically directed to the site of noxious stimulus delivery.
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For example, Chapters III-V have demonstrated IP acid-induced depression of nesting and
stimulation of facial grimace, two behaviors shown to be produced regardless of site of noxious
stimulus delivery and attenuated by clinically-effective analgesics (Langford et al., 2010; Negus
et al., 2015; Oliver et al., 2018; Alexander et al., 2019; Siemian et al., 2021).
Preclinical and clinical evidence across a variety of acute and chronic noxious stimuli
suggest that spinal-bulbar-limbic circuits, particularly mesolimbic dopamine (DA) signaling
from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), play an important role
in “affective” pain-related behaviors (Price, 2003; Almeida et al., 2004; Leitl et al., 2014;
Benarroch, 2016; Martikainen et al., 2018; Markovic et al., 2021). Our lab has previously shown
that IP acid produces depression of both intracranial self-stimulation (ICSS) and NAc DA levels,
with ketoprofen and morphine alleviating both IP acid-induced depression of both behavior and
mesolimbic DA (Leitl et al., 2014). This suggests that pain-depressed behaviors are mediated in
part by depression of DA signaling in the mesolimbic system. Increasing evidence has shown the
rostromedial tegmental nucleus (RMTg), previously called the tail of the VTA, as a critical
regulator of the mesolimbic DA system (Taylor et al., 2019; Jhou, 2021). This cluster of
GABAergic cells located caudal to the posterior end of the VTA are suggested to act as a
“brake” on dopaminergic signaling (Barrot et al., 2012; Jhou, 2021), and has been shown to play
an important role in coding of aversive stimuli, pain, and antinociception (Barrot et al., 2012;
Taylor et al., 2019; Markovic et al., 2021).
Multiple brain regions shown to be involved in pain-processing have excitatory afferents
synapsing in the RMTg (see Figure I.III), including regions associated with ascending pain
pathways (e.g. parabrachial nucleus), descending pain pathways (e.g. periaqueductal gray), and
the “affective” dimension of pain (e.g. lateral habenula) (Barrot et al., 2012; Dostrovsky and
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Craig, 2013; Heinricher and Fields, 2013; Zhang et al., 2020). Additionally, both opioids and
cannabinoids have been shown to produce disinhibition of DA neurons in the VTA through
inhibition of RMTg GABAergic neurons (Barrot et al., 2012; Jhou, 2021). An interesting point
should be made regarding opioid receptor activation on the cell bodies vs. terminals of RMTg
GABAergic neurons. Opioids administered in the VTA (more anterior) can bind MORs on
RMTg GABAergic synaptic terminals to produce local disinhibition of DA signaling. However,
small doses of opioids targeted to the RMTg produce widespread disinhibition of DA neurons in
the VTA, effectively amplifying disinhibitory effects of smaller opioid doses (Kaufling et al.,
2009; Jalabert et al., 2011; Matsui and Williams, 2011; Barrot et al., 2012). As pointed out in
Barrot et al, care should be taken when evaluating opioid or cannabinoid effects in the VTA, as
the posterior VTA overlap with the RMTg may produce different neuronal and behavioral
effects.
Based on this evidence, we hypothesize that IP acid-depressed behaviors are mediated in
part by depression of DA signaling in the mesolimbic system. More specifically, we propose that
NAc DA signaling is depressed by IP acid in part via pain-related activation of RMTg
GABAergic neurons and subsequent inhibition of VTA DA neurons. Moreover, we hypothesize
that antinociceptive effects of MAGL inhibitors like MJN110 may be mediated in part by
inhibition of these pain-activated RMTg GABAergic neurons. To evaluate this hypothesis, the
neuroanatomical signaling of the IP acid noxious stimulus must first be characterized.
Accordingly, this dissertation includes an appendix aimed to develop an immunohistochemical
method for assessment of IP acid-induced neuronal activation in mouse spinal cord, NAc, VTA,
and RMTg.
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Expression of the immediate early gene transcription factor cFos was used as a correlate
of neuronal activation. Under basal conditions cFos is expressed at relatively low levels in
neurons and glial cells. cFos expression is rapidly induced in neurons activated by a variety of
stimuli, with neuronal activity increasing synaptic intracellular Ca2+ levels through N-methyl-Daspartate (NMDA) and voltage-sensitive calcium channels (VSCCs), which then activates the
ERK/MAPK pathway that phosphorylates transcription factors Elk-1/SRF and CREB on the cfos
promoter, leading to transcription and translation of the cFos protein. Finally, cFos forms a
heterodimer with c-Jun to form the AP-1 early response transcription factor (Cruz et al., 2013;
Chung, 2015; McReynolds et al., 2018). Time course for cFos production has been well
characterized, with cfos mRNA peaking around 30 minutes and cFos protein peaking between 13 hrs after stimulus delivery (McReynolds et al., 2018). Accordingly, studies in the appendix
collected tissue 60-70 minutes after stimulus administration for cFos detection, which agrees
with previous work evaluating visceral noxious stimulus-induced cFos expression in rodent brain
(Sinniger et al., 2004; Jurik et al., 2015).
Similar to how functional magnetic resonance imaging (fMRI) methods draw activitybased conclusions from indirect changes in blood oxygenation, cFos is not a direct measure of
neuronal activation but rather a measure of calcium-mediated signaling pathways.
Electrophysiological methods would be necessary to directly measure neuronal activation;
however, characterization of neuronal activity across large tissue areas is not easily amenable to
electrophysiological recordings. cFos mRNA and/or protein expression offers a relatively simple
method for evaluating large sections of tissue following a wide variety of stimuli, with activity
profiles helping guide more specific manipulations intended to evaluate the degree to which
activation of a given neural circuit is necessary and/or sufficient for a given behavioral response.
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While cFos immunohistochemistry allows identification of the location of activated
neurons, additional labeling with other markers is required for chemical phenotyping of activated
neurons. Chemical phenotyping of RMTg GABAergic neurons in this dissertation work was
attempted by targeting the enzyme glutamate decarboxylase (GAD), which functions to convert
glutamate into GABA (Molinoff, 2011). GAD has two main isoforms: GAD65, which is
predominantly expressed in synaptic terminals, and GAD67, which is expressed more diffusely
throughout the axon and cell body (Esclapez et al., 1994; Ge et al., 2019). Identification of DA
neurons in the VTA was also performed in this dissertation by targeting tyrosine hydroxylase
(TH), the rate-limiting enzyme for catecholamine biosynthesis that converts tyrosine to DOPA,
which is then converted to DA by dopamine-𝛽-hydroxylase (Sanders-Bush and Hazelwood,
2011). While TH is not selective for DA neurons as norepinephrine (NE) is synthesized from
dopamine, noradrenergic neurons are not located in the VTA or RMTg, allowing anatomical
specificity for TH to accurately identify DA neurons in the VTA (Molinoff, 2011).
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Figure I.I
PS = Pain Stimulus
GMD = General Motor Depressant
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Figure I.I: Example data demonstrating fundamental differences in susceptibility of painstimulated and pain-depressed behaviors for false-positives. (A) Baseline rates of painstimulated behaviors are very low and increase following delivery of a noxious stimulus.
Delivery of an effective analgesic decreases the behavior; however, these decreases are
indistinguishable from depression from drugs that produce general behavioral suppression. (B)
Baseline rates of pain-depressed behaviors are high and decrease following delivery of a noxious
stimulus. Delivery of an effective analgesic produces functional restoration of the pain-depressed
behavior. Importantly, drugs that decrease general behavior will produce either no change or
exacerbation of the pain-related behavioral depression. Drugs that produce general motor
stimulation may produce false-positive effects on pain-depressed endpoints. While general motor
depressants can simultaneously depress all behavior, general motor stimulants increase a subset
of behaviors as animals can only express a limited number of behaviors at one time. This
suggests a higher likelihood for false positives from general motor depressants on painstimulated behaviors.
20

Figure I.II

Figure I.II: Simplified overview of endocannabinoid system components at the neuronal
synapse. Vesicular release of excitatory or inhibitory neurotransmitters from the presynaptic
nerve terminal (blue) produces postsynaptic activity (yellow), leading to increased intracellular
levels of Ca2+ and synthesis of 2-AG and AEA. These highly lipophilic molecules travel across
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the synapse to bind and produce retrograde signaling on the presynaptic nerve terminal via
CB1Rs. Activation of these Gi/o-coupled GPCRs inhibits adenylyl cyclase, enhances inwardly
rectifying potassium channels, and inhibits calcium channels, effectively dampening further
anterograde neurotransmitter release (Reggio, 2010; Lu and Mackie, 2016). 2-AG signaling is
terminated through degradation by MAGL into AA and glycerol in the presynaptic nerve
terminal, and AEA signaling is terminated through degradation by FAAH into AA and EA in the
postsynaptic nerve terminal. 2-AG: 2-arachidonyl glycerol; AEA: anandamide; CB1Rs:
cannabinoid 1 receptors; GPCRs: G-protein coupled receptors; MAGL: monoacylglycerol lipase;
AA: arachidonic acid; FAAH: fatty acid amide hydrolase; EA: ethanolamine.
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Figure I.III

Figure I.III: Illustration of spinal and supra-spinal nociceptive pathways that can modify
mesolimbic dopamine signaling via the RMTg. (A) A peripheral noxious stimulus will activate
primary nociceptive neurons with cell bodies in the DRG that synapse onto secondary neurons in
the dorsal horn of the spinal cord. These can either synapse onto tertiary cells in the ventral horn
as part of a reflexive arc to elicit nocifensive responses, or decussate and ascend via the
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spinothalamic tract to synapse on tertiary neurons in the thalamus (B). These tertiary thalamic
neurons then project to the somatosensory and motor cortexes, completing the three-neuron
spinothalamocortical ascending pain pathway. Quaternary afferents can then project to other
regions, such as the PFC, which can modulate dopaminergic activity in the VTA through
excitatory projections to the RMTg. The spinal-bulbar-limbic pathway can also modulate
mesolimbic signaling, with ascending spinal afferents synapsing in the PB, which stimulates the
RMTg that then inhibits VTA signaling. The PAG, which mediates descending pain pathway
signaling, also has afferent projections to the RMTg. Additionally, the LHb provides a large
number of excitatory inputs to the RMTg. Abbreviations: DH = dorsal horn; VH = ventral horn;
DRG = dorsal root ganglia; PB = parabrachial nucleus; PAG = periaqueductal gray; RMTg =
rostromedial tegmental nucleus; VTA = ventral tegmental nucleus; LHb = lateral habenula; NAc
= nucleus accumbens; SSC = somatosensory cortex; MC = motor cortex; ACC = anterior
cingulate cortex; PFC = prefrontal cortex.
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Chapter II: Experimental Design and Analysis
for Consideration of Sex as a Biological Variable
(This chapter is an adapted form of the Diester et al. 2019 article
published in Neuropsychopharmacology, PMCID: PMC6897955)
Introduction
The National Institutes of Health (NIH) issued a policy in 2015 to promote inclusion of both
male and female subjects in preclinical biomedical research (Miller et al., 2017). As guidance to
address this policy, NIH has articulated “The Four Cs of Studying Sex to Strengthen Science”
(https://orwh.od.nih.gov/sex-gender/nih- policy-sex-biological-variable): (1) Consider (design
studies that take sex into account, or explain why it is not incorporated), (2) Collect (tabulate
sex-based data), (3) Characterize (analyze sex-based data), and (4) Communicate (report and
publish sex-based data). This article describes a general, multi-step approach to address The Four
Cs when investigation of sex differences is not the primary aim, and sample sizes required to
detect sex differences are not known.

We acknowledge that there are many instances where sex may be a top priority; however, as
written, the NIH policy and associated “Four C’s” guidance recognize that this is not invariably
the case. The factors that may contribute to an individual researcher’s prioritization of sex
differences among all possible independent variables are beyond the scope of this chapter. In
those instances where sex is not the primary variable of interest, we suggest that priority of
analyses should be assigned to those primary variables that have been adequately powered based
on initial study design with additional analyses of secondary variables such as sex addressed
through appropriately designed follow-up studies.
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The expression and treatment of pain constitute one domain in which sex differences are
apparent in both humans and laboratory animals (Greenspan et al., 2007), and preclinical
research is playing a major role in analgesic drug development in response to the NIH “Helping
to End Addiction Long-term” (HEAL) initiative. Accordingly, this is one area where preclinical
research is active, the new NIH policy is pertinent, and inclusion of both males and females is
warranted.

Materials and Methods
Subjects
Adult male and female ICR mice (Envigo, Frederick, MD) were 6-8 weeks old upon arrival and
housed in an AAALAC approved facility. All subjects were littermates group-housed 3/cage,
with a cardboard tube added to the cage environment for additional enrichment to decrease
fighting. Throughout the study, mice had ad libitum access to food (Teklad LM-485 Mouse/Rat
Diet, Harlan Laboratories) and water, and were maintained on a 12-hour light/dark cycle (lights
on from 6:00AM to 6:00PM) in a temperature-controlled room, with testing occurring during the
light phase. All subjects were acclimated to the vivarium for at least one week before beginning
studies and acclimated to the experimental room for at least 1 day before the first test day and at
least 1 hour before testing.

Stretching Assay
For this illustrative study, which used methods similar to those previously described (Bagdas et
al., 2016), adult male and female mice received an intraperitoneal injection of dilute lactic acid
(IP acid) as an acute visceral pain stimulus immediately before being placed into 4-inch diameter
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plexiglass cylinders for 20-min periods of videotaped observation. Two observers blinded to
experimental treatment scored each video by counting the number of pain-related stretches
(defined as contraction of the abdomen followed by extension of the hind limbs). Observer
scores for each session were averaged for subsequent analysis. The cyclooxygenase inhibitor
ketoprofen was also evaluated for its effectiveness to block IP acid effects in a separate group
(Bagdas et al., 2016). The following steps in experimental design and analysis were incorporated
to address The Four Cs.

Data Analysis
Experimental design to address The Four Cs
The following steps in experimental design and analysis were incorporated to address The Four
Cs:
(1) IP acid alone was tested in one group of 12 mice, ketoprofen + IP acid was tested in a
separate group of 12 mice, and each group contained equal numbers of male and female mice (N
= 6/sex). The total group size, which was modestly larger than the N = 6-10 mice used in our
previous study with only males (Bagdas et al., 2016), was selected based on the observation that
confidence-interval widths for any normally distributed population decline with increasing
sample size and approach an asymptote at approximately N = 12 (van Belle, 2008). We further
chose to constitute this N = 12 group size with equal numbers of N = 6 mice per sex in part to
comply with published guidance by the British Journal of Pharmacology for use of equal sample
sizes of N ≥ 5 across groups (Curtis et al., 2015). However, it is important to note that NIH
guidance does not specify minimum group sizes or allocations by sex, and our approach could be
used regardless of the numbers of males and females included in a study.
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(2) Sex was not the primary independent variable of interest in this study, so the primary analysis
pooled data from both sexes and used repeated-measures one-way ANOVA (Prism 8.0, GraphPad, La Jolla, CA) to evaluate effects of IP acid or ketoprofen dose. A significant ANOVA was
followed by Dunnett’s post hoc test to compare acid or ketoprofen effects to vehicle effects. The
criterion for significance for this and all other statistical tests was p < 0.05.

(3) Secondary analyses to address sex as a biological variable proceeded in two steps. First, data
in each panel of Fig. 1 were segregated by sex and analyzed by repeated-measures one-way
ANOVA. Second, data from males and females in each panel were also analyzed by two-way
ANOVA with sex as a between-subjects factor and IP acid or ketoprofen dose as a withinsubjects factor. A significant interaction was followed by a Holm-Sidak post hoc test.

(4) Lastly, all one-way and two-way ANOVA results were submitted to power analyses to
calculate three variables (a) Cohen’s f effect size, (b) achieved power (1-𝛽), and (c) the total
number of animals predicted as necessary to detect a significant effect given the empirically
determined effect size and criterion levels of 𝛼 = 0.05 and power (1-𝛽) = 0.8 (G*Power (Faul et
al., 2007), free and publicly available: http://www.gpower.hhu.de).

Power analyses
Power analysis complements the ANOVA results in three ways. First, “effect size” provides a
basis for comparing the magnitude of sex differences or other effects across studies (Nakagawa
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and Cuthill, 2007). In this data set, for example, all of the effect sizes for IP acid alone were
greater than the effect sizes for ketoprofen antinociception.

Second, “power” provides a basis for confidence in drawing conclusions based on the ANOVA
results. In particular, just as “𝛼” values specify the probability of a Type 1 (false-positive) error,
so the “𝛽” values specify the probability of a Type 2 (false-negative) error. Moreover, just as
convention accepts 𝛼 ≤ 0.05 as an acceptable criterion for Type 1 errors in concluding that an
effect is PRESENT, so convention also generally accepts 𝛽 ≤ 0.2 as an acceptable criterion for
Type 2 errors in concluding that an effect is ABSENT (Marino, 2018). Insofar as the term
“power” represents 1-𝛽, then this criterion is equivalent to power ≥ 0.8. Given this criterion, it is
appropriate to conclude that an effect of sex (or any other variable) is absent only if the
experiment is sufficiently powered to reach that conclusion at power ≥ 0.8.

Lastly, the “predicted N” can inform experimental design for future studies that might pursue
evaluation of sex differences. Thus, the effect size observed for a treatment in an initial sample
of subjects from some population can be used to predict the sample size required to achieve
target statistical criteria (e.g., 𝛼 ≤ 0.05, 𝛽 ≤ 0.2) for confidence in reaching positive or negative
conclusions regarding that treatment effect in other subjects from that population. Importantly,
this prediction is founded on the assumption that the effect size observed in the initial sample
size is representative of the whole population, but this of course is an empirical question (see
(Marino, 2018) for commentary). In this study for example, power analysis predicts that total
sample sizes of 56 (28/ sex) and 16 (8/sex) would be required to adequately characterize the
presence or absence of a main effect of sex and a dose × sex interaction, respectively, for two-
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way ANOVA of effects produced by IP acid alone. Similarly, samples sizes would need to be
increased to 15 (males) or 10 (females) to adequately characterize effects of ketoprofen by oneway ANOVA in males or females alone.

Results
Primary and secondary ANOVA analyses
The data to illustrate this approach are shown in Figure 1 and Table 1. Primary repeatedmeasures one-way ANOVA of pooled data showed IP acid to produce a dose-dependent
stimulation of stretching and ketoprofen to dose-dependently block IP acid effects. Secondary
repeated-measures one-way ANOVA analysis of data from each panel segregated by sex showed
IP acid stimulating stretching in both sexes; however, ketoprofen failed to significantly decrease
IP acid effects in either sex. For secondary two-way ANOVA with sex as a between-subjects
factor and IP acid or ketoprofen dose as a within-subjects factor, IP acid alone produced a
significant main effect of acid dose but not of sex. The acid dose x sex interaction was
significant, but post hoc analysis did not reveal a sex difference at any acid dose. For ketoprofen
+ IP acid, there was a significant main effect of ketoprofen dose but not of sex, and the
ketoprofen dose x sex interaction was also not significant.

Results and implications from power analyses
In this data set, most sex-based analyses failed to reach the criterion for statistical significance,
and even with the significant dose × sex interaction for effects of IP acid alone, the post hoc
analysis failed to reveal a significant sex difference at any acid dose. However, power analysis
indicated that it would be inappropriate to conclude from these ANOVA results that a sex
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difference was absent for either IP acid or ketoprofen, because none of the analyses involving
sex achieved power ≥ 0.8. The same principle applies to interpretation of ketoprofen effects in
males or females alone. Although ketoprofen failed to produce a significant decrease in IP acidstimulated stretching in either males or females, power was well under 0.8 in both sexes.
Consequently, it would be inappropriate to conclude from these ANOVA results that ketoprofen
had no effect. Notably, power ≤ 0.8 is not problematic in the event that a significant effect is
deemed to be present, because in these cases, the concern is with potential false-positive
conclusions (addressed by α) and not with potential false-negative conclusions (addressed by β).
For example, the pooled analysis of ketoprofen effects had power < 0.8 (0.752); however, the
ketoprofen data met the criterion for a significant effect, so there was no need to address the
potential of a false-negative conclusion.

Discussion
In summary, this approach establishes a general, multi-step approach to address The Four Cs
articulated by the National Institutes of Health (NIH) when preclinical investigation of sex
differences is not the primary aim and sample sizes required to detect sex differences are not
known. Inclusion of both males and females is responsive to the “Consider” mandate for the
experimental design that takes sex into account. The pooling of data across sex permits focus on
the primary variable(s) of interest, while segregation of data by sex addresses the “Collect”
mandate for tabulating sex-based data. The secondary analyses address the “Characterize”
mandate by using ANOVAs to analyze sex-based differences with existing sample sizes and
power analyses to guide both interpretation of the ANOVA results and design of any future
studies that might focus on sex differences. Finally, the results of ANOVAs (F statistics) and
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power analyses (effect size, power, and predicted Ns) provide a useful array of statistical
outcome measures that fulfill the “Communicate” mandate for reporting and publishing sexbased data.
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Figures

Figure II.I. Effects of IP lactic acid administered alone or after pretreatment with
ketoprofen on pain-related stretching behavior in male and female mice. Abscissae:
concentration of lactic acid (left panel, diluted in sterile water and administered IP in a volume of
10 ml/kg) or dose of ketoprofen (right panel, administered subcutaneously as a 30-min
pretreatment to 0.32% IP acid). Veh = vehicle for IP acid (left panel) or ketoprofen before 0.32%
IP acid (right panel). Ordinates: number of stretches observed during a 20-min observation
period. Points show mean ± SEM for all mice (black circles, N = 12), just males (blue squares, N
= 6), and just females (pink diamonds, N = 6). Filled symbols indicate significantly different
from Veh as determined by one-way ANOVA and Dunnett’s post hoc test for pooled data,
males, or females. $ Indicates a significant sex × dose interaction as determined by two-way
ANOVA, but follow-up analysis with the Holm–Sidak post hoc test did not reveal a significant
effect of sex at any acid dose. The results of ANOVA and power analysis for data in each panel
are shown in Table 1.
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Chapter III: Behavioral Battery for Testing Candidate Analgesics in Mice. I. Validation
with Positive and Negative Controls
(Published in Journal of Pharmacology & Experimental Therapeutics: Diester et al., 2021,
PMCID: PMC8058504)

Introduction
The goal of this study was to evaluate a battery of pain-stimulated, pain-depressed, and painindependent behaviors for preclinical pharmacological assessment of candidate analgesics in ICR
mice. Intraperitoneal injection of dilute lactic acid (IP acid) served as an acute visceral noxious
stimulus to produce the following four pain-related behaviors: 1) stimulation of stretching, 2)
stimulation of facial grimace, 3) depression of rearing, and 4) depression of nesting.
Additionally, both horizontal locomotor activity and nesting were measured in the absence of the
noxious stimulus to assess pain-independent drug effects. As stated in Chapter II, the study
design included male and female subjects. These six behaviors were used to compare effects of
two mechanistically distinct but clinically effective positive controls (ketoprofen, oxycodone)
and two active negative controls that are not clinically approved as analgesics but produce either
general motor depression (diazepam) or general motor stimulation (amphetamine).

Materials and Methods
Subjects
Subjects were male and female ICR mice (Harlan Laboratories, Frederick, MD) that were 6-8
weeks old upon arrival to the laboratory. Males weighed 25-45g and females weighed 20-35g
throughout the study. In an AAALAC approved facility, mice were housed in cages (31.75cm
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long x 23.50 cm wide x 15.25cm deep) with corncob bedding (Harlan Laboratories) and a
“nestlet” composed of pressed cotton (Ancare, Bellmore, NY). All mice had ad libitum access to
food (Teklad LM-485 Mouse/Rat Diet, Harlan Laboratories) and water, and cages were mounted
in a RAIR HD Ventilated Rack (Lab Products, Seaford, DE) in a temperature-controlled room
with a 12-hour light/dark cycle (lights on from 6:00 AM to 6:00 PM). Mice used in studies of
stretching, grimace, and rearing were littermates group housed 3/cage, and mice used in nesting
studies were individually housed. For group-housed mice, a cardboard tube was added to the
cage environment to provide enrichment and minimize fighting. All experiments were performed
during the light phase of the daily light/dark cycle beginning at least one week after arrival at the
laboratory. Additionally, for singly housed mice in nesting studies, experiments were performed
in their home cages at least two days after a cage change. Animal-use protocols were approved
by the Virginia Commonwealth University Institutional Animal Care and Use Committee and
complied with the National Research Council Guide for the Care and Use of Laboratory
Animals.

Overview of Experimental Design
The goal of the study was to compare effects of two clinically effective positive-control
analgesics (ketoprofen, oxycodone) and two behaviorally active negative controls (diazepam,
amphetamine) on a panel of pain-stimulated, pain-depressed, and pain-independent behaviors in
mice. Pain-related behaviors were elicited by intraperitoneal (IP) injection of dilute lactic acid as
the noxious stimulus, and an initial study determined the potency of IP acid (0-0.32%) to
produce these behaviors in two groups of mice. These two groups and all other groups described
below consisted of 12 mice (6 males and 6 females) to permit exploratory analysis of sex
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differences as described in Chapter II (Diester et al., 2019). One group of mice was used to
evaluate IP acid-induced stimulation of abdominal stretching and facial grimace behaviors as
well as IP acid-induced depression of rearing. A second group was used to evaluate IP acidinduced depression of nesting behavior. Thus, behavioral assessment focused on two painstimulated behaviors (stretching, grimace) and two pain-depressed behaviors (rearing, nesting).
In each group, all mice received all IP acid concentrations in a within-subject repeated-measures
design. The order of presentation for different acid concentrations was randomized across mice
using a Latin-square design, and tests were conducted once per week in each mouse.

On the basis of this initial study, a concentration of 0.32% IP acid was used as the noxious
stimulus for all subsequent studies with test drugs. Antinociception dose-effect curves for each
test drug were determined in two groups of mice, one to assess drug effects on IP acid-induced
changes in stretching, facial grimace, and rearing, and a second to assess drug effects on IP acidinduced depression of nesting. Effects of each test drug on pain-independent behaviors were
determined in two additional groups of mice, one to assess drug effects on control nesting in the
absence of the IP acid noxious stimulus, and a second to assess drug effects on locomotion in the
absence of the noxious stimulus. In each group, all mice received all drug doses, and dose order
was randomized across mice using a Latin-square design. Doses for each drug were varied in 0.5
or 1.0 log-unit increments across a ≥10-fold dose range with the intent of progressing from low
doses that produced little or no effect to high doses that produced either significant
antinociception on one or more endpoints of pain-related behavior or significant changes in
nesting or locomotor activity as pain-independent behaviors. Data were analyzed to evaluate the
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degree to which each test drug alleviated pain-related behaviors at doses below those that altered
pain-independent behaviors.

Test drug doses, pretreatment times, and supporting references were as follows: the
cyclooxygenase1/2 inhibitor ketoprofen, 0.1-32 mg/kg, 30 min (Negus et al., 2015); the muopioid receptor agonist oxycodone, 0.32-10 mg/kg, 30 min (Beardsley et al., 2004); the gamma
aminobutyric acid receptor A (GABAA) receptor positive allosteric modulator diazepam, 1-10
mg/kg, 30 min (Rosland et al., 1987; Schwienteck et al., 2017); and the dopamine and
norepinephrine transporter substrate amphetamine, 0.32-10 mg/kg, 30 min (Tyler and Tessel,
1979; Nevins et al., 1993).

Behavioral Procedures
Stretching/Grimace/Rearing Procedure. Studies of stretching, grimace, and rearing were
conducted in a procedure room separate from the housing room. Mice were acclimated for at
least 1 hr to the procedure room at least one day before the first test day, and on all subsequent
test days, mice were again acclimated to the procedure room for at least 1 hr before testing.
Testing occurred once per week for each subject and was initiated by subcutaneous (SC)
administration of the specified test drug dose followed by return of the mouse to its home cage
for the pretreatment time specified above. Subsequently, mice received IP acid immediately
before being placed into individual plexiglass cylinders (4” diameter) and filmed for 20.5 min
without any researchers in the room. Videos were later scored for stretching, facial grimace, and
rearing by two trained and blinded observers, and scores across the two observers were averaged.
The number of stretches and rears was counted for the first 20-min of the observation period. A
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stretch was defined as a horizontal extension of the abdomen followed by extension of at least
one hind limb. A rear was defined as vertical extension of the mouse with both front paws off the
ground followed by return of at least one front paw to the ground. Importantly, a rear was not
counted when a mouse was resting on its hind legs without vertical extension (e.g. during
grooming). Facial grimace was scored during the last 0.5 min of the observation period by
evaluating ptosis and ear position with criteria similar to those described previously (Langford et
al., 2010). Specifically, ptosis was scored on a graded scale with 0 = eyes fully open, 0.5 = eyes
half to a quarter closed, and 1 = eyes fully closed. Ear position was also scored on a graded scale
by reference to a line drawn following the top of the whisker line along the snout. If the center
tip of the mouse’s ear was above the line, it was scored as a 0, through the center of the ear was a
0.5, and below was a 1. Scores for ptosis and ear position were assigned based on observer
impressions for the entire 0.5 min observation period and summed to yield a total score for each
mouse, with a minimum score of 0 and maximum score of 2.

Nesting Procedure. A nesting procedure described previously (Negus et al., 2015) was modified
to accommodate testing in the housing room and provide a continuous quantitative dependent
variable. Additionally, mice were excluded from nesting studies if they failed to nest during the
initial acclimation week in the housing room (3 mice over the course of the study). On test days,
which occurred once per week for each subject, mice received a SC injection with the specified
test drug before being returned to their home cages on the housing rack. After the specified pretreatment time, mice were removed from their cage and received either IP acid or vehicle. Old
nesting material was removed, two 1-in2 nestlet squares were placed 11 in apart in the center of
the opposing short walls of the cage (see Supp. Figure I), and the mouse was again returned to its
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home cage. After a 90-min nesting period with no researcher in the room, the cage top was
removed, the position of the nestlets was photographed from above, and the distance between the
center of mass for each nestlet was measured to the nearest quarter inch. For the initial study to
examine the potency and time course of IP acid effects, nestlet position was also evaluated every
30 min during the 90 min nesting period (Supp. Figure I); however, for all remaining
experiments, nestlet position was evaluated only at 90 min to minimize cage disturbances during
the experiment. The primary dependent variable was % Maximal Nestlet Consolidation
(%MNC), defined as [(11-End)/11] x 100], where 11 and End were the distances in inches
between the nestlets at the start and end of the nesting period, respectively.

Locomotor Procedure. Horizontal locomotor activity was assessed during 30-min sessions in
16.8 cm wide x 12.7 cm deep x 12.7 cm high boxes housed in sound-attenuating chambers (Med
Associates, St. Albans, VT) and located in a procedure room separate from the housing room.
Each box had black plexiglass walls, a clear plexiglass ceiling equipped with a house light, bar
floors, and six photobeams arranged at 3 cm intervals across the long wall and 1 cm above the
floor. Beam breaks were monitored by a microprocessor operating Med Associates software. The
primary dependent variable was the total number of beam breaks, excluding consecutive
interruptions of the same beam, during the 30-min session. Test sessions were conducted twice a
week with at least 48 hr between sessions. On test days, mice were brought to the procedure
room at least 2 hr before session onset. After SC test-drug administration, mice were returned to
their home cages for the 30-min pretreatment interval, then placed into the locomotor activity
boxes at session onset.
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Data Analysis
Stretching, rearing, nesting, and locomotor data were treated as ratio variables and analyzed by
parametric statistics, whereas facial grimace was treated as an ordinal variable and analyzed with
non-parametric statistics. Data for each treatment on each endpoint were analyzed in four phases
as described in Chapter II (Diester et al., 2019). As this study was designed based on power to
assess treatment effects for pooled data (N=12), data for males and females were first pooled and
evaluated using a repeated-measures one-way ANOVA followed by Dunnett’s post hoc test for
parametric data or Friedman’s test followed by Dunn’s post hoc for non-parametric data. Second,
data were segregated by sex and evaluated by repeated-measures one-way ANOVA to assess
drug effects within each sex, and as with pooled data, a significant ANOVA was followed by
Dunnett’s post hoc test for parametric data, whereas a significant Friedman’s test was followed
by Dunn’s post hoc for non-parametric data. Third, male and female parametric data for a given
endpoint were analyzed by two-way ANOVA to directly compare data from males and females,
with sex as a between-subjects factor and IP acid concentration or drug dose as a within-subjects
factor. A significant sex x treatment interaction was followed by a Holm-Sidak post hoc test. For
non-parametric data, multiple t-tests with correction for multiple comparisons were used. These
first three steps of data analysis were performed using GraphPad Prism (LaJolla, CA) with a
criterion for significance of p<0.05. Lastly, results were submitted to power analyses to calculate
the Cohen’s f effect size, achieved power (1-β), and the total number of animals predicted as
necessary to detect a significant effect given the effect size, α = 0.05 and power (1-β) = 0.8 using
the free statistical analysis program G*Power (Faul et al., 2007). There is currently no consensus
method for power analysis of non-parametric data so grimace data was not submitted for further
power analyses in this study (Lehmann, 2006; Motulsky, 2020).
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Drugs
Lactic acid (Fisher Scientific, Hampton, NH) was diluted in sterile water and administered IP.
Ketoprofen was obtained as a commercially available solution (100 mg/mL; Ford Dodge, IA)
and diluted in sterile saline. Oxycodone and amphetamine were provided by the National
Institute on Drug Abuse Supply Program (Bethesda, MD), and were prepared in sterile saline.
Diazepam was obtained as a commercially available solution (5 mg/ml, Hospira, Lake Forest,
IL) and diluted in 1:4:5 ethanol, propylene glycol, and saline. All test drugs were administered
SC in volumes of 0.1 to 0.9 ml.

Results
Effects of IP Lactic Acid Alone
Figure III.I shows the effects of IP injection with vehicle or increasing concentrations of lactic
acid on stretching, facial grimace, rearing, and nesting behaviors. After IP vehicle, stretching and
facial grimace scores were low, whereas rearing and nesting scores were high. IP acid produced
concentration-dependent increases in both stretching and grimace, with significant increases for
both pain-stimulated behavioral endpoints at 0.18% and 0.32% (see Table III.I for all statistical
results with pooled data from both sexes). Conversely, IP acid produced concentration-dependent
decreases in rearing and nestlet consolidation, with significant decreases for rears at 0.18% and
0.32% and significant decreases in nesting for all three acid concentrations. The time course of
nesting behavior in 30-min intervals after vehicle or acid treatment is shown in Supplemental
Figure III.I. Results of statistical analysis to examine sex as a determinant of IP acid effects are
shown in Supplemental Table III.I. With these sample sizes, only stretching showed a significant
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sex x dose interaction; however, further post hoc analysis showed no difference between males
and females for any concentration compared to vehicle (Supp. Fig. III.II). Based on these results,
a concentration of 0.32% IP acid was used for all subsequent studies with test drugs.

Overview of Data Presentation
Each test drug was evaluated for its potency and effectiveness to block each of the four IP acidinduced behaviors, and results are shown in Figures III.II-III. Additionally, each test drug was
administered alone in the nesting and locomotor procedures to evaluate general behavioral
effects in the absence of the IP acid noxious stimulus, and results are shown in Figure III.IV.
Figure III.V compares the potencies of each test drug to significantly attenuate IP acid effects
and to alter nesting and locomotor behaviors when the test drug was administered alone. An
optimal test-drug profile would be significant attenuation of all IP acid-induced behaviors at
doses that did not affect nesting or locomotion when the test drug was administered alone. Table
I shows the results of ANOVA and power analyses for pooled data across sexes. Supplemental
Tables III.I-II show results of ANOVA and power analyses for data segregated by sex.
Supplemental Tables III-VII report results of statistical analysis to examine sex as a determinant
of effects for each drug on each endpoint, and figures are included for selected effects when
there was either a significant main effect of sex or a significant dose x sex interaction.

Effects of Ketoprofen and Oxycodone
Figure II shows the effectiveness of the COX inhibitor ketoprofen and the MOR agonist
oxycodone to block IP acid-induced pain-related behaviors. Ketoprofen (0.1-10 mg/kg)
significantly blocked IP acid-stimulated stretching and facial grimace, and also blocked IP acid-
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induced depression of both rearing and nesting. Ketoprofen alone at doses up to 32 mg/kg had no
effect on nesting or locomotion (Figure III.IV). Thus, ketoprofen blocked all IP acid-induced
changes in behaviors at doses that had no effect on nesting or locomotion when ketoprofen was
administered alone (Figure III.V). Table I summarizes the ANOVA and power analysis results
for these pooled data. Results of statistical analysis to examine sex as a determinant of
ketoprofen effects are shown in Supplemental Table III.IV. No endpoint showed a significant sex
x dose interaction, and only nesting in the presence of IP acid had a significant main effect of sex
(greater nesting in females; Supp. Figure III.III).

Oxycodone (0.32-3.2 mg/kg) significantly blocked IP acid-stimulated stretching at all three
doses and facial grimace at 1.0 and 3.2 mg/kg. No oxycodone dose tested blocked IP acidinduced depression of rearing, and only 1.0 mg/kg significantly attenuated IP acid-depressed
nesting to a mean %MNC of 42.2±10.96. Oxycodone alone significantly decreased nesting at 10
mg/kg, and significantly stimulated locomotion at 3.2 and 10 mg/kg (Figure III.IV). Thus,
oxycodone decreased IP acid-stimulation of both stretching and facial grimace and attenuated
acid-induced depression of nesting at doses lower than those that produced significant effects on
nesting and locomotion when administered alone (Figure III.V). The ANOVA and power
analysis results for these pooled data are summarized in Table III.I. Supplemental Table III.V
shows the results of the statistical analyses to examine sex as a determinant for oxycodone
effects. No endpoint showed a significant main effect of sex for the given sample and effect
sizes, and only nesting in the absence of the noxious stimulus produced a significant sex x dose
interaction; however, further post hoc analysis did not reveal an individual dose being
significantly different between males and females (Supp. Figure III.IV).
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Effects of Diazepam and Amphetamine
Figure III.III shows the effects of the GABAA positive allosteric modulator diazepam and the
DAT/NET substrate amphetamine on IP acid-induced pain-related behaviors. The highest dose
of diazepam (10 mg/kg) significantly attenuated IP acid-stimulated stretching and grimace, but
diazepam did not attenuate IP acid-induced depression of either rearing or nesting; rather, 10
mg/kg diazepam exacerbated IP acid-induced depression of rearing. Diazepam administered
alone significantly decreased nesting at 10 mg/kg and significantly decreased locomotion at 3.2
and 10 mg/kg (Figure III.IV). Thus, diazepam reduced IP acid-stimulated stretching and grimace
only at a dose that exacerbated IP acid-induced depression of rearing and significantly decreased
nesting and locomotion when administered alone (Figure III.V). ANOVA and power analysis
data summarizing these results is shown in Table III.I. Results of statistical analysis to examine
sex as a determinant of diazepam are shown in Supplemental Table III.VI. No endpoints in the
presence of IP acid resulted in a significant sex x dose interaction or main effect of sex for the
given sample and effect sizes. Diazepam alone did produce a significant main effect of sex in
locomotion, but further post hoc analysis showed no individual dose to be significantly different
between males and females (Supplemental Figure III.IV).

Amphetamine (0.32-3.2 mg/kg) significantly reduced IP acid-induced stimulation of both
stretching and facial grimace at the highest dose tested. Additionally, 3.2 mg/kg amphetamine
attenuated IP acid-induced depression of rearing and nesting. Amphetamine delivered alone
(0.32-10 mg/kg) significantly decreased nesting at 10 mg/kg and significantly increased
locomotion at both 3.2 and 10 mg/kg (Figure III.IV). Thus, amphetamine blocked all IP acidinduced behaviors, but only at a dose that significantly increased locomotion when administered
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in the absence of the noxious stimulus (Figure III.V). Table III.I summarizes the ANOVA and
power analysis results for these pooled data. Supplemental Table III.VII shows the results of the
statistical analyses to examine sex as a determinant for amphetamine effects. No endpoints
showed a significant sex x dose interaction or main effect of sex for the given sample and effect
sizes.

Discussion
This study compared the effects of two clinically effective analgesics (ketoprofen and
oxycodone) and two active negative controls (diazepam and amphetamine) on a panel of painstimulated, pain-depressed, and pain-independent behaviors in male and female mice. There
were three main findings. First, IP acid served as an effective chemical noxious stimulus to
produce a concentration-dependent stimulation of stretching and facial grimace and depression
of rearing and nesting as putative pain-related behaviors. Test drugs could then be evaluated for
their profiles of antinociceptive effectiveness to alleviate these IP acid effects. Second, the
positive-control analgesics ketoprofen and oxycodone produced antinociception in assays of both
pain-stimulated and pain-depressed outcome measures (with ketoprofen being the most effective)
at doses below those that altered nesting and/or locomotion in the absence of the IP acid noxious
stimulus, whereas the negative controls diazepam and amphetamine did not. These results
suggest that analgesic potential of test drugs can be predicted by higher potency to alleviate painrelated stimulation and depression of behavior than to produce pain-independent motor
disruption in mice. Lastly, sex differences in drug effects were not a primary focus of the present
study, and few sex differences were identified; however, the inclusion of equal numbers of male
and female mice permitted exploratory power analysis of sex differences that could guide future
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studies designed to focus on sex as a primary variable of interest. Overall, this study outlines an
experimental design and framework of results with positive and negative controls that can be
used to study and interpret effects of candidate analgesic drugs.
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Figures

Figure III.I. Effects of intraperitoneal lactic acid (IP Acid) on stretching, facial grimace,
rearing, and nesting behaviors in male and female mice. Abscissae: concentration of lactic
acid diluted in sterile water and administered intraperitoneally in a volume of 10 ml/kg (log
scale). Ordinates: number of stretches (A), grimace score (B), number of rears (C), and nesting
expressed as percent maximum nestlet consolidation (D). Each point shows mean ± S.E.M. for
12 mice (6 males, 6 females). Filled symbols indicate a significant difference from vehicle (Veh)
as determined by repeated-measures one-way ANOVA and Dunnett’s post hoc test for
parametric data (A, C, and D) or by Friedman’s and Dunn’s post hoc test for nonparametric data
(B), P ≤ 0.05. Results of ANOVA and power analysis for each panel are shown in Table III.I.
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Figure III.II. Effects of the clinically-effective positive controls ketoprofen and oxycodone
on IP acid-induced pain behaviors. Abscissae: doses of ketoprofen or oxycodone in mg/kg (log
scale). Ordinates: number of stretches (A), grimace score (B), number of rears (C), and nesting
expressed as percent maximum nestlet consolidation (D). Each point shows mean ± SEM for 12
mice (6 male, 6 female). Filled symbols indicate a significant difference from vehicle (Veh) as
determined by RM one-way ANOVA and Dunnett’s post hoc test for parametric data (A, C & D)
or by Friedman’s and Dunn’s post hoc test for nonparametric data (B), p<0.05. Results of
ANOVA and power analysis data for each panel are shown in Table III.I.
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Figure III.III. Effects of the active negative controls diazepam and amphetamine on IP
acid-induced pain behaviors. Abscissae: doses of diazepam or amphetamine delivered SC in
mg/kg (log scale). Ordinates: number of stretches (A), grimace score (B), number of rears (C),
and nesting expressed as percent maximum nestlet consolidation (D). Each point shows mean ±
SEM for 12 mice (6 male, 6 female). Filled symbols indicate a significant difference from
vehicle (Veh) as determined by RM one-way ANOVA and Dunnett’s post hoc test for parametric
data (A, C & D) or by Friedman’s and Dunn’s post hoc test for nonparametric data (B), p<0.05.
Results of ANOVA and power analysis data for each panel are shown in Table III.I.
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Figure III.IV. Effects of all drugs on nesting and locomotion in the absence of the IP acid
noxious stimulus. Abscissae: Doses of ketoprofen, diazepam, oxycodone and amphetamine
delivered in mg/kg (log scale). Ordinates: nesting expressed as percent maximum nestlet
consolidation (A) and locomotor counts (B). Each point shows mean ± SEM for 12 mice (6 male,
6 female). Filled symbols indicate a significant difference from vehicle (Veh) as determined by
RM one-way ANOVA and Dunnett’s post hoc test, p<0.05. Results of ANOVA and power
analysis data for each panel are shown in Table III.I.
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Figure III.V. Drug profiles for comparing potency to produce antinociceptive effects versus
general behavioral disruption. Abscissae: Drug dose for either ketoprofen (A), oxycodone (B),
diazepam (C) or amphetamine (D). Open bars span the dose range over which each drug
significantly attenuated IP acid-induced stimulation of stretching (S) or facial grimace (G) or IP
acid-induced depression of rearing (R) or nesting (N). In each panel, bars for pain-stimulated
behaviors (PSB) and pain-depressed behaviors (PDB) are shown above and below the dose line,
respectively. The gray zone in each panel spans doses over which each drug disrupted nesting
and/or locomotion when administered alone in the absence of the IP acid noxious stimulus.
Ketoprofen (A) did not alter nesting or locomotion at does up to 32 mg/kg, so no gray zone is
indicated.
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Table III.I: Summary of power analysis results from pooled one-way ANOVA data from
Figures 1-4.
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Supplemental Figure III.I. Time course data for nestlet consolidation behavior. Panel A shows
a photograph of the starting configuration for each experiment, and panel B shows an example of
a complete nest, with a “% Maximal Nestlet Consolidation” (%MNC) of 0% for panel A and
100% for panel B. Panel C shows the time course of nestlet consolidation after vehicle or
increasing concentrations of IP lactic acid, with abscissa as time in minutes and the ordinate as
%MNC. Each point represents mean ± SEM for 12 mice (6 male, 6 female). Filled symbols
indicate a significant difference from vehicle as determined by RM two-way ANOVA and
Dunnett’s post hoc test, p<0.05. For vehicle data, an additional RM one-way ANOVA and
Dunnett’s post hoc test was performed, with 30 min, 60 min and 90 min being significantly
different from 0 min.
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Supplemental Figure III.II. Effects of IP lactic acid on stretching, facial grimace, rearing
and nesting behaviors in male and female mice. Abscissae: concentration of lactic acid diluted
in sterile water and administered IP in a volume of 10 ml/kg. Ordinates: number of stretches (A),
grimace score (B), number of rears (C), and nesting expressed as percent maximum nestlet
consolidation (D). All points represent the mean ± SEM for either 6 males (blue) or 6 females
(pink). Filled symbols indicate a significant difference from vehicle (Veh) as determined by RM
one-way ANOVA and Dunnett’s post hoc test for parametric data (A, C & D) or by Friedman’s
and Dunn’s post hoc test for nonparametric data (B), p<0.05. $ Indicates a significant sex x dose
interaction as determined by 2-way ANOVA and Holm-Sidak post hoc test of data segregated by
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sex. Results of ANOVA and power analysis data for each panel are shown in Table III.I.
Statistical results for the 2-way ANOVA (parametric) or multiple t-test (non-parametric) data are
as follows. (A) Significant main effect of acid dose [F(2.264, 22.64)=28.10; p<0.0001], but no
main effect of sex. Significant sex x dose interaction [F(3,30)=3.059; p=0.043], but post hoc
analysis did not reveal a significant effect of sex at any dose. (B) Significant main effect of dose
[F(2.361, 23.61)=14.28; p=<0.0001], but no significant main effect of sex or sex x dose
interaction. (C) No significant difference for any lactic acid concentration between males and
females. (D) Significant main effect of dose [F(1.655, 16.55)=16.90; p=0.0002], but no main
effect of sex or sex x dose interaction. Results of ANOVA and power analyses are shown in
Supp. Tables III.I-III.
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Supplemental Figure III.III. Effects of the clinically-effective positive control ketoprofen on
IP acid-induced pain behaviors. Abscissae: doses of ketoprofen delivered SC in a volume of 10
ml/kg. Ordinates: number of stretches (A), grimace score (B), number of rears (C), and nesting
expressed as percent maximum nestlet consolidation (D). All points represent the mean ± SEM
for either 6 males (blue) or 6 females (pink). Filled symbols indicate a significant difference
from vehicle (Veh) as determined by RM one-way ANOVA and Dunnett’s post hoc test for
parametric data (A, C & D) or by Friedman’s and Dunn’s post hoc test for nonparametric data
(B), p<0.05. # Indicates a significant main effect of sex as determined by 2-way ANOVA and
Holm-Sidak post hoc test for parametric data segregated by sex. Nonparametric data (B) were
assessed for sex differences by multiple t tests using the Holm-Sidak method to correction for
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multiple comparisons. Statistical results for the 2-way ANOVA (parametric) or multiple t-test
(non-parametric) data are as follows. (A) Significant main effect of dose [F(1.555, 15.55)=7.64;
p=0.0075], but no significant main effect of sex or sex x dose interaction. (B) Significant main
effect of dose [F(2.344, 23.44)=6.151; p=0.0052], but no significant main effect of sex or sex x
dose interaction. (C) No significant differences between males and females for any ketoprofen
dose. (D) Significant main effect of dose [F(2.089, 20.89)=28.13; p<0.0001] and significant
main effect of sex [F(1, 10)=9.565; p=0.0114] with data collapsed across dose showing F>M
effect [Welch’s two-tailed t-test, p=0.0140], but no significant sex x dose interaction. Results of
ANOVA and power analysis data for each panel are shown in Supp. Tables III.I, II, & IV.
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Supplemental Figure III.IV. Effects of oxycodone and diazepam on nesting and locomotion
in the absence of the noxious stimulus. Abscissae: doses of oxycodone (A) or diazepam (B)
delivered SC in a volume of 10 ml/kg. Ordinates: nesting expressed as percent maximum nestlet
consolidation (A) and locomotor counts (B). All points represent the mean ± SEM for either 6
male (blue) or 6 female (pink). Filled symbols indicate a significant difference from vehicle
(Veh) as determined by RM one-way ANOVA and Dunnett’s post hoc test, p<0.05. # Indicates a
significant main effect of sex and $ indicates a significant sex x dose interaction as determined
by 2-way ANOVA and Holm-Sidak post hoc test for parametric data segregated by sex.
Statistical results for the 2-way ANOVA data are as follows. (A) Significant main effect of dose
[F(2.009, 20.09)=50.61; p<0.0001] and sex x dose interaction [F(4,40)=2.690; p=0.0447] with
further post hoc analysis showing no individual dose as significantly different between males and
females, and no significant main effect of sex. (B) Significant main effect of dose [F(2.532,
25.32)=10.13; p=0.0003] and main effect of sex [F(1, 10)=5.608; p=0.0394] with data collapsed
across sex showing a significant F>M effect [Welch’s two-tailed t-test, p=0.0395], but no
significant sex x dose interaction. Results of 1-way ANOVA and power analyses can be found in
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Supp. Tables III.I & II, and results of 2-way ANOVA and power analyses can be found in Supp.
Table III.V (oxycodone) and Supp. Table III.VI (diazepam).

Supplemental Tables
Supplemental Tables show one-way ANOVA results and power analyses for each drug in males
(Table III.I) and females (Table III.II) and two-way ANOVA results and power analyses for each
drug with sex included as a variable (Tables III.III-VII). Note that grimace was scored as a
nonparametric variable, and as a result, grimace data were not submitted to ANOVA or power
analyses. rather, grimace data were evaluated by multiple t-tests with corrections for multiple
comparisons using the Friedman statistic.
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Supplemental Table III.I
Supplemental Table 1. Summary of power analysis results from male one-way ANOVA data from Figures 1-4
IP Acid
Current Effect
Current
Sample Size:
Friedman statistic;
Male
F Statistic, p value
Size (Cohen's f)
Power
Power≥ 0.8
p value
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(1.435, 7.175)=43.55;
p=0.0002*
F(1.746, 8.732)=3.935;
p=0.0644
F(1.498, 7.491)=7.253;
p=0.022*
-

2.951

0.99

4

-

0.449

0.167

29

-

-

-

-

F=16.25; p<0.0001*

1.205

0.735

7

-

-

-

-

-

-

-

-

-

Ketoprofen
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting

Locomotor

F(1.244, 6.22)=3.31;
p=0.114
F(2.131, 10.66_=2.614;
p=0.1171
F(1.385, 6.924)=30.18;
p=0.0006*

-

0.813

0.363

13

0.509
-

0.227
-

21
-

F=14.37; p=0.0002*

2.458

0.999

4

-

F(1.861, 9.303)=0.7242;
p=0.5006

0.381

0.136

38

-

F(3.309, 16.55)=0.9731;
p=0.4358

0.441

0.226

20

-

-

Oxycodone
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(1.143, 5.714)=8.013;
p=0.0295*
F(1.825, 9.125)=1.905;
p=0.2041
F(1.487, 7.434)=1.977;
p=0.2048
F(1.695, 8.475)=17.2;
p=0.0013*
F(1.759, 8.796)=14.23;
p=0.0021*

-

1.267

0.675

8

0.617
-

0.288
-

16
-

F=10.86; p=0.0052*

0.628

0.263

18

-

1.856

0.989

4

-

1.687

0.976

5

-

-

Diazepam
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(2.148, 10.74)=2.668;
p=0.1122
F(1.868, 9.340)=1.68;
p=0.2377
F(1.746, 8.728)=2.229;
p=0.1674
F(1.303, 6.515)=36.03;
p=0.0005*
F(2.012, 10.06)=4.959;
p=0.0316*

0.731

0.43

11

0.579
-

0.262
-

18
-

0.667

0.321

15

2.683

1

4

0.996

0.676

8

F=12.00; p=0.0035*
-

Amphetamine
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(2.057, 12.34)=6.621;
p=0.0107*
F(1.754, 10.52)=0.5711;
p=0.5599
F(1.416, 7.079)=3.96;
p=0.0787
F(1.58, 7.9)=31.93;
p=0.0002*
F(1.304, 6.518)=8.839;
p=0.0188*

1.05

0.833

7

0.308
-

0.118
-

59
-

0.89

0.458

11

2.53

1

4

1.33

0.766

7

F=14.26; p=0.0026*
-
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Supplemental Table III.II
Supplemental Table 2. Summary of power analysis results from female one-way ANOVA data from Figures 1-4
IP Acid
Current Effect
Current
Sample Size:
Friedman statistic;
Female
F Statistic, p value
Size (Cohen's f)
Power
Power≥ 0.8
p value
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(2.086, 10.43)=7.84;
p=0.0079*
F(1.602, 8.01)=11.71;
p=0.0054*
F(1.94, 9.7)=12.36;
p=0.0022*
-

1.253

0.879

6

-

0.745

0.368

13

-

-

-

-

F=15.79; p<0.0001*

1.57

0.969

5

-

-

-

-

-

-

-

-

-

Ketoprofen
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting

Locomotor

F(1.227, 6.134)=5.717;
p=0.049*
F(2.234, 11.17)=3.673;
p=0.0558
F(2.252, 11.26)=7.963;
p=0.0060*

-

1.07

0.558

9

0.548
-

0.265
-

18
-

F=12.68; p=0.0012*

1.26

0.903

5

-

F(1.885, 9.427)=0.6267;
p=0.5463

0.353

0.124

43

-

F(2.131, 10.65)=0.3154;
p=0.749

0.25

0.089

76

-

-

Oxycodone
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(1.515, 7.574)=7.773;
p=0.0183*
F(1.93, 9.649)=1.849;
p=0.2093
F(1.525, 7.625)=2.187;
p=0.18
F(1.745, 8.723)=56.58;
p<0.0001*
F(2.512, 12.56)=4.063;
p=0.0366*

-

0.245

0.767

7

0.608
-

0.291
-

16
-

F=14.88; p<0.0001*

0.661

0.29

16

-

3.369

1

3

-

0.901

0.665

8

-

-

Diazepam
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(2.188, 10.94)=3.728;
p=0.0553
F(1.375, 6.873)=2.654;
p=0.1458
F(1.448, 7.239)=1.048;
p=0.3722
F(2.343, 11.72)=24.26;
p<0.0001
F(2.368, 11.84)=5.701;
p=0.0154*

0.863

0.575

9

0.731
-

0.323
-

15
-

0.157

0.157

31

2.202

1

3

1.068

0.798

7

F=11.00; p=0.0026*
-

Amphetamine
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor

F(1.366, 6.83)=11.05;
p=0.0101*
F(1.113, 5.564)=7.624;
p=0.0338*
F(2.069, 10.35)=1.972;
p=0.1876
F(1.58, 7.9)=31.93;
p=0.0002*
F(1.774, 8.87)=12.36;
p=0.0032*

1.488

0.867

6

0.124
-

0.643
-

8
-

0.327

0.327

15

2.53

1

4

1.572

0.957

5

F=11.40; p=0.0036*
-
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Supplemental Table III.III
Supplemental Table 3. Summary of power analysis results from two-way ANOVA data from Figures 1-4
IP Acid
Main Effect of
Current Effect Size
Current
Sample Size:
F Statistic, p value
Dose
(Cohen's f)
Power
Power≥ 0.8
Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor
Main Effect of
Sex

F(2.264, 22.64)=28.10;
p<0.0001*
F(2.361, 23.61)=14.28;
p=<0.0001*
F(1.655, 16.55)=16.90;
p=0.0002*
-

1.674

1

5

1.195

0.999

7

-

-

-

1.299

1

4

-

-

-

-

-

-

-

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,10)=4.337; p=0.0639

0.383

0.225

56

Grimace

F(1,10)=7.98^-5; p=0.993
-

0.0033
-

0.05
-

>100
-

Nesting + Acid

F(1, 10)=2.764; p=0.4942

0.297

0.154

92

Nesting
Locomotor

-

-

-

-

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3,30)=3.059; p=0.043*
F(3,30)=2.4; p=0.0901
F(3, 30)=1.086; p=0.37
-

0.553
0.487
0.33
-

0.657
0.538
0.719
-

16
19
14
-

Stretch + Acid
Rear + Acid

Stretch + Acid
Rear + Acid
Grimace
Nesting + Acid
Nesting
Locomotor
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Supplemental Table III.IV
Supplemental Table 4. Summary of power analysis results from two-way ANOVA data from Figures 1-4
Ketoprofen
Main Effect of
Current Effect Size
Sample Size:
F Statistic, p value
Current Power
Dose
(Cohen's f)
Power≥ 0.8
Stretch + Acid
Rear + Acid
Nesting + Acid

F(1.555, 15.55)=7.64;
p=0.0075*
F(2.344, 23.44)=6.151;
p=0.0052*
F(2.089, 20.89)=28.13;
p<0.0001*

0.874

0.844

12

0.785

0.881

11

1.677

1

4

Nesting

F(2.518, 25.18)=0.3046;
p=0.7877

0.551

0.986

7

Locomotor

F(2.972, 29.72)=0.8099;
p=0.4975

0.285

0.527

21

F Statistic, p value

Current Effect Size
(Cohen's f)

Current Power

Sample Size:
Power≥ 0.8

0.053

0.053

>100

0.184

0.089

>100

0.664

0.547

20

0.138

0.072

>100

0.097

0.061

>100

Current Effect Size
(Cohen's f)

Current Power

Sample Size:
Power≥ 0.8

0.202

0.121

94

0.139

0.082

>100

0.247

0.451

24

0.283

0.572

19

0.212

0.42

25

Main Effect of
Sex
Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Dose x Sex
Interaction

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor

F(1,10)=0.051;
p=0.8266
F(1,10)=0.5569;
p=0.4727
F(1, 10)=9.565;
p=0.0114*
F(1, 10)=0.7676;
p=0.4015
F(1, 10)=0.1317;
p=0.7242

F Statistic, p value
F(3,30)=0.4075;
p=0.749
F(3,30)=0.1885;
p=0.9034
F(3, 30)=0.6074;
p=0.6154
F(3, 30)=0.8008;
p=0.5032
F(5, 50)=0.4545;
p=0.808
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Supplemental Table III.V
Supplemental Table 5. Summary of power analysis results from two-way ANOVA data from Figures 1-4
Oxycodone
Main Effect of
Current Effect Size
Current
Sample Size:
F Statistic, p value
Dose
(Cohen's f)
Power
Power≥ 0.8
F(1.703, 17.03)=11.10;
p=0.0012*
F(2.215, 22.15)=2.194;
p=0.1310
F(1.556, 15.56)=3.909;
p=0.0509
F(2.009, 20.09)=50.61;
p<0.0001*
F(2.623, 26.23)=15.03;
p<0.0001*

1.053

1

5

0.469

0.909

10

0.6252

0.97

8

2.25

1

<3

1.226

1

4

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,10)=0.4191; p=0.5320

0.132

0.07

>100

F(1,10)=2.704; p=0.1311

0.3168

0.169

81

Nesting + Acid

F(1, 10)=4.764; p=0.0541

0.295

0.153

93

Nesting

F(1, 10)=3.525; p=0.0899

0.377

0.22

58

Locomotor

F(1, 10)=2.829; p=0.1235

0.395

0.236

53

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3,30)=0.1605; p=0.9220

0.127

0.142

87

F(3,30)=0.4788; p=0.6994

0.219

0.362

30

F(3, 30)=0.3449; p=0.7931

0.186

0.267

41

F(4, 40)=2.69; p=0.0447*

0.519

0.996

6

F(4, 40)=0.8627; p=0.4946

0.293

0.672

16

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Main Effect of
Sex
Stretch + Acid
Rear + Acid

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
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Supplemental Table III.VI
Supplemental Table 6. Summary of power analysis results from two-way ANOVA data from Figures 1-4
Diazepam
Main Effect of
Current Effect Size
Current
Sample Size:
F Statistic, p value
Dose
(Cohen's f)
Power
Power≥ 0.8
F(2.305,23.05)=5.979;
p=0.0062*
F(1.726,17.26)=3.896;
p=0.0454*
F(2.284, 22.84)=2.859;
p=0.0719
F(2.025, 20.25)=58.87;
p<0.0001*
F(2.532, 25.32)=10.13;
p=0.0003*

0.773

1

5

0.624

0.979

8

0.534

0.97

8

2.43

1

<3

1.226

1

4

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,10)=0.0307; p=0.8645

0.041

0.052

>100

F(1,10)=0.3356; p=0.5752

0.134

0.07

>100

F(1,10)=0.2021; p=0.6626

0.074

0.056

>100

F(1, 10)=2.945e-015;
p>0.9999

Cannot compute

Cannot
compute

Cannot compute

Locomotor

F(1, 10)=5.608; p=0.0394

0.393

0.235

53

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3,30)=0.1533; p=0.9268

0.123

0.137

91

F(3,30)=0.6254; p0.6042

0.25

0.143

24

Nesting + Acid

F(3, 30)=0.5411; p=0.6579

0.233

0.405

27

Nesting

F(3, 30)=0.7015; p=0.5586

0.265

0.512

21

Locomotor

F(4, 40)=0.6448; p=0.6338

0.078

0.085

>100

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Main Effect of
Sex
Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting

Stretch + Acid
Rear + Acid
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Supplemental Table III.VII
Supplemental Table 7. Summary of power analysis results from two-way ANOVA data from Figures 1-4
Amphetamine
Main Effect of
Current Effect Size
Current
Sample Size:
F Statistic, p value
Dose
(Cohen's f)
Power
Power≥ 0.8
F(2.041, 22.45)=8.319;
p=0.0019*
F(2.396, 26.36)=3.646;
p=0.0331*
F(2.046, 20.46)=5.158;
p=0.0149*
F(2.698, 28.98)=37.33;
p<0.0001*
F(1.659, 16.59)=20.42;
p<0.0001*

0.870

1

5

0.576

0.994

7

0.682

0.997

6

1.932

1

<3

1.428

1

4

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,11)=4.626; p=0.0546

0.422

0.285

46

F(1,11)=0.0625; p=0.8072

0.048

0.053

>100

Nesting + Acid

F(1, 10)=0.8445; p=0.3797

0.0904

0.059

>100

Nesting

F(1, 10)=0.1146; p=0.742

0.062

0.054

>100

Locomotor

F(1, 10)=4.242; p=0.0664

0.303

0.458

88

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3, 33)=2.120; p=0.1164

0.439

0.957

9

F(3, 33)=1.846; p=0.1580

0.41

0.726

10

Nesting + Acid

F(3, 30)=0.1433; p=0.9332

0.119

0.13

98

Nesting

F(4, 40)=1.262; p=0.3010

0.355

0.851

11

Locomotor

F(4, 40)=0.1765; p=0.9492

0.132

0.161
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Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Main Effect of
Sex
Stretch + Acid
Rear + Acid

Stretch + Acid
Rear + Acid
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Chapter IV: Behavioral Battery for Testing Candidate Analgesics in Mice. II. Effects of
Endocannabinoid Catabolic Enzyme Inhibitors and 9-Tetrahydrocannabinol
(Published in Journal of Pharmacology & Experimental Therapeutics: Diester et al., 2021,
PMCID: PMC8058502)
Introduction
Enhanced signaling of the endocannabinoid (eCB) system through inhibition of the main eCB
catabolic enzymes monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH)
has received increasing interest for development of candidate analgesics. This study compared
the effects of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH)
inhibitors with effects of the exogenous cannabinoid 1&2 receptor (CB1/2R) agonist ∆9tetrahydrocannabinol (THC) using the behavioral battery validated in Chapter III. The following
spectrum of six eCB catabolic enzyme inhibitors were evaluated: the MAGL-selective inhibitors
MJN110 and JZL184, the dual MAGL/FAAH inhibitors JZL195 and SA57, and the FAAHselective inhibitors URB597 and PF3845. The selectivity of these test compounds for inhibition
of MAGL and FAAH in mouse brain tissue is illustrated in Figure IV.I.

Materials and Methods
Subjects
Subjects were male and female ICR mice (Harlan Laboratories, Frederick, MD) that were 6-8
weeks old upon arrival to the laboratory. Males weighed 25-45g and females weighed 20-35g
throughout the study. Other details of housing and husbandry are identical to Chapter III.

Overview of Experimental Design
The goal of this study was to compare effects of the direct cannabinoid receptor agonist ∆9tetrahydrocannabinol (THC) and a series of endocannabinoid (eCB) catabolic enzyme inhibitors
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covering a broad spectrum of selectivity for MAGL vs FAAH on a battery of pain-stimulated,
pain-depressed, and pain-independent behaviors in mice as described in Chapter III (Diester et
al., 2021a). Pain-related behaviors were elicited by intraperitoneal (IP) injection of dilute lactic
acid, and antinociception dose-effect curves for each test drug were determined in two groups of
mice: (a) one to assess drug effects on IP acid-induced changes in stretching, facial grimace, and
rearing, and (b) a second to assess drug effects on IP acid-induced depression of nesting. Two
additional groups were used to test effects of each test drug on two pain-independent behaviors:
(a) one group to assess control nesting in the absence of the IP acid noxious stimulus, and (b) a
second group to assess locomotion in the absence of the noxious stimulus. To further probe the
effects observed with the MAGL-selective inhibitor MJN110, two additional nesting groups
were used to assess time course and sensitivity to cannabinoid receptor antagonists. Each group
consisted of 12 mice (6 males, 6 females) to provide adequate power for detection of drug effects
and permit exploratory analysis of sex differences as described in Chapters II and III (Diester et
al., 2019). In general, all mice in a given group received all doses of single drug, dose order was
randomized across mice using a Latin-square design, and tests were conducted once per week in
each mouse. Doses for each drug were varied in 0.5 or 1.0 log-unit increments across a ≥10-fold
dose range with the intent of progressing from low doses that produced little or no effect to high
doses that produced either significant antinociception on one or more endpoints of pain-related
behavior or significant changes in nesting or locomotor activity as pain-independent behaviors.
The only exception was for eCB catabolic enzyme inhibitors tested in locomotor studies, in
which each group of mice was used to test vehicle and two eCB catabolic enzyme inhibitors at
the highest dose tested in antinociception studies. Data were analyzed to evaluate the degree to
which each test drug alleviated pain-related behaviors at doses below those that altered painindependent behaviors.
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Test drug doses, pretreatment times, and supporting references were as follows: the cannabinoid
receptor1/2 direct agonist ∆9-tetrahydrocannibinol, 1.0-30 mg/kg, 30 min (Grim et al., 2017); the
selective MAGL>>FAAH inhibitors (Figure IV.I) MJN110, 0.1-10 mg/kg, 2 hours (Niphakis et
al., 2013; Ignatowska-Jankowska et al., 2015a) and JZL184, 3.2-32 mg/kg, 2 hours (Long et al.,
2009a; Ignatowska-Jankowska et al., 2015a; Wiebelhaus et al., 2015); the dual MAGL=FAAH
inhibitor (Figure IV.I) JZL195, 3.2-32 mg/kg, 2 hours (Long et al., 2009c; Anderson et al., 2014;
Hruba et al., 2015); the dual MAGL<FAAH inhibitor (Figure I) SA57, 1.0-10 mg/kg, 2 hours
(Niphakis et al., 2012; Owens et al., 2016), and the selective MAGL<<FAAH inhibitors (Figure
IV.I) URB597, 1.0-10 mg/kg, 60 min (Kinsey et al., 2009; Naidu et al., 2009; Naidu et al., 2010)
and PF3845, 1.0-32 mg/kg, 2 hours (Booker et al., 2012; Wiebelhaus et al., 2015).

Behavioral Procedures
Stretching/Grimace/Rearing Procedure. Studies of stretching, grimace, and rearing were
conducted using methods identical to those described in Chapter III. A different group of mice
was used to test each drug.

Nesting Procedure. Dose-effect studies to evaluate effects of each drug on nesting in the
presence or absence of the IP acid noxious stimulus were conducted using methods identical to
those described in Chapter III. Two different groups of mice were used to test each drug, one
group for dose-effect studies with IP acid, and a second group to test each drug without IP acid.
Additionally, time course and antagonism studies were conducted in two additional groups of
mice. For time course studies, 1.0 mg/kg MJN110 was administered at different pretreatment
times ranging from 10 min to 24 hr, and the sequence of pretreatment times was presented in a
Latin-square order across mice. For antagonism studies, mice received a SC pretreatment of
vehicle, the CB1R antagonist rimonabant (3 mg/kg) or the CB2R antagonist SR144528 (3 mg/kg)
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10 minutes before 1.0 mg/kg MJN110 or vehicle, and the nesting session commenced 2hr later.
Again, these treatments were administered in a Latin-square design. Antagonist doses and
pretreatment times were based on previous studies (Booker et al., 2012; Ignatowska-Jankowska
et al., 2015a).

Locomotor Procedure. Locomotor activity studies were conducted using general procedures
identical to those described in Chapter III. One group of mice was used to test a range of THC
doses. Three additional groups were used to test the eCB enzyme inhibitors, with vehicle and a
single high dose of each of two eCB enzyme inhibitors tested in each group.

Data Analysis
Data analysis was identical to that described in Chapter III.

Drugs
Lactic acid (Fisher Scientific, Hampton, NH) was diluted in sterile water and administered IP.
∆9-tetrahydrocannibinol (THC, 20 mg/m in ethanol), JZL184, URB597, and PF3845 were
provided by the National Institute on Drug Abuse Supply Program (Bethesda, MD). MJN110
and SA57 were kindly provided by Dr. Michah Niphakis, currently at Lundbeck La Jolla
Research Center. JZL195 was purchased from Tocris/Bio-Techne (Minneapolis, MN). The CB1R
antagonist rimonabant (SR141716A) (rimonabant) and CB2R antagonist SR144528, were
provided by the National Institute on Drug Abuse Supply Program (Bethesda, MD). All drugs
were prepared in a vehicle of 1:1:18 ethanol, emulphor (Alkamuls-620, Sanofi-Aventis,
Bridgewater, NJ), and saline. In general, final concentrations were prepared as clear solutions;
however, final concentrations of JZL184 (≥ 1.0 mg/ml) and JZL195 (≥ 3.2 mg/ml) were
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suspensions thoroughly shaken immediately before preparation of syringes and injection. All test
drugs and antagonists were administered SC in volumes of 0.1 to 0.9 ml.

Results
Overview of Data Presentation
Figures IV.II-V show antinociception dose-effect curves for each drug on each endpoint of IP
acid-induced behaviors (stimulation of stretching and facial grimace in left panels, depression of
rearing and nesting in right panels). Figure IV.VI shows effects of each compound on nesting
and locomotion in the absence of the noxious stimulus to determine IP acid-independent effects
of each test drug. Figure IV.VII compares the potencies of each drug to produce antinociceptive
effects vs. IP acid-independent effects, in which an ideal drug would produce antinociception at
doses below those that produce IP acid-independent effects. Figure IV.VIII shows the time
course, CB1/2R antagonism, and sex differences for the MAGL-selective inhibitor MJN110.
ANOVA results and power analyses for pooled data across sexes are presented in Table IV.I.
Supplemental Tables IV.I-II show ANOVA results for data segregated by sex, and Supplemental
Tables IV.III-IX show results from 2-way ANOVA examining sex as a determinant of effects for
each test drug on each endpoint. For any significant main effects of sex or sex x dose
interactions, additional supplemental figures are added and denoted in the results below.

Effects of ∆9-THC
Figure IV.II shows that the direct CB1/2 receptor agonist THC significantly decreased IP acidstimulated stretching (3.2-10 mg/kg) and facial grimace (10 mg/kg), but failed to alter IP acidinduced depression of either rearing or nesting. Figure IV.VI shows that THC significantly
decreased both nesting and locomotion in the absence of the noxious stimulus at 30 mg/kg. Thus,
THC displayed a 0.5-1.0 log higher potency to produce antinociception compared to general
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motor effects in the absence of the noxious stimulus, but only for IP acid-stimulated behaviors,
as it had no significant effect for either IP acid-depressed behavior (Figure IV.VII). Additionally,
there were no main effects of sex or dose x sex interactions for any endpoint (Supp. Table
IV.III).

Effects of MAGL>>FAAH-selective Inhibitors
Figure IV.III shows antinociceptive effects of the MAGL>>FAAH-selective inhibitors MJN110
and JZL184. MJN110 significantly decreased both IP acid stimulated stretching and grimace at
1.0 mg/kg, but only stretching was significantly decreased at 3.2 mg/kg. MJN110 did not alter IP
acid-induced depression of rearing, but doses of 0.32-3.2 mg/kg attenuated IP acid-induced
depression of nesting. No dose of MJN110 up to 10 mg/kg altered nesting in the absence of the
noxious stimulus, and 3.2 mg/kg did not alter locomotion (Figure IV.VI). Thus, MJN110
produced significant antinociception for three of the four IP acid-induced behaviors at doses that
did not alter IP acid-independent behaviors (Figure IV.VII). IP acid-depressed nesting was the
only endpoint that showed a significant effect of sex as a determinant of MJN110 effects, where
1-way ANOVAs segregated by sex showed a significant effect for females and not males, and 2way ANOVA showed a main effect of sex (females > males) (Supp. Figure IV.I, Supp. Tables
IV.I, II, & IV). Additional evaluation of sex as a determinant of MJN110 effects on IP acidinduced depression of nesting is described below.

JZL184 did not significantly alter IP acid-stimulated stretching at any dose, but 32 mg/kg
JZL184 significantly decreased facial grimace. No dose significantly altered IP acid-induced
depression of rearing, but 3.2 and 32 mg/kg attenuated depression of nesting. No dose up to 32
mg/kg of JZL184 altered nesting in the absence of IP acid, and 32 mg/kg did not significantly
affect locomotion (Figure IV.VI). Thus, JZL184 produced antinociception for one IP acid73

stimulated behavior (facial grimace) and one IP acid-depressed behavior (nesting) at doses that
did not significantly alter IP acid-independent behaviors (Figure IV.VII). Two-way ANOVA of
sex differences showed main effects of sex for JZL184 effects on IP acid-stimulated stretching,
IP acid-induced depression of rearing (data collapsed across dose show males > females), and
nesting in the absence of the noxious stimulus, but there were no sex x dose interactions on any
endpoint (Supp. Table IV. IV., Supp. Figure IV.I).

Effects of Dual MAGL and FAAH Inhibitors
Figure IV.IV shows antinociceptive effects of the dual MAGL≅FAAH inhibitor JZL195 and the
dual MAGL<FAAH inhibitor SA57. JZL195 significantly blocked IP acid-stimulated stretching
at 32 mg/kg but did not block acid-stimulated facial grimace. Although IP acid-depressed rearing
was not affected, IP acid-depressed nesting was attenuated at 32 mg/kg. No dose of JZL195 up to
32 mg/kg affected nesting in the absence of IP acid, and 32 mg/kg did not alter locomotor
behavior (Figure IV.VI). Thus, JZL195 had antinociceptive effectiveness on one IP acidstimulated behavior (stretching) and one IP acid-depressed behavior (nesting) at doses that did
not produce effects on acid-independent behaviors (Figure IV.VII). In analysis of sex as a
determinant of JZL195 effects, there was a main effect of sex in locomotion (females > males),
but there were no sex x dose interactions on any endpoint (Supp. Table IV.VI, Supp. Figure
IV.II).

SA57 also significantly blocked IP acid-stimulated stretching (10 mg/kg) but not facial grimace.
SA57 did not alter IP acid-depressed rearing, but it significantly attenuated IP acid-depressed
nesting. No dose of SA57 significantly affected nesting or locomotion in the absence of the
noxious stimulus (Figure IV.VI). Thus, like JZL195, SA57 blocked IP acid-stimulated stretching
and attenuated IP acid-induced depression of nesting at doses that did not significantly alter
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nesting or locomotion when administered alone (Figure IV.VII). For SA57, there was a
significant main effect of sex for stretching (females < males) and locomotion (females > males),
but there were no sex x dose interactions on any endpoint (Supp. Table IV.VII, Supp. Figure
IV.II).

Effects of MAGL<<FAAH-selective Inhibitors
Figure IV.V shows the antinociceptive effectiveness of the MAGL<<FAAH-selective inhibitors
URB597 and PF3845. URB597 did not significantly block either IP acid-stimulated behavior at
any dose tested, and it also did not alter IP acid-induced depression of rearing. It attenuated IP
acid-depressed nesting at 10 mg/kg, and no dose of URB597 significantly affected nesting or
locomotion when administered in the absence of IP acid (Figure IV.VI). Thus, URB597 showed
antinociceptive effectiveness for only one IP acid-depressed behavior (nesting) at a dose that did
not alter nesting or locomotion in the absence of the noxious stimulus (Figure IV.VII). Analysis
of sex as a determinant of URB597 effects showed no significant effects of sex (Supp. Table
IV.VII).

PF3845 did not produce antinociception on any endpoint. The highest dose of 32 mg/kg
significantly decreased nesting in the absence of the noxious stimulus and produced a
nonsignificant trend toward reduced locomotion (Figure IV.VI). Thus, PF3845 did not produce
antinociceptive effects up to doses that decreased behavior in the absence of the noxious stimulus
(Figure IV.VII). There were no sex differences for any endpoints (Supp. Table IV.IX).

Time course, CB1/2R Antagonism, and Sex Differences for MJN110 Effects
Follow-up studies in the assay of IP acid-depressed nesting were conducted with 1.0 mg/kg
MJN110 because it was the eCB catabolic enzyme inhibitor that produced antinociception on the
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greatest number of endpoints. Results are shown in Figure 8, and statistical results are reported
in the figure legend. In time-course studies, MJN110 significantly attenuated IP acid-induced
depression of nesting with pretreatment times from 40 min to 6 hr. In antagonism studies,
MJN110 antinociception was significantly blocked by the CB1R antagonist but not by the CB2R
antagonist SR144528. The effects of 2 hr pretreatment with vehicle and 1.0 mg/kg MJN110 were
determined in a total of 18 male and 18 female mice from the original study (Figure IV.IIID) and
from the two follow-up studies (2hr pretreatment for time-course study, vehicle pretreatment for
antagonism study). Figure IV.VIIIC compares effects of vehicle and 1.0 mg/kg MJN110 for all
these male and female mice. Two-way ANOVA indicated only significant main effects of dose
(1.0 mg/kg MJN110>vehicle) and sex (collapsed data across dose show females > males); the
dose x sex interaction approached but did not reach the criterion for statistical significance.

Discussion
There were three main findings in this study. First, THC significantly attenuated IP acidstimulated stretching and facial grimace at doses that did not produce general motor disruption,
but THC did not alleviate IP acid-induced depression of either rearing or nesting. Second, for the
eCB catabolic enzyme inhibitors, the MAGL-selective inhibitor MJN110 produced
antinociception without motor disruption on three of four endpoints, including significant
alleviation of IP acid-induced depression of nesting, whereas the FAAH-selective inhibitor
PF3845 failed to produce antinociception on any endpoint up to a dose that produced motor
disruption. Other eCB catabolic enzyme inhibitors produced effects between these extremes.
Lastly, time course and antagonism studies for MJN110 in the assay of IP acid-induced
depression of nesting indicated a long duration of antinociceptive action (40 min to 6 hrs) and
mediation by CB1R but not CB2R. Overall, these results support further consideration of MAGLselective inhibitors, especially MJN110, as candidate analgesics.
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Figures

Figure IV.I. Selectivity of test compounds for the main endocannabinoid catabolic enzymes
monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) based on
competitive substrate binding and activity-based protein profiling (ABPP) assays. Data
were obtained from the literature as cited below, with competitive substrate binding used for
calculating selectivity if available, and ABPP if no substrate binding data were available. All
data are from assays using mouse brain tissue. No data for MAGL binding could be found for
either endpoint for PF3845, which is considered to be a highly selective FAAH inhibitor that
would fall at the far left of the figure. As a result, no selectivity ratio could be calculated for this
inhibitor. PF3845: Ahn et al., 2009 (main paper denoting FAAH selectivity); URB597: Kathuria
et al., 2003; SA57: Niphakis et al., 2012; JZL195: Long et al., 2009; JZL184: Long et al., 2009;
MJN110: Niphakis et al., 2013.
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Figure IV.II. Effects of △9-tetrahydrocannabinol (THC) on IP acid-induced stretching,
facial grimace, rearing and nesting behaviors in male and female mice. Abscissae: dose of
THC delivered SC in mg/kg (log scale). Ordinates: number of stretches (A), grimace score (B),
number of rears (C), and nesting expressed as percent maximum nestlet consolidation (D). Each
point shows ± SEM for 12 mice (6 male, 6 female). Filled symbols indicate a significant
difference from vehicle (Veh) as determined by RM one-way ANOVA and Dunnett’s post hoc
test for parametric data (A, C & D) or by Friedman’s and Dunn’s post hoc test for nonparametric
data (B), p<0.05. Results of ANOVA and power analysis data for each panel are shown in Table
IV.1.
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Figure IV.III. Effects of the MAGL-selective inhibitors MJN110 and JZL184 on IP-acid
induced stretching, facial grimace, rearing and nesting behaviors in male and female mice.
Abscissae: doses of MJN110 or JZL184 in mg/kg (log scale). Ordinates: number of stretches (A),
grimace score (B), number of rears (C), and nesting expressed as percent maximum nestlet
consolidation (D). Other details as in Figure IV.II.
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Figure IV.IV. Effects of the dual MAGL and FAAH inhibitors JZL195 and SA57 on IP
acid-induced stretching, facial grimace, rearing and nesting behaviors in male and female
mice. Abscissae: doses of JZL195 or SA57 in mg/kg (log scale). Ordinates: number of stretches
(A), grimace score (B), number of rears (C), and nesting expressed as percent maximum nestlet
consolidation (D). Other details as in Figure IV.II.
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Figure IV.V. Effects of the FAAH-selective inhibitors UR597 and PF3845 on IP acidinduced stretching, facial grimace, rearing and nesting behaviors in male and female mice.
Abscissae: doses of UR597 and PF3845 in mg/kg (log scale). Ordinates: number of stretches (A),
grimace score (B), number of rears (C), and nesting expressed as percent maximum nestlet
consolidation (D). Other details as in Figure IV.II.
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Figure IV.VI. Effects of endocannabinoid catabolic enzyme inhibitors and △9tetrahydrocannabinol (THC) on nesting and locomotor behaviors in male and female mice
in the absence of the IP acid noxious stimulus. Abscissae: doses of endocannabinoid catabolic
inhibitors or THC in mg/kg. Doses of endocannabinoid catabolic enzyme inhibitors for
locomotor studies were the highest tested in antinociception assays, whereas THC (inset in B)
was tested across a range of doses. Ordinates: nesting expressed as % maximum nestlet
consolidation (A), and locomotor counts (B). Each point shows ± SEM for 12 mice (6 male, 6
female). Filled symbols in Panel A and the asterisk in Panel B inset indicate a significant
difference from vehicle (Veh) as determined by RM one-way ANOVA and Dunnett’s post hoc
test, p<0.05. Results of ANOVA and power analysis data for each panel are shown in Table
IV.I.
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Figure IV.VII. Drug profiles for comparison of potency to produce antinociceptive effects
on IP acid-stimulated and IP acid-depressed behaviors versus general behavioral
disruption. Abscissae: Drug dose in mg/kg (log scale). Boxed letters (S, G, R, N) denote the
dose range over which each drug significantly attenuated IP acid-induced stimulation of
stretching (S) or facial grimace (G) or IP acid-induced depression of rearing (R) or nesting (N).
In each panel, boxes for pain-stimulated behaviors (PSB) and pain-depressed behaviors (PDB)
are shown above and below the dose axis, respectively. The gray zone at the right of edge of
panels for THC and PF3845 show doses that produced motor disruption in assays of nesting
and/or locomotion in the absence of the IP acid noxious stimulus. For the other drugs, no tested
dose altered nesting or locomotion in the absence of the noxious stimulus, and no gray zone is
indicated. The test compounds for inhibition of the two main endocannabinoid degradative
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enzymes MAGL and FAAH are organized by their selectivity, going from MAGL-selective to
FAAH-selective, as indicated by the selectivity arrows on the right.
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Figure IV.VIII. Effects of time, cannabinoid receptor (CBR) antagonism, and sex on
MJN110 attenuation of IP acid-induced depression of nesting in male and female mice.
Abscissae: (A) Pre-treatment time of 1.0 mg/kg MJN110 before administration of 0.32% IP acid,
(B) treatments for assessment of the CB1R-selective antagonist rimonabant (3 mg/kg) and the
CB2R-selective antagonist SR144528 (3 mg/kg), and (C) effect of sex on 1.0 mg/kg MJN110
antinociception, all delivered SC in a volume of 10 ml/kg. Ordinates: nestlet consolidation
expressed as percent maximal nestlet consolidation. An asterisk (*) indicates a significant
difference from or Veh+Acid (A,C) or from Antagonist Veh:MJN110 (B), as determined by RM
one-way ANOVA and Dunnett’s post hoc test (A,B) or two-way ANOVA and Holm-Šídák post
hoc test (C), p<0.05. Statistical results are as follows: (A) Significant main effect of time
[F(2.738, 30.12)=7.367; p=0.001]. (B) Significant main effect of treatment [F(3.931,
43.24)=7.84; p<0.0001]. (C) # Indicates that there were significant main effects of treatment
[F(1, 34)=53.41; p<0.0001], and sex [F(1, 34)=7.661; p=0.0091] but no treatment x sex
interaction [F(1, 34)=3.605; p=0.0661].
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Table IV.I: Summary of power analysis results from pooled one-way ANOVA data from Figures IV.I-IV
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Supplemental Figure IV.I. Endpoints showing a main effect of sex in studies with JZL184 (A,B,C) and
MJN110 (D). Abscissae: doses of JZL184 or MJN110 in mg/kg (log scale). Ordinates: number of stretches (A),
number of rears (B), and nesting expressed as percent maximum nestlet consolidation (C,D). All points
represent the mean ± SEM for either 6 male (blue, squares) or 5-6 female (grey, circles). # Indicates a
significant main effect of sex as determined by a 2-way ANOVA and Holm-Sidak post hoc test, with data
collapsed across dose showing a significant M>F effect for JZL184 attenuation of IP acid-induced depression of
rearing [Welch’s two-tailed t-test, p=0.0157] (B) and MJN110 attenuation of IP acid-induced depression of
nesting [Welch’s two-tailed t-test, p=0.0168] (D). All other statistical results are shown in Supplemental Tables
IV.IV and IV.V.
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Supplemental Figure IV.II. Sex differences with the dual MAGL and FAAH eCB catabolic enzyme
inhibitors JZL195 and SA57 on IP acid-stimulated stretching and locomotion in the absence of IP acid.
Abscissae: doses of JZL195 or SA57 in mg/kg (log scale). Ordinates: number of stretches (A) and locomotion
in the absence of the noxious stimulus (B). All points represent the mean ± SEM for either 6 male (blue,
squares) or 6 female (grey, circles). # Indicates a significant main effect of sex as determined by a 2-way
ANOVA and Holm-Sidak post hoc test for parametric data segregated by sex, with statistical results shown in
Supplemental Table IV.VI and IV.VII.
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Supplemental Tables
Supplemental Tables show one-way ANOVA results and power analyses for each drug in males (Table IV.I)
and females (Table IV.II) and two-way ANOVA results and power analyses for each drug with sex included as
a variable (Tables IV.III-IX). Note that grimace was scored as a nonparametric variable, and as a result, grimace
data were not submitted to ANOVA or power analyses. rather, grimace data were evaluated by multiple t-tests
with corrections for multiple comparisons using the Friedman statistic.

Supplemental Table IV.I. Summary of power analysis results from male one-way ANOVA data from Figures
IV.II-VI.
Supplemental Table IV.I
Male &
Female
Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor

F Statistic, p value
F(1.439, 7.194)=7.872;
p=0.0198*
F(1.391,
6.957)=0.2079;
p=0.7400
F(1.707,
8.536)=0.9699;
p=0.4032
F(1.614, 8.071)=21.05;
p=0.0009*
F(1.772, 8.861)=7.171;
p=0.0157*

△9-Tetrahydrocannabinol
Current Effect
Current
Sample Size:
Size (Cohen's f)
Power
Power≥ 0.8

Friedman statistic;
p value

1.260

0.755

7

-

0.204

0.07

>100

-

-

-

-

0.44

0.16

31

-

2.05

0.996

4

-

1.197

0.791

7

-

MJN-110
Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor
Stretch +
Acid

F(2.011, 10.06)=4.235;
p=0.0462*
F(2.013,
10.07)=0.3134;
p=0.7392
F(1.488, 7.442)=2.724;
p=0.1355
F(1.640,
8.200)=0.6485;
p=0.5184
F(1.443, 7.215)=1.244;
p=0.3249
F(2.766, 13.83)=1.678;
p=0.2192

-

0.921

0.604

9

0.25
-

0.087
-

>100
-

0.739

0.346

40

-

0.36

0.121

46

-

0.498

0.178
JZL-184

28

0.579

0.333

14

-

-

-

89

Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor
Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting

Locomotor

Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor

Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor

Stretch +
Acid

F(1.916,
9.578)=0.4136;
p=0.6643
F(2.482, 12.41)=4.792;
p=0.0235*
F(1.865,
9.325)=0.3369;
p=0.7081
F(1.443, 7.215)=1.244;
p=0.3249
F(2.090, 10.45)=5.664;
p=0.0207*
F(1.365,
6.825)=0.2338;
p=0.7162
F(1.526, 7.632)=3.631;
p=0.0852
F(1.256,
6.281)=0.4887;
p=0.5516
F(1.367,
6.833)=0.5788;
p=0.5242
F(1.712, 8.561)=1.295;
p=0.3156
F(1.301, 6.507)=1.345;
p=0.3028
F(7.77, 8.848)=2.076;
p=0.1837
F(1.117, 5.583)=2.343;
p=0.1816
F(1.367,
6.833)=0.5788;
p=0.5242
F(1.609,
8.043)=0.2694;
p=0.7249
F(1.088, 5.44)=1.249;
p=0.317
F(1.475, 7.376)=4.29;
p=0.0658
F(1.0, 5.0)=1.0;
p=0.3632
F(1.913, 9.563)=3.596;
p=0.0699
F(2.376,
11.88)=0.7164;
p=0.5311

0.287
-

0.098
-

>100
-

0.978

0.737

7

-

0.259

0.088

78

-

0.498

0.178
JZL-195

28

1.06

0.75

7

0.217
-

0.072
-

>100
-

0.853

0.448

11

0.323

0.095

72

0.341

0.106
SA-57

57

0.509

0.201

24

0.519
-

0.18
-

27
-

0.644

0.304

16

0.684

0.255

19

0.341

0.106
URB-597

57

0.232

0.078

>100

0.157
-

0.06
-

>100
-

0.927

0.502

10

0.448

0.13

43

0.847

0.513
PF-3845

10

0.378

0.149

33

-

-

-

-

-

-

-

-

-

90

Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor

F(1.625,
8.127)=0.3943;
p=0.6458
F(1.626, 8.131)=1.302;
p=0.3138
F(1.334, 6.668)=13.67;
p=0.0064*
F(1.913, 9.563)=3.596;
p=0.0699

0.378
-

0.128
-

42
-

0.511

0.197

24

0.511

0.197

24

0.847

0.513

10

-

Supplemental Table IV.II. Summary of power analysis results from female one-way ANOVA data from
Figures IV.II-VI.
Supplemental Table IV.II
△9-Tetrahydrocannabinol
Male &
Female

Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid

F Statistic, p value

Current Effect
Size (Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Friedman statistic;
p value

F(1.956, 9.780)=4.514;
p=0.0415*

0.150

0.063

>100

-

F(1.722,
8.608)=0.5581;
p=0.5669

0.333

0.112

51

-

-

-

-

-

F(1.577, 7.883)=1.043;
p=0.3775

0.457

0.164

30

-

Nesting

F(1.298, 6.492)=31.63;
p=0.0007*

2.521

0.999

4

-

Locomotor

F(2.353, 11.77)=4.574;
p=0.0296*

0.957

0.697

7

-

MJN-110
Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid

F(2.378, 11.89)=4.829;
p=0.025*
F(1.722,
8.608)=0.5581;
p=0.5669
F(2.581, 12.91)=6.962;
p=0.0062*

0.982

0.725

7

-

0.418
-

0.156
-

32
-

1.33

0.957

5

-

-

Nesting

F(1.647, 8.236)=2.867;
p=0.1185

0.757

0.385

13

Locomotor

F(1.230, 6.15)=0.962;
p=0.3855

0.291

0.088

83

-

JZL-184
Stretch +
Acid
Rear + Acid
Grimace

F(2.509, 10.04)=1.801;
p=0.2127
F(1.390,
5.559)=0.5091;
p=0.5635
-

0.67

0.314

12

-

0.67
-

0.218
-

17
-

91

Nesting +
Acid

F(1.760, 8.800)=1.370;
p=0.2988

Nesting
Locomotor

0.523

0.214

22

-

F(2.097, 10.49)=0.597;
p=0.5755

0.346

0.126

42

-

F(1.230, 6.15)=0.962;
p=0.3855

0.291

0.088

83

-

JZL-195
Stretch +
Acid

F(2.203,
11.01)=0.9629;
p=0.4198

0.438

0.18

26

F(1.770,
8.850)=0.5697;
p=0.5652
-

0.337
-

0.114
-

49
-

F(2.316, 11.58)=1.035;
p=0.3962

0.456

0.165

30

Nesting

F(1.618, 8.091)=1.041;
p=0.3792

0.456

0.165

30

Locomotor

F(1.560, 7.801)=2.19;
p=0.1784

0.662

0.296

16

Rear + Acid
Grimace
Nesting +
Acid

-

-

-

SA-57
Stretch +
Acid
Rear + Acid
Grimace
Nesting +
Acid
Nesting
Locomotor

F(1.631, 8.153)=9.812;
p=0.0084*

1.399

0.879

6

F(1.768,
8.840)=0.9036;
p=0.4273
-

0.425
-

0.155
-

32
-

F(1.532, 7.659)=2.968;
p=0.1175

0.562

0.222

22

F(1.0, 5.0)=2.5;
p=0.1747

0.707

0.252

19

F(1.560, 7.801)=2.19;
p=0.1784

0.662

0.296

16

-

-

URB-597
Stretch +
Acid

F(1.728, 8.641)=1.530;
p=0.2668

0.553

0.231

21

F(1.301,
6.504)=0.2285;
p=0.7097
-

0.215
-

0.071
-

>100
-

Nesting +
Acid

F(1.257,
5.027)=0.6671;
p=0.4858

0.408

0.106

43

Nesting

F(1.0, 5.0)=1.0;
p=0.3632

0.448

0.13

43

F(1.93, 9.651)=0.6194;
p=0.5529

0.352

0.124

43

Rear + Acid
Grimace

Locomotor

-

-

PF-3845

92

Stretch +
Acid
Rear + Acid
Grimace

F(1.693,
8.464)=0.4552;
p=0.6181
F(1.559,
7.793)=0.2239;
p=0.7519
-

0.301

0.099

63
-

0.212
-

0.073
-

>100
-

F(1.492,
7.460)=0.9055;
p=0.4147

0.425

0.144

36

Nesting

F(2.113, 10.57)=5.743;
p=0.0195*

1.07

0.761

7

Locomotor

F(1.93, 9.651)=0.6194;
p=0.5529

0.352

0.124

43

Nesting +
Acid

-

Supplemental Table IV.III. Summary of power analysis results from two-way ANOVA data from
Figures IV.II.
Supplemental Table IV.III
△9-Tetrahydrocannabinol
F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(2.276, 22.76) = 11.11;
p=0.0003*

1.050

1

4

Rear + Acid

F(1.42, 14.20)=0.3329;
p=0.6496

0.182

0.178

72

Nesting + Acid

F(2.468, 24.68)=1.91;
p=0.1622

1.294

1

4

Nesting

F(2.362, 23.62)=48.89;
p<0.0001*

2.211

1

<3

Locomotor

F(2.353, 23.53)=10.89;
p=0.0003*

1.312

1

4

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,10)=0.0089; p=0.9267
F(1,10) = 1.310; p=0.2791
F(1, 10)=0.032; p=0.8615

0.146
0.19
0.0744

0.075
0.092
0.0563

>100
>100
>100

F(1, 10)=1.109; p=0.3172
F(1,10)=2.674; p=0.1331

0.167
0.293

0.082
0.15

>100
89

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3,30)=0.3275; p=0.8054

0.182

0.257

43

F(3,30)=0.1170; p=0.9495
F(4, 40)=0.08749; p=0.9858

0.11
0.094

0.118
0.102

>100
>100

F(4 40)=1.878; p=0.1331
F(3, 30)=0.2928; p=0.8302

0.433
0.17

0.964
0.228

8
49

Main Effect of
Dose

Main Effect of
Sex
Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Dose x Sex
Interaction

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
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Supplemental Table IV.IV. Summary of power analysis results from two-way ANOVA for MJN110
from Figure IV.III.
Supplemental Table 4
MJN-110
F Statistic, p value

Current Effect
Size (Cohen's f)

Current Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(2.651, 26.51)=6.940;
p=0.0019*

0.834

1

5

Rear + Acid

F(2.063, 20.36)=0.9685;
p=0.3979

0.311

0.507

22

F(2.32, 23.30)=6.99;
p=0.003*

0.837

1

5

Nesting

F(1.913, 19.13)=2.748;
p=0.0912

0.525

0.922

8

Locomotor

F(1.440, 14.10)=1.986;
p=0.1788

0.446

0.796

13

F Statistic, p value

Current Effect
Size (Cohen's f)

Current Power

Sample Size:
Power≥ 0.8

F(1, 10)=4.719; p=0.0550

0.33

0.179

75

F(1,10)=1.851; p=0.2035

0.234

0.114

>100

Nesting + Acid

F(1,10)=8.235; p=0.0167*

0.461

0.306

40

Nesting

F(1, 10)=1.359; p=0.2708

0.209

0.101

>100

Locomotor

F(1, 10)=0.6880; p=0.4262

0.301

0.156

89

Dose x Sex
Interaction

F Statistic, p value

Current Effect
Size (Cohen's f)

Current Power

Sample Size:
Power≥ 0.8

F(4, 40)=2.006; p=0.1121

1.415

1

<3

F(4,40)=0.5332; p=0.7121

0.232

0.451

24

Nesting + Acid

F(4, 40)=1.842; p=0.1398

0.43

0.961

8

Nesting

F(4, 40)=0.839; p=0.5088

0.289

0.658

16

F(2, 20)=0.08436;
p=0.9194

0.092

0.092

>100

Main Effect of
Dose

Nesting + Acid

Main Effect of
Sex
Stretch + Acid
Rear + Acid

Stretch + Acid
Rear + Acid

Locomotor

94

Supplemental Table IV.V. Summary of power analysis results from two-way ANOVA for JZL184
from Figure IV.III.
Supplemental Table IV.V
JZL-184
F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(3.392, 30.53)=2.732;
p=0.0549

0.551

0.991

7

Rear + Acid

F(1.942, 17.48)=0.3787;
p=0.6843

0.204

0.217

49

Nesting + Acid

F(2.623, 26.23)=5.031;
p=0.0089*

0.71

1

6

Nesting

F(2.037, 20.39)=0.5950;
p=0.5639

0.234

0.351

32

Locomotor

F(1.440, 14.10)=1.986;
p=0.1788

0.446

0.796

13

Main Effect of
Sex

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(1, 9)=5.388; p=0.0454*

2.788

1

5

Nesting + Acid

F(1, 9)=9.663; p=0.0125*
F(1, 10)=0.5152; p=0.4893

0.341
0.167

0.173
0.082

70
>100

Nesting

F(1, 10)=5.922; p=0.0352

0.293

0.151

94

Locomotor

F(1, 10)=0.6880; p=0.4262

0.301

0.156

89

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(4, 36)=0.8497; p=0.5033

0.3025

0.653

15

Rear + Acid
Nesting + Acid

F(4, 36)=0.3130; p=0.8674
F(4, 40)=0.4105; p=0.800

0.188
0.201

0.275
0.346

36
31

Nesting

F(3, 30)=0.1895; p=0.9027

0.138

0.161

74

Locomotor

F(2, 20)=0.08436; p=0.9194

0.092

0.092

>100

Main Effect of
Dose

Rear + Acid

Supplemental Table IV.VI. Summary of power analysis results from two-way ANOVA for JZL195
from Figure IV.IV.
Supplemental Table IV.VI
JZL-195
Main Effect of
Dose

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

95

Stretch + Acid

F(2.472, 24.72)=5.210;
p=0.009*

0.721

1

5

Rear + Acid

F(2.420, 24.20)=0.259;
p=0.8133

0.16

0.186

64

Nesting + Acid

F(2.191, 21.91)=3.973;
p=0.0306*

0.6298

0.994

7

Nesting

F(1.599, 15.99)=1.109;
p=0.3407

0.333

0.522

21

F(1.55, 15.50)=2.732; p=0.1039

0.446

0.819

12

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1,10)=2.681; p=0.1326
F(1,10)=0.02897; p=0.8683
F(1,10)=1.408; p=0.2628

0.522
0.041
0.309

0.373
0.052
0.163

31
>100
85

F(1,10)=1.085; p=0.3221
F(1, 10)=14.62; p=0.0034*

0.132
0.841

0.07
0.747

>100
14

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3,30)=1.447; p=0.2486

0.38

0.845

11

F(3, 30)=0.6602; p=0.5830
F(3,30)=1.555; p=0.2207

0.257
0.395

0.486
0.874

23
11

F(3,30)=0.5434; p=0.6564
F(2, 20)=0.9772; p=0.3936

0.234
0.313

0.411
0.587

27
19

Locomotor
Main Effect of
Sex
Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Dose x Sex
Interaction

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor

Supplemental Table IV.VII. Summary of power analysis results from two-way ANOVA for SA57 from
Figure IV.IV.
Supplemental Table IV.VII
SA-57
F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(2.226, 22.26)=4.922;
p=0.0145*

0.702

0.999

4

Rear + Acid

F(2.421, 24.21)=0.3686;
p=0.7344

0.193

0.256

44

Nesting + Acid

F(1.913, 19.13)=4.249;
p=0.0311*

0.562

0.992

7

Nesting

F(1.101, 11.01)=4.643;
p=0.0515

0.681

0.95

9

Locomotor

F(1.55, 15.50)=2.732;
p=0.1039

0.446

0.819

12

Main Effect of
Sex

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid
Rear + Acid

F(1, 10)=5.188; p=0.046*
F(1,10)=0.0222; p=0.8845

0.694
0.03

0.583
0.051

19
>100

Main Effect of
Dose
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Nesting + Acid
Nesting
Locomotor
Dose x Sex
Interaction

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor

F(1,10)=0.007; p=0.9347
F(1,10)=0.3414; p=0.572

0.014
0.135

0.05
0.071

>100
>100

F(1, 10)=14.62; p=0.0034*

0.841

0.747

14

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3, 30)=2.832; p=0.0550

0.533

0.991

7

F(3, 30)=1.708; p=0.1864
F(3,30)=0.6439; p=0.5929
F(3,30)=0.1504; p=0.9286

0.413
0.253
0.123

0.905
0.471
0.137

10
23
91

F(2, 20)=0.9772; p=0.3936

0.313

0.587

19

Supplemental Table IV.VIII. Summary of power analysis results from two-way ANOVA for URB597
from Figure IV.V.
Supplemental Table IV.VIII
URB-597
Main Effect of
Dose

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid

F(2.656, 26.56)=1.202;
p=0.3251

0.346

0.724

14

Rear + Acid

F(1.351, 13.51)=1.138;
p=0.3258

0.337

0.483

23

Nesting + Acid

F(1.908, 19.08)=3.360;
p=0.0581

0.579

0.972

8

Nesting

F(1.721, 17.21)=0.5996;
p=0.5362

0.246

0.324

35

Locomotor

F(1.949, 19.49)=3.229;
p=0.0626

0.568

0.983

7

Main Effect of
Sex

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor

F(1,10)=1.181; p=0.3027
F(1, 10)=0.5780; p=0.4646
F(1,10)=0.2623; p=0.6196
F(1,10)=0.01015; p=0.9217
F(1, 10)=2.872; p=0.121

0.227
0.173
0.11
0.02
0.41

0.11
0.084
0.064
0.05
0.251

>100
>100
>100
>100
49

Dose x Sex
Interaction

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3, 30)=0.5332; p=0.6630
F(3, 30)=1.088; p=0.3690
F(3,30)=2.094; p=0.1219
F(3,30)=1.4; p=0.2619

0.232
0.33
0.11
0.375

0.403
0.719
0.118
0.834

27
14
>100
12

F(2, 20)=0.3896; p=0.6824

0.196

0.262

44

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor

97

Supplemental Table IV.IX. Summary of power analysis results from two-way ANOVA for PF3845
from Figure IV.V.
Supplemental Table IV.IX
PF3845
F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(2.561, 25.61)=0.5551;
p=0.6227

0.237

0.381

29

Rear + Acid

F(1.998, 19.98)=0.24;
p=0.7887

0.048

0.06

>100

Nesting + Acid

F(1.706, 17.06)=1.910;
p=0.1817

0.436

0.755

14

Nesting

F(2.154, 21.54)=17.29;
p<0.0001*

1.312

1

4

Locomotor

F(1.949, 19.49)=3.229;
p=0.0626

0.568

0.983

7

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(1, 10)=0.1126; p=0.7442

0.072

0.056

>100

F(1, 10)=1.031; p=0.3339
F(1,10)=0.6999; p=0.4223

0.185
0.119

0.089
0.066

>100
>100

F(1,10)=0.2573; p=0.6230
F(1, 10)=2.872; p=0.121

0.097
0.41

0.061
0.251

>100
49

F Statistic, p value

Current Effect Size
(Cohen's f)

Current
Power

Sample Size:
Power≥ 0.8

F(3, 30)=0.3898; p=0.5654
F(3,30)=0.4743; p=0.7025
F(4, 40)=0.2741; p=0.8930

0.264
0.217
0.167

0.508
0.357
0.22

21
31
51

F(4, 40)=0.9107; p=0.4670
F(2, 20)=0.3896; p=0.6824

0.301
0.196

0.631
0.262

17
44

Main Effect of
Dose

Stretch + Acid

Main Effect of
Sex
Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
Dose x Sex
Interaction

Stretch + Acid
Rear + Acid
Nesting + Acid
Nesting
Locomotor
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Chapter V: Effects of repeated MJN110 on pain-related depression of nesting
in male and female mice
Introduction
Chapters III and IV demonstrated IP acid’s reproducible and robust acute depression of nesting behavior, and
Chapter IV showed acute antinociceptive effectiveness of 1.0 mg/kg MJN110 to attenuate acute IP acid-induced
depression of nesting. Previous studies have shown functional tolerance following chronic administration of the
MAGL-selective inhibitor JZL184 (Schlosburg et al., 2010), and the few studies that have evaluated the
antinociceptive effectiveness of repeated MJN110 show mixed results regarding development of tolerance
(Burston et al., 2016; Thompson et al., 2020). Accordingly, the goal of this study was to assess the effects of
repeated administration of 1.0 mg/kg MJN110 on IP acid-depressed nesting behavior across 7 days. Male and
female mice were divided into four groups that received either MJN110 or its vehicle 2 hours prior to
administration of IP acid or its vehicle, and nesting consolidation data was collected to evaluate MJN110 and IP
acid effects on nesting behavior.

Materials and Methods
Subjects
Male and female ICR mice (Envigo Laboratories, Indianapolis, IN) were 6-8 weeks old upon arrival,
individually housed, and acclimated for at least one week before beginning studies. In an AAALAC-approved
facility, mice had ad libitum access to food (Teklad LM-485 Mouse/Rat Diet, Harlan Laboratories) and water in
cages (31.75 x 23.50cm2 floor x 15.25cm high) mounted in a RAIR HD Ventilated Rack (Lab Products,
Seaford, DE) with corncob bedding (Harlan Laboratories) and a “nestlet” composed of pressed cotton (Ancare,
Bellmore, NY). The temperature-controlled housing room was maintained on a 12-hour light/dark cycle (lights
on from 7:00AM to 7:00PM), and all testing occurred during the light phase. Females weighed 20-35g and
males weighed 25-45g throughout the study. Animal use protocols were approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committee and complied with the National
Research Council Guide for the Care and Use of Laboratory Animals.
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Behavioral Procedures
Nesting Procedure. Studies were conducted in two cohorts of 48 mice tested five months apart (24 female and
24 male mice in each cohort; 96 mice total). Behavioral and pharmacological procedures were identical between
the two cohorts as described below, and all mice met an inclusion criterion that required them to build a nest
within 24hr of arrival to the laboratory. After 1 week of acclimation, testing occurred over a 7-day period as
shown in Figure V.I, and mice were randomly allocated into the following four treatment groups
(N=6/sex/treatment/cohort) to receive daily treatment with SC injection of 1.0 mg/kg MJN110 or its vehicle
(Veh) followed 2h later by IP injection of 0.32% lactic acid or its vehicle (H 2O). The routes of administration,
doses, and pretreatment times for MJN110 and IP acid were based on previous studies (Niphakis et al., 2013;
Ignatowska-Jankowska et al., 2015a; Diester et al., 2021b), and IP injections alternated between the subject’s
left and right sides across the 7-day study. Immediately after the IP injection, old nesting material was removed
from the subject’s home cage, two 1-in2 nestlet squares were placed 11 inches apart in the center of the
opposing short walls of the cage, and the mouse was returned to its home cage for a 90-min nesting session as
described previously (Diester et al., 2021a). At the conclusion of the session, the position of the nestlets was
photographed from above and the distance between the center of mass for each nestlet was measured to the
nearest quarter inch. Studies were conducted at the same time each day in each mouse (starting at 10:00 AM) to
minimize potential environmental or light-cycle confounds. Additionally, mice were weighted prior to
injections on each test day. At 24-28h after the last nesting session, mice were euthanized by rapid decapitation
and the following tissue regions were collected for studies of cannabinoid agonist-stimulated GTPɣS binding:
spinal cord (lumbar, rest of cord), cingulate cortex, caudate putamen, nucleus accumbens, amygdala,
periaqueductal gray, ventral tegmentum area, cerebellum, and hippocampus. These data are not shown within
this dissertation, but they will be analyzed and prepared for publication with this chronic behavioral dataset.

100

Data Analysis
Nesting Data. The primary dependent variable was % Maximal Nestlet Consolidation on each test day in each
mouse, defined as [(11-End)/11] x 100], where 11 and End were the distances in inches between the nestlets at
the start and end of the observation period, respectively. This nesting measure was treated as a ratio variable and
analyzed by parametric statistics. Because results from the two cohorts were similar (Supp. Figure 1, Supp.
Table 4), all data from the two cohorts were combined to yield 24 mice (12 female, 12 male) for each of the
four treatment groups. Data analysis proceeded in a series of steps similar to our previously described method
for assessment of sex as a biological variable in studies that include both sexes but are not intended a priori to
be powered for detection of sex differences (Diester et al., 2019), with expansion to include the factor of time
(days). The approach complies with the National Institutes of Health mandate to include both sexes in
preclinical research and to include analyses that segregate results by sex (Miller et al., 2017; Tannenbaum et al.,
2019). All analyses described below were conducted using GraphPad Prism (LaJolla, CA) with a criterion of
significance set to p<0.05, inclusion of a Geisser-Greenhouse correction for repeated measures to correct for
unequal variance, and post hoc analysis for significant ANOVAs using the Holm-Sidak test.

Our primary analysis focused on data across the 7-day study. Pooled data from both sexes and segregated data
for each sex were first analyzed by a repeated-measures three-way ANOVA, with MJN110 and IP acid
treatments as between-subject variables and days as a within-subject variable. If the three-way interaction was
significant, follow-up two-way ANOVAs were conducted to evaluate variance of any two variables across each
level of the third variable (MJN110, Acid, Days) (Kirk, 1995). If the three-way interaction and main effect of
days were not significant but there was a significant MJN110 x Acid interaction, data were collapsed across
days and analyzed by a two-way ANOVA. Lastly, to directly compare data from males and females, results
were collapsed across days and analyzed by three-way ANOVA, with MJN110 treatment, IP acid treatment, and
sex as the three between-subject variables.
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Weight Data. Repeated IP acid may decrease body weight as a surrogate measure for pain-related and
analgesic-reversible depression of feeding behavior (Stevenson et al., 2006; Legakis et al., 2020). Accordingly,
weights for each subject were collected daily immediately prior to MJN110 or Veh administration. As with
nesting data, our primary analysis focused on pooled data across both sexes and data segregated by sex.
Specifically, Day-7 body weights for pooled data, females, and males were expressed as a percentage of Day-1
weights and analyzed by two-way ANOVA (MJN110 x Acid). As a secondary analysis, raw Day-1 weights and
transformed Day-7 weights were also analyzed by three-way ANOVA with treatment groups (MJN110 x Acid)
and sex as the three variables.

Drugs
Lactic acid (Fischer Scientific, NH) was diluted in sterile water and administered intraperitoneally. The MAGLselective inhibitor MJN110 was kindly provided by Dr. Micah Niphakis (currently at Lundbeck La Jolla
Research Center) and diluted in a vehicle (Veh) of 1:1:18 ethanol, emulphor (Alkamuls-620; Sanofi-Aventis,
Bridgewater, NJ) and saline, and administered subcutaneously. All injections were administered in volumes of
0.1-0.9mL.

Results
Overview of Data Presentation
The effectiveness of repeated administration of MJN110 to alleviate IP acid-induced nesting depression was
assessed across 7 days, with evaluation of pooled data shown in Figure V.I and data segregated by sex in Figure
V.II. The effect of repeated MJN110 treatment on bodyweight in the absence and presence of repeated IP acid is
shown in Figure V.III. Data evaluating the comparison between cohorts, effects of sex on MJN110 and IP acid
treatment in pooled data collapsed across days, follow-up two-way ANOVAs for Figure V.IIC, and baseline
weights are shown in Supplemental Figures V.I-IV, respectively. Tables with results for statistical analyses are
shown as follows: three-way ANOVA results in Supplemental Table V.I, two-way ANOVA results collapsed
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across days in Supplemental Table V.II, two-way ANOVA results per day (Figure V.IIC) in Supplemental
Table V.III, and Welch’s t-tests in Supplemental Table V.IV.

Effects of repeated MJN110±IP Acid in pooled data from both sexes. Figure V.I shows the effectiveness of
repeated 1.0 mg/kg SC MJN110 to alleviate daily IP acid-induced nesting depression in pooled data from both
female and male mice. Briefly, the three-way ANOVA indicated a significant MJN110 x Acid interaction with
no main effect of Day or Day x MJN110 x Acid interaction (Figure V.IB, Supp. Table V.I). Accordingly, data
were collapsed across days and analyzed by two-way ANOVA (Figure V.IC, Supp. Table V.II). Vehicle-control
mice (Veh/H2O) nested at high and stable rates across the 7-day study, and MJN110-alone treatment did not
alter nesting behavior following repeated administration (MJN110/H2O). Repeated treatment with IP acid alone
(Veh/Acid) produced a significant and sustained depression of nesting, and repeated dosing of MJN110
produced partial but significant alleviation of IP acid-depressed nesting (MJN110/Acid). Evaluation of sex as a
determinant of treatment effects in Figure V.IC showed no main effect of Sex or interaction between Sex and
Treatment (Supp. Figure V.II, Supp. Table V.I).

Effects of repeated MJN110±IP Acid on nesting in males and females. Although analysis of pooled data
found no significant main effect of Sex or Sex x Treatment interaction, data segregated by sex suggests a
differential trajectory of treatment effects over time in males and females (Figure V.II). In males, each treatment
produced a relatively consistent effect over time, with no significant main effect of Day or Day x Treatment
interaction in the three-way ANOVA (Supp. Table V.I). As with the pooled data, the resulting two-way
ANOVA collapsed across days (Fig. V.IIB) indicated both acid-induced depression of nesting and a weak but
significant partial antinociception by repeated 1.0 mg/kg MJN110 (Supp. Table V.II).

Conversely, the three-way ANOVA in females showed a significant three-way interaction between Day,
MJN110 dose, and IP Acid concentration (Supp. Table V.I). Follow-up two-way ANOVAs of MJN110 x Acid
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treatment effects for each day indicated significant acid-induced depression of nesting for all 7 days and
significant MJN110 partial antinociception only on Days 1, 3, and 5. Supplemental Table V.III shows these
two-way ANOVA results for each treatment day, and Figure V.IID highlights the results for Days 1 and 7. On
Day 1, in agreement with our previously published acute study described in Chapter IV (Diester et al., 2021b),
MJN110 significantly alleviated IP acid-induced depression of nesting; however, on Day 7 there was only a
main effect of acid treatment and no antinociceptive effect of MJN110 (Supp. Table V.III). Additional followup two-way ANOVAs evaluating variance across levels of MJN110 and acid are shown in Supplemental Figure
V.III, with significant interactions followed by a Dunnett’s post-hoc comparison to Day 1 data. These analyses
showed no change in Veh/H2O, Veh/Acid, and MJN110/H2O treatment groups across the 7-day study, and a
significant change in MJN110/Acid treatment effects only on Day 6.

Effects of repeated MJN110±IP Acid on Body Weights. Figure V.III shows treatment effects on body
weights at the end of the study. Two-way ANOVA of pooled data showed main effects of MJN110 treatment
(to increase body weights) and IP acid treatment (to decrease body weights), but the interaction was not
significant (Supp. Table V.II). Thus, although MJN110 alleviated IP acid-induced depression of body weight,
this effect could not be attributed to antinociception because MJN110 increased body weight regardless of IP
acid treatment. Segregation of data by sex indicated that the main effect of MJN110 treatment was driven by the
females, with significant main effects of MJN110 and IP acid treatments for females but only a main effect of
IP acid in the males. Supplemental Figure V.IV shows body weight data with sex included as a variable (Supp.
Table V.I). On Day 1, males were heavier than females, but there were no significant differences in basal
weights across treatment groups. When Day-7 data were expressed as a percentage of Day-1 weights, there was
no main effect of sex and no sex x treatment interaction (Supplemental Figure V.IVB).
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Discussion
Chapter V evaluated the effects of repeated administration of 1.0 mg/kg MJN110 on episodic IP acid-induced
depression of nesting across 7 days of treatment. There were four main findings. First, vehicle control mice
(Veh/H2O) nested at high and steady rates across the 7-day study, suggesting that nesting behavior in mice can
serve as a robust and stable behavioral endpoint for studies of repeated exposure to experimental manipulations.
Second, repeated treatment with MJN110 alone (MJN110/H2O) across 7 days did not alter nesting behavior.
Thus, repeated treatment with this dose of MJN110 alone did not produce evidence of general behavioral
disruption. Third, repeated IP acid alone treatment (Veh/Acid) produced a significant and sustained depression
of nesting across all seven days of testing, with a potential trend for decreased effectiveness in females. Taken
together, these findings of sustained, repeatable, and pain-related nesting depression by IP acid enables repeated
dosing studies with candidate analgesics like MJN110. Lastly, in evaluation of pooled data from both sexes,
MJN110 produced partial but sustained antinociception throughout the 7 days of treatment. Segregation of data
by sex revealed differential effects, with MJN110 producing a weak but sustained partial attenuation of IP acidinduced depression of nesting in males and a loss of antinociceptive effect in females. Overall, the weak
antinociceptive effect in males and variable effects following repeated dosing in females suggest that MJN110
may not be an ideal candidate analgesic for treatment of visceral episodic pain.
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Figures

Figure V.I. Study overview and effects of repeated administration of MJN110 on daily IP acid-induced
nesting depression in mice. (A) Graphical illustration of experimental design for the study. (B) Treatment
effects on nesting behavior across the seven days of treatment. Abscissa: experimental days. Ordinate: nesting
behavior expressed as percent maximal nestlet consolidation. Each point shows mean±SEM for 24 mice (12 per
sex). (C) Data from Panel B collapsed across days. Abscissa: treatment with IP H2O or IP Acid. Ordinate:
nesting behavior expressed as percent maximal nestlet consolidation. Bars show mean±SEM for 24 mice (12
per sex) in each treatment group, and circles (Veh pretreatment) and squares (MJN110 pretreatment) show
individual data. Asterisks (*) indicates a significant difference as determined by two-way ANOVA and Holm106

Sidak post hoc test, p<0.05. Three-way ANOVA results for (B) are shown in Supp. Table V.I, and two-way
ANOVA results for (C) are shown in Supp. Table V.II.
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Figure V.II. Differential effects of repeated MJN110±IP acid treatment in female and male mice.
Treatment effects on nesting behavior across seven days of treatment in males (Panel A&B) and females (Panel
C&D). Abscissae for panels A&C: experimental days. Ordinates for panels A&C: nesting behavior expressed as
percent maximal nestlet consolidation, with each point representing mean±SEM for 12 mice per treatment.
Abscissae for panels B&D: treatment with IP H2O or IP Acid. Ordinates for panels B&D: nesting behavior
expressed as percent maximal nestlet consolidation, with bars representing mean±SEM for 12 mice in each
treatment group, and circles (Veh pretreatment) and squares (MJN110 pretreatment) showing individual data.
For males in Panel A, the three-way interaction was not significant, and there was no significant effects of Day
or Day x Treatment interaction. Accordingly, data were collapsed across days, evaluated by two-way ANOVA,
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and results are shown in Panel B. For females in Panel C, the three-way interaction was significant, and data on
each day were analyzed by two-way ANOVA, with data for Days 1 and 7 highlighted in Panel D. Asterisks (*)
indicate significant effects determined by two-way ANOVA and Holm-Sidak post hoc tests (p<0.05). Threeway ANOVA results for (A) and (C) are shown in Supp. Table V.I, two-way ANOVA results for (B) are shown
in Supp. Table V.II, and two-way ANOVA results for (D) are shown in Supp. Table V.III.
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Figure 3
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Figure V.III. Opposing effects of MJN110 and IP acid treatment on body weight. Abscissae: MJN110 or
Veh treatment, delivered SC in a volume of 10 ml/kg. Ordinates: bodyweight expressed as percent of baseline
Day 1 weights. Bars show mean±SEM for 12 mice per sex in each treatment group, and circles (H 2O treatment)
and triangles (IP acid treatment) show individual data. Significant main effects determined by two-way
ANOVA and Holm-Sidak post hoc test (p<0.05) are displayed above each panel. Detailed two-way ANOVA
results for all above panels are shown in Supp. Table V.II.
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Supplemental Table V.I: Summary of statistical analyses from three-way ANOVA data. Asterisks (*) indicate
a significant main effect or interaction (p<0.05).
Figure

F statistic

p value

1B

Days: F(5.592, 508.9) = 0.4017
MJN110: F(1, 91) = 3.667
Acid: F(1, 91) = 165.1
Days x MJN110: F(6, 546) = 2.762
Days x Acid: F(6, 546) = 1.507
MJN110 x Acid: F(1, 91) = 16.70
Days x MJN110 x Acid: F(6, 546) = 1.207

0.8666
0.0586
<0.0001*
0.0118*
0.1736
<0.0001*
0.3010

2A

Days: F(5.262, 226.3) = 0.6207
MJN110: F(1, 43) = 0.4142
Acid: F(1, 43) = 100.2
Days x MJN110: F(6, 258) = 0.6973
Days x Acid: F(6, 258) = 1.011
MJN110 x Acid: F(1, 43) = 9.627
Days x MJN110 x Acid: F(6, 258) = 0.3625

0.6924
0.5233
<0.0001*
0.6520
0.4188
0.0034*
0.9022

2C

Days: F(5.218, 229.6) = 0.5829
MJN110: F(1, 44) = 3.908
Acid: F(1, 44) = 65.62
Days x MJN110: F(6, 264) = 3.326
Days x Acid: F(6, 264) = 1.338
MJN110 x Acid: F(1, 44) = 6.790
Days x MJN110 x Acid: F(6, 264) = 2.643

0.7203
0.0544
<0.0001*
0.0036*
0.2404
0.0125*
0.0166*

Supp. 1A

Sex: F(1, 87) = 0.3477
MJN110: F(1, 87) = 3.506
Acid: F(1, 87) = 162.9
Sex x MJN110: F(1, 87) = 0.9676
Sex x Acid: F(1, 87) = 1.121
MJN110 x Acid: F(1, 87) = 16.20
Sex x MJN110 x Acid: F(1, 87) = 0.06765

0.5569
0.0645
<0.0001*
0.3280
0.2926
0.0001*
0.7954

Supp. 2A

MJN110: F(1, 87) = 0.5851
Sex: F(1, 87) = 255.7
Acid: F(1, 87) = 0.1580
MJN110 x Sex: F(1, 87) = 0.0009
MJN110 x Acid: F(1, 87) = 1.637
Sex x Acid: F(1, 87) = 0.0019
MJN110 x Sex x Acid: F(1, 87) = 0.2346

0.4464
<0.0001*
0.6820
0.9761
0.2042
0.9655
0.6294

Supp. 2B

MJN110: F(1, 87) = 7.614
Sex: F(1, 87) = 0.2260
Acid: F(1, 87) = 13.35
MJN110 x Sex: F(1, 87) = 0.02271
MJN110 x Acid: F(1, 87) = 1.565
Sex x Acid: F(1, 87) = 1.079
MJN110 x Sex x Acid: F(1, 87) = 0.1923

0.0071*
0.6357
0.0004*
0.8806
0.2142
0.3017
0.6621

111

Supplemental Table V.II: Summary of statistical analyses from two-way ANOVA data. Asterisks (*) indicate
a significant main effect or interaction (p<0.05).
Figure

F statistic

1C

Acid: F(1, 91) = 165.1
MJN110: F(1, 91) = 3.667
Acid x MJN110: F(1, 91) = 16.70

<0.0001*
0.0586
<0.0001*

Acid: F(1, 43) = 100.2
MJN110: F(1, 43) = 0.4142
Acid x MJN110: F(1, 43) = 9.627

<0.0001*
0.5233
0.0034*

Acid: F(1, 91) = 13.57
MJN110: F(1, 91) = 7.964
Acid x MJN110: F(1, 91) = 1.670

0.0004*
0.0059*
0.1995

Acid: F(1, 44) = 5.104
MJN110: F(1, 44) = 6.319
Acid x MJN110: F(1, 44) = 2.130

0.0289*
0.0157*
0.1515

Acid: F(1, 43) = 8.190
MJN110: F(1, 43) = 2.530
Acid x MJN110: F(1, 43) = 0.2456

0.0065*
0.1190
0.6227

2B

3A

3B

3C

p value
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Supplemental Table V.III: Summary of two-way ANOVA results for Figure V.IIC. Asterisks (*) indicate a
significant main effect or interaction (p<0.05).
Day

F statistic

p value

1

Acid: F(1, 44) = 76.66
MJN110: F(1, 44) = 12.66
Acid x MJN110: F(1, 44) = 19.85

<0.0001*
0.0009*
<0.0001*

2

Acid: F(1, 44) = 19.91
MJN110: F(1, 44) = 6.951
Acid x MJN110: F(1, 44) = 0.6952

<0.0001*
0.0115*
0.4089

3

Acid: F(1, 44) = 21.60
MJN110: F(1, 44) = 2.834
Acid x MJN110: F(1, 44) = 4.990

<0.0001*
0.0994
0.0306*

4

Acid: F(1, 44) = 12.24
MJN110: F(1, 44) = 0.6592
Acid x MJN110: F(1, 44) = 3.077

0.0011*
0.4212
0.0864

5

Acid: F(1, 44) = 22.24
MJN110: F(1, 44) = 5.233
Acid x MJN110: F(1, 44) = 5.535

<0.0001*
0.0270*
0.0232*

6

Acid: F(1, 44) = 47.61
MJN110: F(1,44) = 2.222
Acid x MJN110: F(1, 44) = 1.223

<0.0001*
0.1432
0.2748

7

Acid: F(1, 44) = 14.73
MJN110: F(1, 44) = 0.05755
Acid x MJN110: F(1, 44) = 1.903

0.0004*
0.8115
0.1748
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Supplemental Table V.IV: Summary of statistical analyses from Welch’s t-tests in Supp. Figure V.I. Asterisks
(*) indicate a significant effect (p<0.05).
Cohort 1 vs 2
Treatment
Groups

Welch’s corrected t; p value

Veh/H2O

t = 0.7201; p = 0.7201

F = 4.067; p = 0.0284*

Veh/Acid

t = 0.417; p = 0.6422

F = 1.263; p = 0.7057

MJN110/H2O

t = 0.2496; p = 0.8052

F = 1.048; p = 0.9392

MJN110/Acid

t = 0.3899; p = 0.7022

F = 3.853; p = 0.0366*

F-test (variance); p value
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Supplemental Figure V.I. Comparison of treatment effects between Cohorts 1 and 2. Each panel shows
one of the four treatment groups of Veh/H2O (A), Veh/Acid (B), MJN110/H2O (C), and MJN110/Acid (D).
Abscissae: cohort number (left bars) and Difference Score between cohorts (right point). Ordinates: the left axis
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denotes nestlet consolidation expressed as percent maximal nestlet consolidation, and the right axis denotes the
difference between the means for each cohort calculated as Group2 – Group1. Circles represent an average for
each subject across the 7-day study (N=12/Cohort/Group). Dashed lines represent means from each respective
group, and squares represent the difference between means for each respective treatment group. Data across
cohorts were compared by a two-tailed t-test with Welch’s correction for unassumed equal standard deviation.
There was not a significant difference in the means between cohorts in any treatment group, so cohorts were
combined for all subsequent analyses. Welch’s t-test results for all panels are shown in Supp. Table V.IV.
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Supplemental Figure V.II. Evaluation of sex as a determinant of MJN110 effects on pooled data collapsed
across days. Abscissae: male or female subjects (N=12/sex/treatment) with data collapsed across days.
Ordinates: nestlet consolidation expressed as percent maximal nestlet consolidation. Data are visualized across
the three variables, with bars representing H2O (blue) and IP acid (maroon) treatments and boxed groups
representing Vehicle (left group) and MJN110 (right group). 0.32% IP acid or H 2O were delivered IP, and 1.0
mg/kg MJN110 or Vehicle were administered SC, with all administered in a volume of 10 ml/kg. Data were
analyzed by three-way ANOVA and Holm-Sidak post hoc test, p<0.05. Significant main effects and interactions
are shown above the graph. Complete three-way ANOVA results are shown in Supp. Table V.I.
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Supplemental Fig 3
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Supplemental Figure V.III. Follow-up two-way ANOVA analyses for female nesting data across MJN110
and Acid levels. Abscissae: experimental days. Ordinates: nesting behavior expressed as percent maximal
nestlet consolidation. Each point shows mean±SEM for 12 female mice. Given the significant Days x MJN110
x Acid interaction in female nesting data (Supp. Table V.I), follow-up two-way ANOVAs were conducted to
evaluate variance of days and acid across levels of MJN110 (Panels A&B) and variance of days and MJN110
across levels of acid treatment (Panels C&D). Significant interactions and main effects are displayed above each
panel, with a significant Dunnett post hoc comparison to Day 1 indicated by a filled symbol (p<0.05).
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Supplemental Figure V.IV. Baseline weights and evaluation of sex as a determinant of repeated
MJN110±IP Acid effects on weight. Abscissae: Veh or 1.0 mg/kg MJN110 treatment delivered SC in a
volume of 10 ml/kg. Ordinates: baseline Day 1 weight in grams of male and female mice (A) and Day 7
bodyweight expressed as percent of baseline Day 1 weights (B), N=12/sex/treatment. Symbols and colors for
groups are as follows: circles represent female data, triangles represent male data, blue represents H2O
treatment, and gray represents IP acid treatment. An asterisk (*) indicates a significant difference as determined
by a three-way ANOVA, p<0.05. Main effects for panel (B) are shown at the top of the panel. Complete threeway ANOVA results for both panels are shown in Supp. Table V.I.
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Chapter VI: Discussion
Summary
One of the largest discrepancies between preclinical and clinical assessment of pain and analgesia is the
type of behavioral endpoint used. Although most preclinical research has historically focused on drug
effectiveness to block reflexive withdrawal behaviors stimulated by a noxious stimulus, increasing evidence
shows that drug-induced restoration of pain-depressed behaviors provides increased clinical translation with
decreased susceptibility to false-positives. Accordingly, the first portion of this dissertation designed a
behavioral battery that featured pain-depressed behaviors as well as more conventional pain-stimulated
behaviors for testing candidate analgesics in male and female mice. The main findings are as follows. (1)
Intraperitoneal injection of dilute lactic acid (IP acid) served as an effective visceral chemical noxious stimulus
to produce concentration-dependent stimulation of two behaviors (stretching and facial grimace; painstimulated behaviors) and depression of two behaviors (rearing and nesting; pain-depressed behaviors). (2)
Pharmacological characterization with two positive control analgesics (ketoprofen, oxycodone) and two active
negative controls (diazepam, amphetamine) validated a strategy for distinguishing analgesics from
nonanalgesics by profiling drug effects in this battery of complementary pain-stimulated and pain-depressed
behaviors along with two additional pain-independent behaviors (nesting and locomotor activity in the absence
of the IP acid noxious stimulus). (3) A National Institutes of Health mandate for consideration of Sex as a
Biological Variable (SABV) was published at the start of this dissertation research. Accordingly, we developed
an experimental design for considering SABV when sex differences are not the principle independent variable,
with emphases on exploratory power analyses (effect size, power, predicted N) and segregation of data by sex
to allow transparent analysis of SABV and help guide future study designs.
The second portion of this dissertation applied this behavioral battery and SABV data-analysis strategy
to evaluate a spectrum of endocannabinoid (eCB) catabolic enzyme inhibitors ranging in selectivity for the eCB
catabolic enzymes monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), which have
received increasing interest for development of candidate analgesics. The main findings are as follows: (1)
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antinociceptive effectiveness decreased as MAGL-selectivity decreased, with the most MAGL-selective
inhibitor MJN110 producing the most effective antinociceptive profile, (2) time course and antagonism studies
for MJN110 showed a long duration of antinociceptive action (40min – 6hrs), mediation by CB1R but not CB2R, a tendency for greater effects in females, and (3) repeated administration of MJN110 produced partial but
sustained attenuation of IP acid-induced depression of nesting, with segregation of data by sex demonstrating
sustained but weak antinociception in males and variable effects following repeated dosing in females.
Overall, these data provide a framework for predicting the analgesic potential of test drugs in preclinical
pain models in male and female mice, and suggest that MJN110 may have only partial effectiveness as a
candidate analgesic for treatment of visceral episodic pain.

Implications for Chapter II
Overview
Chapter II establishes a general, multi-step approach to address The Four Cs articulated by the National
Institutes of Health (NIH) when preclinical investigation of sex differences is not the primary aim and sample
sizes required to detect sex differences are not known. Inclusion of both males and females is responsive to the
“Consider” mandate for the experimental design that takes sex into account. The pooling of data across sex
permits focus on the primary variable(s) of interest, while segregation of data by sex addresses the “Collect”
mandate for tabulating sex-based data. The secondary analyses address the “Characterize” mandate by using
ANOVAs to analyze sex-based differences with existing sample sizes and power analyses to guide both
interpretation of the ANOVA results and design of any future studies that might focus on sex differences.
Finally, the results of ANOVAs (F statistics) and power analyses (effect size, power, and predicted Ns) provide
a useful array of statistical outcome measures that fulfill the “Communicate” mandate for reporting and
publishing sex-based data.
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Following the NIH mandate for inclusion of sex as a biological variable (SABV) in 2015, multiple
groups have evaluated incorporation of SABV across preclinical disciplines (Guizzetti et al., 2016; Galea et al.,
2020; Garcia-Sifuentes and Maney, 2021; Li et al., 2021). These studies almost exclusively operate under the
assumption that analyses for sex differences should be conducted prior to any other statistical analyses,
regardless of initial study design. For studies designed with sex as a primary variable, initial sex difference
analyses would be appropriate. However, it should be noted sex is one of many secondary variables present
within most preclinical study designs, and these other variables including species, age, strain, and environment.
Any variable intended for secondary analysis should not be treated as a primary variable, regardless of
highlighted interest.
Reporting of underpowered comparisons between males and females may lead to misleading false
negatives and contradictory conclusions within the literature. As sex-dependent conclusions can only be
determined through direct comparisons of males and females, studies underpowered for such analyses should
practice transparency in reporting of sex differences (i.e. study design and power analyses) and segregate data
by sex to identify possible underlying sex differences that would otherwise be masked through underpowered
ANOVA comparisons and pooled datasets (Miller et al., 2017; Galea et al., 2020; Duffy and Epperson, 2021).
Chapter 5 nicely displays examples where only relying on direct comparison of males vs females via ANOVAs
would have shown no sex differences for MJN110 antinociceptive effectiveness to alleviate IP acid-induced
depression of nesting, while segregation of data by sex elucidated this effect to be predominately driven by
females.
Intentional design of studies that include SABV as a secondary variable for preliminary studies does not
imply that there is not a need for increased inclusion of SABV in preclinical research. There is a growing
literature detailing how fundamental neurobiological processes differ between sexes that may help rectify
clinical discrepancies in male and female treatments (Anderson, 2008; Sorge et al., 2011; Kokras and Dalla,
2014; Bangasser and Wicks, 2017; Golden and Voskuhl, 2017; Fullerton et al., 2018; Shansky, 2018; De Bellis
et al., 2020). As fields of research evolve to continually improve our understanding of a plethora of multifaceted
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clinical diseases, it will be crucial to ensure clear frameworks for appropriate study designs (with attention to
behavioral contingencies of researchers) are developed to generate reproducible and clinically impactful
research.

Implications for Chapter III
Overview
Chapter III compared the effects of two clinically effective analgesics (ketoprofen, oxycodone) and two active
negative controls (diazepam and amphetamine) on a panel of pain-stimulated, pain-depressed, and painindependent behaviors in male and female mice. There were three main findings. First, IP acid served as an
effective chemical noxious stimulus to produce a concentration-dependent stimulation of stretching and facial
grimace and depression of rearing and nesting as putative pain-related behaviors. Test drugs could then be
evaluated for their profiles of antinociceptive effectiveness to alleviate these IP acid effects. Second, the
positive-control analgesics ketoprofen and oxycodone produced antinociception in assays of both painstimulated and pain-depressed outcome measures (with ketoprofen being the most efficacious) at doses below
those that altered nesting and/or locomotion in the absence of the IP acid noxious stimulus, whereas the
negative controls diazepam and amphetamine did not. These results suggest that analgesic potential of test
drugs can be predicted by higher potency to alleviate pain-related stimulation and depression of behavior than
to produce pain-independent motor disruption in mice. Lastly, sex differences in drug effects were not a primary
focus of the present study and few sex differences were identified; however, the inclusion of equal numbers of
male and female mice permitted exploratory power analysis of sex differences that could guide future studies
designed to focus on sex as a primary variable of interest. Overall, this study outlines an experimental design
and a framework of results with positive and negative controls that can be used to study and interpret effects of
candidate analgesic drugs.

Effects of IP lactic acid as a noxious stimulus
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The results in Chapter III confirm and extend previous studies in finding that IP injection of dilute acid
serves as an effective noxious stimulus to stimulate stretching (Koster et al., 1959; Collier et al., 1968;
Stevenson et al., 2006; Booker et al., 2009; Do Carmo et al., 2009; Miller et al., 2012; Bagdas et al., 2016; de la
Puente et al., 2017; Alexander et al., 2019) and facial grimace (Langford et al., 2010) and to depress rearing
(Cho et al., 2013; Cobos and Portillo-Salido, 2013) and nesting (Negus et al., 2015; Lewter et al., 2017;
Alexander et al., 2019). The present study builds on these previous results by showing that potency of IP lactic
acid was similar across all four endpoints. Additionally, our approach assessed stretching, facial grimace, and
rearing simultaneously during the same video sessions to provide cost- and time-efficient data collection on
both pain-stimulated and pain-depressed behaviors in the same subject. Nesting was assessed in different
subjects tested in their home cages, which provided an opportunity to assess generality of results across
different subjects and testing environments. Finally, the current study improved the primary dependent measure
of IP acid-depressed nesting from an ordinal variable (Negus et al., 2015) to a ratio variable to decrease
subjectivity and enable utility of parametric statistical analyses.

Effects of ketoprofen and oxycodone
The data presented in Chapter III agree with previous evidence that ketoprofen and other COX inhibitors
are effective to produce antinociception against a range of chemical and inflammatory pain stimuli producing an
array of pain-related behaviors including stretching (Seguin et al., 1995; Bagdas et al., 2016; Alexander et al.,
2019), facial grimace (Leach et al., 2012; Matsumiya et al., 2012; Tuttle et al., 2018a; Cho et al., 2019; de
Almeida et al., 2019), depression of rearing (Matson et al., 2007; Nagase et al., 2012) and depression of nesting
(Negus et al., 2015; Oliver et al., 2018; Alexander et al., 2019). In the present study, ketoprofen potency and
efficacy were similar to alleviate IP acid-induced stimulation of stretching and facial grimace and depression of
nesting, and although ketoprofen was less potent to alleviate IP acid-induced depression of rearing, it did
significantly restore rearing at 10 mg/kg. The antinociceptive effectiveness of ketoprofen on endpoints of both
pain-stimulated and pain-depressed behaviors provides one source of evidence to suggest that ketoprofen effects
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reflected sensory blockade of the acid noxious stimulus rather than production of nonspecific motor effects that
might impede expression of nociceptive behaviors. This conclusion is further supported by the finding that
antinociceptive ketoprofen doses did not alter nesting or locomotion in the absence of the IP acid noxious
stimulus. Previous studies have also reported ketoprofen antinociception at doses without evidence of motor
disruption (Niemegeers et al., 1975; Julou et al., 1976; Negus et al., 2015; Alexander et al., 2019). Taken
together, these findings are consistent with the clinical analgesic efficacy of ketoprofen and other COX
inhibitors for treatment of inflammatory pain (Moore and McQuay, 2013), and they also demonstrate sensitivity
of this panel of behavioral endpoints to a clinically effective analgesic as a positive control.
The MOR agonist oxycodone is also a clinically effective analgesic to treat inflammatory and other
types of pain, but it produced a profile of effects distinct from that of ketoprofen. Like ketoprofen, oxycodone
attenuated acid-induced stimulation of stretching and facial grimace and depression of nesting at doses that did
not alter locomotion or nesting in the absence of the noxious stimulus. This agrees with other evidence to
suggest that MOR agonists can alleviate some inflammation-related pain-stimulated and pain-depressed
behaviors at doses that do not alter other pain-independent behaviors (Matson et al., 2007; Cobos et al., 2012;
Cobos and Portillo-Salido, 2013; Bagdas et al., 2016; Lewter et al., 2017; Negus, 2019). However, unlike
ketoprofen, oxycodone produced only a partial alleviation of acid-induced depression of nesting, and it failed to
alleviate acid-induced depression of rearing. Previous studies have also reported limited effectiveness of MOR
agonists to alleviate some types of pain-related behavioral depression, and this limited efficacy appears to
reflect MOR agonist-induced motor effects that prevent antinociceptive restoration of function in assays of
pain-depressed behavior (Matson et al., 2007; Cobos et al., 2012; Elhabazi et al., 2012; Cho et al., 2013;
Kendall et al., 2016; de la Puente et al., 2017). In the present study, for example, oxycodone significantly
increased locomotion and produced a small though nonsignificant decrease in control nesting at 3.2 mg/kg.
These motor effects could have contributed to the descending limb of the inverted-U shaped dose-effect curve
for oxycodone effects on IP acid-induced nesting depression and prevented expression of oxycodone
antinociception on acid-induced rearing depression (which was also less responsive to ketoprofen, see above).
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Taken together, these results suggest that this panel of behaviors is also sensitive to MOR agonist analgesics
and provides data that can be used to interpret interactions between analgesic and motoric drug effects.

Effects of diazepam and amphetamine
The GABAA receptor positive allosteric modulator diazepam produced significant antinociception
against both IP acid-stimulated stretching and grimace, a finding that agrees with other evidence for
antinociception by diazepam and related benzodiazepines in preclinical assays of pain-stimulated behaviors
elicited by chemical noxious stimuli (Rosland et al., 1987; Fidecka and Pirogowicz, 2002; Munro et al., 2008;
Chiba et al., 2009). However, as in these previous studies, diazepam antinociception was observed only at a
high dose that also produced evidence of motor impairment in the absence of the noxious stimulus, suggesting
that apparent antinociception reflected motor impairment rather than analgesia. This conclusion was further
supported by the failure of diazepam to alleviate IP acid-induced depression of either rearing or nesting, and
indeed, diazepam only exacerbated IP acid-induced depression of rearing. Moreover, this conclusion is also
consistent with the lack of diazepam analgesic effectiveness in humans (Raft et al., 1977) and for the absence of
a clinical indication for diazepam as a stand-alone treatment for pain (Physician's Desk Reference, 2020).
Overall, these results illustrate the vulnerability of traditional assays of pain-stimulated behavior to
false-positive effects with drugs that produce sedation or motor impairment. A traditional strategy to address
this vulnerability has been to compare drug potency to produce antinociception with potency to impair motor
performance in the absence of the noxious stimulus, but this approach is not always reliable (Seguin et al.,
1995). Combined drug evaluation in complementary assays of both pain-stimulated and pain-depressed
behavior as shown here can further reduce false positives and enhance selectivity for clinically effective
analgesics while also probing drug effects on clinically relevant outcome measures related to behavioral
depression and functional impairment (Cobos et al., 2012; Negus et al., 2015; Bagdas et al., 2016; Negus,
2019).
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Like the non-analgesic behavioral depressant diazepam, the psychostimulant and dopamine/norepinephrine
releaser amphetamine also failed to produce antinociception at doses lower than those that altered locomotor
activity as a pain-independent behavior. This data demonstrates the utility of including locomotion to capture
pain-independent increases, as basal nesting occurs near assay capacity. This data is consistent with previous
evidence that amphetamine and other related psychostimulants (e.g. dopamine transporter inhibitors like
cocaine) can produce antinociception in assays of both pain-stimulated behavior (Tocco and Maickel, 1984;
Gatch et al., 1999; Connor et al., 2000; Alexander et al., 2019) and pain-depressed behavior (Matson et al.,
2007; Negus et al., 2012; Rosenberg et al., 2013). However, amphetamine and related psychostimulants
generally produce antinociception only at doses that also stimulate behavior in the absence of a noxious
stimulus (suggesting a lack of behavioral selectivity), and they do not always restore pain-related behavioral
depression in preclinical studies (Matson et al., 2007; Alexander et al., 2019) (suggesting limited effectiveness).
Nonetheless, it is noteworthy that amphetamine produced antinociception on all four nociceptive endpoints in
this study. Although amphetamine is not approved for use as an analgesic, it has been found to produce weak
analgesic effects in humans and can augment the analgesic effects of opioids (Dalal and Melzack, 1998;
Westfall and Westfall, 2011). These analgesic effects may be related to effectiveness of amphetamine and
related psychostimulants to alleviate pain-related depression of mesolimbic dopamine signaling (Wood, 2008;
Leitl et al., 2014; Martikainen et al., 2018; Watanabe and Narita, 2018). As increased dopamine also can cause
increases in general motor behavior, this proves difficult to parse true analgesia from psychostimulant effects.
With regard to its effects on pain-independent behaviors in the present study, the inverted-U shaped
dose-effect curve for amphetamine in the assay of locomotor activity is consistent with previous studies (Rethy
et al., 1970; Tyler and Tessel, 1979). In particular, the decrease in locomotion at 10 mg/kg likely reflected
recruitment of stereotypies that competed with and reduced horizontal locomotion (Tyler and Tessel, 1979;
Matson et al., 2007). High baseline nesting near the ceiling of the assay’s dynamic range may have prevented
detection of any stimulation of nesting by lower amphetamine doses; however, depression of nesting by 10
mg/kg amphetamine may also have reflected stereotypies that competed with and reduced nesting behavior.
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Implications for Chapter IV
Chapter IV characterized THC and a spectrum of endocannabinoid catabolic enzyme inhibitors ranging in
selectivity from MAGL-selective to FAAH-selective in a battery of pain-stimulated, pain-depressed, and painindependent behaviors pharmacologically characterized in Chapter III. There were three main findings in this
study. First, THC significantly attenuated IP acid-stimulated stretching and facial grimace at doses that did not
produce general motor disruption, but THC did not alleviate IP acid-induced depression of either rearing or
nesting. Second, for the eCB catabolic enzyme inhibitors, the MAGL-selective inhibitor MJN110 produced
antinociception without motor disruption on three of four endpoints, including significant alleviation of IP acidinduced depression of nesting, whereas the FAAH-selective inhibitor PF3845 failed to produce antinociception
on any endpoint up to a dose that produced motor disruption. Other eCB catabolic enzyme inhibitors produced
effects between these extremes. Lastly, time course and antagonism studies for MJN110 in the assay of IP acidinduced depression of nesting indicated a long duration of antinociceptive action (40 min to 6 hrs) and
mediation by CB1R but not CB2R. Overall, these results support further consideration of MAGL-selective
inhibitors, especially MJN110, as candidate analgesics.

Effects of 9-THC
The results in Chapter IV agree with previous work that showed subcutaneous THC to be more potent to
decrease IP acid-stimulated stretching than to produce locomotor impairment (Booker et al., 2009). In contrast,
THC is less potent in assays with acute thermal and mechanical noxious stimuli, resulting in relatively similar
potencies to produce antinociception and locomotor impairment (Sofia et al., 1975; Cravatt et al., 2001; Varvel,
2005; Grim et al., 2016; Britch et al., 2017; Grim et al., 2017). The present study extended this literature by
including facial grimace as a second pain-stimulated behavior and assessment of the two pain-depressed
endpoints nesting and rearing. THC was less potent and effective to decrease IP acid-stimulated facial grimace
than stretching. Moreover, in agreement with our previous work with pain-depressed behaviors in rats (Kwilasz
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and Negus, 2012; Leitl and Negus, 2016), THC failed to attenuate IP acid-induced depression of either nesting
or rearing. The poor efficacy of THC to alleviate signs of pain-related behavioral depression aligns with clinical
studies that show weak or no analgesic efficacy of THC on measures of acute pain in humans (Raft et al., 1977;
Greenwald and Stitzer, 2000; Wallace et al., 2007; Lötsch et al., 2018; Mun et al., 2020). As such, these results
support the translational validity of preclinical assays of pain-depressed behaviors.

Effects of MAGL>>FAAH-selective inhibitors
Previous studies have demonstrated that selective MAGL inhibition produces antinociception in assays
of pain-stimulated behavior through increasing central 2-AG levels and enhancing endogenous eCB tone
(Niphakis et al., 2013; Ignatowska-Jankowska et al., 2015a; Donvito et al., 2018). While other studies have
shown antinociceptive effectiveness of MAGL-selective inhibitors in models of acute thermal pain and chronic
inflammatory or neuropathic pain (Niphakis et al., 2013; Ignatowska-Jankowska et al., 2015a; Burston et al.,
2016; Wilkerson et al., 2018; Thompson et al., 2020), our study extended this literature by assessing their
effectiveness using an acute visceral inflammatory stimulus. MJN110 potency to decrease IP acid-stimulated
stretching was similar to its potency in inflammatory/neuropathic models and higher than its potency for acute
thermal nociception. We further extended the literature by assessing IP acid-stimulated facial grimace and IP
acid-depressed nesting and rearing. The potency of MJN110 was similar in assays of IP acid-stimulated grimace
and stretching, but the effect on grimace was small and not dose dependent. Although MJN110 did not alleviate
IP acid-induced depression of rearing, it did alleviate IP acid-depressed nesting with a stable level of
antinociceptive effectiveness across a 10-fold dose range. Doses that produced antinociception did not alter
pain-independent behaviors in our study; however, MJN110 doses of 1.25 and 2.5 mg/kg increased locomotor
speed and distance traveled in another study (Ignatowska-Jankowska et al., 2015a). Accounting for possible
differences in sensitivity between these two measures of locomotion, this hyperlocomotive effect is particularly
intriguing as it is diametrically opposed to typical CB1/2R agonist-induced hypolocomotion (Figure 6) (Stark
and Dews, 1980; Varvel, 2005; Wiebelhaus et al., 2015; Grim et al., 2017).
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Further assessment for the antinociceptive time course of 1.0 mg/kg MJN110 in the assay of IP aciddepressed nesting agreed with previous studies that showed behavioral effects and increased 2-AG levels
starting after ~1 hour and lasting several hours (Niphakis et al., 2013; Ignatowska-Jankowska et al., 2015a).
While all reports agree with our results showing MJN110 antinociception is blocked by rimonabant to implicate
CB1R, the role of CB2R is less clear (Ignatowska-Jankowska et al., 2015a; Burston et al., 2016; Thompson et
al., 2020). This may reflect differential recruitment of CB2R across the noxious stimuli assessed in these studies,
with neuropathic and chronic inflammatory manipulations being more likely to enhance CB2R expression and
signaling (Burston et al., 2013; Donvito et al., 2018). Our studies agree with previous evidence that CB2R are
not necessary for MJN110 antinociception in acute-pain models (Ignatowska-Jankowska et al., 2015a). The role
of sex as a determinant of MNJ110 effects is discussed below.
The other MAGL-selective inhibitor JZL184 did not significantly alleviate IP acid-stimulated stretching
(Long et al., 2009a; Sakin et al., 2015). Similar to MJN110, it weakly reduced facial grimace and alleviated IP
acid-induced depression of nesting but not rearing at doses that did not alter pain-independent behaviors. The
poor effectiveness of JZL184 on the present measures of pain-stimulated behavior contrasts with previous
evidence for antinociception across multiple acute pain-stimulated endpoints (Long et al., 2009b; Long et al.,
2009c; Schlosburg et al., 2010; Kamimura et al., 2018). Additionally, the failure of JZL184 to alter painindependent behaviors contrasts with previous evidence that JZL184 doses of 20-40 mg/kg increase (Aliczki et
al., 2013; Bedse et al., 2018) or decrease (Long et al., 2009b; Kinsey et al., 2011; Ignatowska-Jankowska et al.,
2015a; Wiebelhaus et al., 2015) other behaviors. These discrepancies may reflect two issues. First, these
previous studies only included male subjects, and the role of sex as a determinant of drug effects is discussed
below. Second, JZL184 was delivered subcutaneously as a suspension in this study. Methods for JZL184
preparation in previous reports are unclear, but communication with authors and published results show varying
preparation techniques aimed at enhancing solubility, including preparation immediately prior to injection,
heating JZL184 solutions, and use of different vehicles (Kinsey et al., 2009; Long et al., 2009b; Long et al.,
2009c). These alterations alongside intraperitoneal administration may produce pharmacokinetic differences
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that result in higher effective doses and stronger antinociception than observed here. However, effectiveness of
JZL184 to alleviate IP acid-induced nesting depression suggests that behaviorally active doses were tested.

Effects of dual MAGL and FAAH inhibitors
Previous evidence supports enhanced antinociceptive effects for dual inhibition of MAGL and FAAH in
comparison to selective inhibition for either enzyme alone to alleviate acute thermal noxious stimuli (Long et
al., 2009c). Our results did not support this for an acute visceral noxious stimulus because the dual
MAGL/FAAH inhibitors JZL195 and SA57 were not more effective than the selective MAGL inhibitors to
produce antinociception. Specifically, both JZL195 and SA57 alleviated IP acid-induced stimulation of
stretching and depression of nesting at doses that did not alter pain-independent behaviors, but neither drug
alleviated IP acid-induced grimace or depression or rearing. The potency of JZL195 to reduce IP acid effects on
stretching and nesting in the present study (32 mg/kg SC) was similar to its potency to produce antinociception
in an assay of warm-water tail-withdrawal in mice (20 mg/kg IP) (Long et al., 2009c). Long et al. (2009c) also
found that 20 mg/kg IP JZL195 decreased locomotor activity and produced catalepsy, and other groups have
also shown decreased locomotor activity or rotarod performance at similar or lower doses (Anderson et al.,
2014; Adamson Barnes et al., 2016). Similarly, SA57 decreased IP acid-stimulated stretching in the present
study at a similar potency (10 mg/kg SC) shown to produce acute thermal antinociception (12.5 mg/kg IP)
(Wilkerson et al., 2017), but previous studies also found that intraperitoneal administration of similar SA57
doses produced many undesirable cannabimimetic effects including increased immobility, catalepsy, and
decreased rectal temperature (Wiebelhaus et al., 2015; Wilkerson et al., 2017). The more selective effects of
JZL195 and SA57 on pain-related vs. pain-independent behaviors in the present study may again reflect
pharmacokinetic differences due to use of subcutaneous vs. intraperitoneal administration.
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Effects of MAGL<<FAAH-selective inhibitors
Our results do not support FAAH-selective inhibitors as candidate analgesics for acute visceral pain.
URB597 produced antinociception on only one endpoint (IP acid-induced nesting depression), and PF3845
failed to produce antinociception on any endpoint up to a dose that depressed locomotion. The effectiveness of
URB597 to alleviate IP acid-induced nesting suppression agrees with previous evidence for URB597
antinociception in other assays of pain-depressed behavior (Miller et al., 2012; Kwilasz et al., 2014); however,
URB597 did not alleviate depression of rearing, and in contrast to previous studies (Naidu et al., 2009; Miller et
al., 2012; Kwilasz et al., 2014), URB597 was not effective to alleviate IP acid-stimulated behaviors. There is a
similar discrepancy in the literature on URB597 antinociception in assays of acute thermal pain-stimulated
behaviors (Kathuria et al., 2003; Miller et al., 2012). PF3845 was the most FAAH-selective inhibitor in this
study, and it produced the least favorable profile of effects. Previous studies have reported small but significant
antinociceptive effectiveness of PF3845 on some acute pain-stimulated behaviors (Schlosburg et al., 2009;
Grim et al., 2014; Ghosh et al., 2015), but such effects were not detected here. Moreover, the failure of PF3845
to alleviate behavioral depression produced by IP acid in the present study agrees with failure of PF3845 to
alleviate depression of marble burying in mice by a chronic constriction injury to the sciatic nerve (Wilkerson et
al., 2018). The decrease in IP acid-independent nesting supports previous studies that have shown a similar
potency to decrease marble burying and intracranial self-stimulation in mice (Kinsey et al., 2011; Wiebelhaus et
al., 2015); however, these same doses were shown to have no effect on immobility time, operant food
responding, or distance traveled (Kinsey et al., 2011; Ghosh et al., 2015; Wiebelhaus et al., 2015).

Sex as a determinant of drug effects
The present study was not powered to detect sex differences, but both females and males were included
to conduct a secondary analysis using a strategy to provide preliminary insights on the role of sex as a
determinant of drug effects (Diester et al., 2019). In general, sex-dependent antinociception was rare, and there
were no sex x dose interactions for any drug on any endpoint. However, MJN110 consistently produced higher
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antinociceptive effects in females than males in the assay of IP acid-induced nesting depression, whereas
JZL184 produced a larger effect in males across three of the six endpoints. This discrepancy may be due in part
to tissue-dependent differential activity of MJN110 and JZL184 with serine hydrolases other than MAGL, such
as ABHD6, C16:0 and C18:1 MAGs (Long et al., 2009b; Niphakis et al., 2013). Further studies will be required
to examine expression and mechanisms of sex differences in effects of eCB catabolic enzyme inhibitors.

Implications for Chapter V
Overview
Chapter V evaluated the effects of repeated administration of 1.0 mg/kg MJN110 on episodic IP acid-induced
depression of nesting across 7 days of treatment. There were four main findings. First, vehicle control mice
(Veh/H2O) nested at high and steady rates across the 7-day study, suggesting that nesting behavior in mice can
serve as a robust and stable behavioral endpoint for studies of repeated exposure to experimental
manipulations. Second, repeated treatment with MJN110 alone (MJN110/H2O) across 7 days did not alter
nesting behavior. Thus, repeated treatment with this dose of MJN110 alone did not produce evidence of general
behavioral disruption. Third, repeated IP acid alone treatment (Veh/Acid) produced a significant and sustained
depression of nesting across all seven days of testing, with a potential trend for decreased effectiveness in
females. Taken together, these findings of sustained, repeatable, and pain-related nesting depression by IP acid
enables repeated dosing studies with candidate analgesics like MJN110. Lastly, in evaluation of pooled data
from both sexes, MJN110 produced partial but sustained antinociception throughout the 7 days of treatment.
Segregation of data by sex revealed differential effects, with MJN110 producing a weak but sustained partial
attenuation of IP acid-induced depression of nesting in males and a loss of antinociceptive effect in females.
Overall, the weak antinociceptive effect in males and variable effects following repeated dosing in females
suggest that MJN110 may not be an ideal candidate analgesic for treatment of visceral episodic pain.
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Effects of repeated IP acid-induced depression of nesting
Results from Chapter V showing repeatable IP acid-induced nesting depression and decreased body
weight in male and female mice support previous studies from our laboratory showing that daily administration
of IP acid produces reliable depression of operant responding and depression of body weights in male and
female rats (Altarifi et al., 2015; Lazenka et al., 2018; Legakis et al., 2020). Additionally, these results extend
the utility of IP acid-induced depression of nesting from acute studies suitable for acute evaluation of test-drug
effects to this model of repeated episodic visceral pain suitable for evaluating effects of repeated test-drug
administration. Chronic pain is a broad umbrella term for multiple pain etiologies and outcome measures. In
preclinical research, chronic pain models often involve inflammatory or neuropathic manipulations that produce
long-term hypersensitive withdrawal responses from mechanical or thermal stimuli. While advancements have
been made in preclinical chronic pain models, such as inclusion of noxious stimuli that model specific disease
states (i.e. bone cancer) and measurement of more clinically relevant endpoints (e.g. effects on spontaneous
behavior) , the temporal pattern of the underlying pain state is often presumed to be relatively constant for
periods of weeks to months (Mercadante et al., 2002; Burma et al., 2017). By contrast, IP acid treatment
produces a relatively transient pain state lasting ~1-2 hr (Koster et al., 1959; Bagdas et al., 2016), with repeated
daily IP acid administration producing repeatable expression of this transient pain state as a model of visceral
episodic chronic pain. Thus, our study provides a model for temporal evaluation of candidate analgesic
effectiveness on non-movement related episodic visceral pain (Mercadante et al., 2002), with concentrationdependent control of the IP acid noxious stimulus intensity (Diester et al., 2021a).

Partial and sustained antinociceptive effectiveness of MJN110
This study used the assay of repeated IP acid-induced nesting depression to examine antinociceptive
effects of repeated treatment with 1.0 mg/kg MJN110, with the dose selected based on our previous acutedosing study in Chapter IV. Our finding in the present study that repeated 1.0 mg/kg MJN110 produced
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sustained partial attenuation of IP acid-induced depression of nesting in analysis of pooled data from both sexes
and in males agrees with previous studies evaluating repeated administration of MJN110 in chronic models of
cancer-induced bone pain (CIBP) (Thompson et al., 2020), and osteoarthritic pain (Burston et al., 2016).
Interestingly, while both studies report sustained antinociceptive effects following repeated MJN110
administration, they suggest opposing conclusions regarding dosing parameters. Thompson et al. show repeated
administration of MJN110 (1-10mg/kg) promoted sensitization to antinociceptive attenuation of CIBPstimulated flinching behavior, while Burston et al. showed dose-dependent (1-5 mg/kg) development of
tolerance to MJN110’s antinociceptive effects on monosodium iodoacetate-stimulated behaviors. As our
repeated dosing study assessed a single dose (1.0 mg/kg) within the lower dosing ranges of these studies,
additional testing would be needed to determine whether repeated higher doses (3.2 & 10 mg/kg) produce
sensitization or tolerance to MJN110’s partial attenuation of IP acid-induced depression of nesting in male
mice.
This work also agrees with studies investigating other MAGL-selective inhibitors, such as JZL184,
which show sustained antinociception during repeated treatment of low JZL184 doses, with development of
antinociceptive tolerance following persistent pharmacological inhibition of MAGL to be dose-dependent and
likely contingent upon inflammatory mediators recruited within different pain models (Schlosburg et al., 2010;
Ghosh et al., 2013; Kinsey et al., 2013). More specifically, repeated 4 mg/kg JZL184 did not produce tolerance
in a variety of behavioral and neurochemical measures, while repeated 40 mg/kg JZL184 administration
produced functional antagonism of antinociceptive effects, cross-tolerance to CB1R agonists and FAAHselective inhibitors, reduced CB1R function and expression, and increased expression of off-target eCB lipids
(Schlosburg et al., 2010; Ghosh et al., 2013; Kinsey et al., 2013). Based on this work, the 32 mg/kg JZL184
dose necessary to attenuate acute IP acid-induced depression of nesting in Chapter IV (Diester et al., 2021b)
would likely lead to functional tolerance of the eCB system following repeated administration.
Finally, it should be noted that partial effectiveness of MJN110 in the present study contrasts with the
more robust effectiveness of repeated treatment with other clinically effective analgesics, particularly for
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treatment of pain-depressed behaviors. Examples for treatments that can fully block IP acid-induced behavioral
depression in rodents include the MOR agonist morphine, the NSAID/COX-inhibitors ketorolac and ketoprofen,
and the dopamine transport inhibitor buproprion (Stevenson et al., 2006; Altarifi et al., 2015; Legakis et al.,
2020; Diester et al., 2021b).

Effects of repeated MJN110 and IP acid in females
Chapter IV shows that acute MJN110 tended to yield greater effectiveness in females compared to males
in the assay of IP acid-induced nesting depression (Diester et al., 2021b). Chapter V extends this to evaluate the
effectiveness of daily 1.0 mg/kg MJN110 treatment in repeated IP acid-induced depression of nesting in female
mice across 7 days. Consistent with our previous acute studies, MJN110 significantly alleviated IP acid-induced
depression of nesting on Day 1 of the study (Diester et al., 2021b). This antinociceptive effect was variable
across the 7-day study, with only three of the seven days significantly different from Veh/Acid treated females.
The basis for the loss of antinociception in this study requires further investigation, but the present results
suggests that two processes may have contributed.
First, IP acid administered alone produced a significant and sustained depression of nesting throughout
the 7-day treatment period; however, there was a trend for declining IP acid effects over time in females. While
the mechanism for this remains to be determined, studies tracking the estrous cycle following neuropathic or
repeated administration of chemical noxious stimuli have shown cycle disruption in adult female rats and mice
(Hernandez-Leon et al., 2018; Guindon et al., 2019). Other studies have shown models of visceral pain-related
behaviors can fluctuate with the female mouse and rat estrous cycle, demonstrating a generally protective and
antinociceptive role for estrogen (Ji et al., 2008; Escudero-Lara et al., 2021; Tramullas et al., 2021).
Additionally, this study delivers the chemical noxious stimulus to the peritoneal cavity, which is open through
the genital canal in females but not in males, providing a potential mechanism for IP acid-induced alterations on
estrous cycle and its associated hormones (Solass et al., 2016). Accordingly, additional work evaluating the
estrous cycle across repeated IP acid treatment should be conducted.
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Second, tolerance may have developed to MJN110-induced antinociception. While it is difficult to
dissociate possible loss of antinociception of MJN110 from decreased nociception masking an antinociceptive
effect, decreased intensity of the noxious stimulus would suggest complementary trends for increased
antinociceptive effectiveness, which was not observed in this study. This behavioral effect was paralleled by
evidence for CB1R desensitization in the lumbar spinal cord of female but not male mice from the MJN110+IP
acid treatment group (data not shown). Overall, the loss of significant antinociception by repeated MJN110 in
females could reflect a decline in IP acid nociception, tolerance to MJN110 antinociception, or both, with future
studies needed to further elucidate these antinociceptive versus nociceptive effects.
Loss of MJN110 antinociception following repeated dosing does not agree with previous studies that
show 1 & 3 mg/kg MJN110 produces sustained antinociceptive effectiveness following 7-day repeated
administration (Burston et al., 2016; Thompson et al., 2020). There are multiple factors for consideration of this
difference in MJN110 antinociception. First, the previous studies were only conducted in males despite growing
evidence for sex differences in pain processing (Greenspan et al., 2007; Sorge et al., 2011; Fullerton et al.,
2018), cannabinoid pharmacology (Craft et al., 2013; Cooper and Craft, 2018; Farquhar et al., 2019), and
endocannabinoid-mediated antinociception (Blanton et al., 2021). Our results showing a tendency for greater
effectiveness of acute MJN110 antinociception in females and potential decreased effectiveness over time in
females (but not males) agree with other reports within the literature that show general trends for increased
sensitivity to antinociceptive effects of cannabinoids in females compared to males (Craft et al., 2013; Blanton
et al., 2021) and increased development of tolerance in females following repeated dosing of CB 1R agonists
(Wakley et al., 2015; Farquhar et al., 2019).
Second, previous studies showing continued antinociception of MJN110 used more sustained models of
chronic pain and demonstrated antinociceptive effectiveness of MJN110 to be CB2R-dependent (Burston et al.,
2016; Thompson et al., 2020). We previously demonstrated a lack of CB2R necessity for MJN110
antinociception in IP acid-induced depression of nesting (Diester et al., 2021b). The differential dependency on
CB1Rs vs CB2Rs between various noxious stimuli is not yet fully understood; however, because CB2Rs are
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predominantly expressed on immune cells, it is possible that repeated MJN110 produces more sustained
antinociception in models that recruit inflammatory mediators and produce more sustained pain-related
behaviors. As MAGL inhibitors such as MJN110 have dual inhibitory capacity for neuronal signaling and
proinflammatory mediators through decreased production of arachidonic acid (AA), antinociception dependent
upon both CBRs combine CB1R-inhibited neuronal signaling, CB2R-activation on infiltrating immune cells, and
decreased proinflammatory prostaglandins (e.g. (Thompson et al., 2020)). While it has not been directly studied,
these additional mechanisms for antinociceptive effects aside from CB1R-activation likely play an important
role for antinociceptive effectiveness, receptor downregulation, and desensitization following repeated dosing.
Taken together, future studies would need to quantify effects of MJN110 treatment and IP acid treatment
on AA and prostaglandins following acute and repeated dosing alongside identifying primary sites of
nociceptive and antinociceptive actions (see Chapter VI), with the goal to better understand the role
prostaglandins and other inflammatory mediators might play in MJN110’s weak CB1R-mediated attenuation of
IP acid-induced depression of nesting in males and variable effects in females. However, given the weak
antinociceptive effect of MJN110 in males and variable effects in females on IP acid-induced depression of
nesting paired with the non-specific weight increase in females, our work provides little support for further
consideration of MJN110 for treatment of episodic visceral pain.

IP acid-independent effects of MJN110 on bodyweights.
Our observation of IP acid-induced depression of body weights in male and female mice agrees with
previous findings from our laboratory showing that 7-day repeated IP acid administration depressed body
weight in male and female rats (Legakis et al., 2020). Moreover, the IP acid-induced depression of body weight
in rats was blocked by the clinically effective analgesic ketoprofen, suggesting that is pain-related (Legakis et
al., 2020). Decreases in body weight may serve as a surrogate measure for pain-related decreases in feeding
behavior, and consistent with this conclusion, IP acid treatment has been shown to reduce more direct measures
of feeding behavior in both mice and rats (Stevenson et al., 2006; Kwilasz and Negus, 2012). As a result, body
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weight may serve as an additional endpoint for assessment of MJN110 effectiveness to alleviate pain-related
behavioral depression.
Repeated MJN110 treatment did alleviate IP acid-induced weight loss in analysis of pooled data from
both sexes and in females; however, this effect manifested as a significant main effect of MJN110 treatment in
the two-way ANOVAs and not as a significant interaction between MJN110 and IP acid treatment, indicating
that MJN110 increased body weight in females regardless of the presence or absence of the noxious stimulus.
Accordingly, MJN110 attenuation of IP acid-induced weight loss cannot be attributed to antinociception in the
pooled data or in females.
Our finding of MJN110-induced and IP acid-independent increases in body weight in females agrees
with studies showing CB1R agonists to produce robust appetite stimulation and antiemetic effects (Sticht et al.,
2015; Brunton et al., 2018). Moreover, our results showing no effect of MJN110 on IP acid-independent body
weight in males agrees with previous work in male rats (Sticht et al. 2019). In Sticht et al.’s study, acute
treatment with a systemic dose of 10 mg/kg MJN110 did not alter body weight in unstressed rats, but it did
significantly decrease feeding in both stressed and unstressed male rats. MJN110-induced depression of feeding
was indicated to be peripherally mediated as centrally administered MJN110 (5 ug i.c.v) did not alter feeding or
body weight (Sticht et al., 2019). Interestingly, pharmacological inhibition of MAGL seems to produce different
effects than genetic deletion from birth, as knockout of MAGL in mice produced sustained body weight
decreases from birth (Chanda et al., 2010). Accordingly, future work will be needed to elucidate the effects of
MJN110 on weight and feeding behavior in male and female mice. For the purposes of the data in Chapter V,
MJN110 alleviation of IP acid-induced decreases in body weight cannot be interpreted as evidence for
antinociception.
Our results in female mice and previous work in male rats support further evaluation of MJN110 for
treatment of emesis. It may be beneficial if future studies aim to optimize MJN110 effects through identification
of pain states clinically shown with nausea or pain-related weight loss as a co-morbidity, such as chemotherapy
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patients with peripheral neuropathy, as MJN110 may be able to alleviate pain-related weight loss even if it
produces only modest pain relief (Rock and Parker, 2016).
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Appendix: Development of Functional Immunohistochemical Staining for Chemical Phenotyping of
Activated Neurons
Introduction
Chapters III-V show that IP acid is an effective acute noxious stimulus that can be employed for assessment of
episodic pain-depressed nesting across 7 days. Based on work from our lab and others (Leitl et al., 2014; Taylor
et al., 2019; Jhou, 2021; Markovic et al., 2021), we hypothesize that pain-depressed behaviors are mediated in
part by depression of dopamine signaling in the mesolimbic system. More specifically, mesolimbic dopamine
signaling is depressed by IP acid in part via negative regulation of VTA dopamine neurons by local GABAergic
neurons in the RMTg. To evaluate mechanisms that might underlie the differential antinociceptive effectiveness
of ketoprofen and MJN110 on IP acid-depressed nesting, the neuroanatomical signaling of the noxious stimulus
must first be characterized. Accordingly, this study aimed to validate a method for assessment of
neuroanatomical patterns of IP acid-induced cFos expression in mouse spinal cord, NAc, VTA, and RMTg
alongside chemical phenotyping of activated neurons.

Materials and Methods
Subjects
Adult 6-8 week old male and female ICR mice (Envigo Laboratories, Indianapolis, IN) were acclimated for at
least one week following arrival before beginning neuroanatomical studies. In cages (31.75 x 23.50cm2 floor x
15.25cm high) mounted in a RAIR HD Ventilated Rack (Lab Products, Seaford, DE) with corncob bedding
(Harlan Laboratories) and a “nestlet” composed of pressed cotton (Ancare, Bellmore, NY), mice had ad libitum
access to food (Teklad LM-485 Mouse/Rat Diet, Harlan Laboratories) and water. Animals were maintained on a
12-hour light/dark cycle (lights on from 7:00AM to 7:00PM) in a temperature controlled AAALAC approved
facility, with testing occurring during the light phase. All mice used for immunohistochemical studies were
individually housed upon arrival, with females weighing 20-30g and males weighing 25-35g throughout the
handling week. Animal use protocols were approved by the Virginia Commonwealth University Institutional
141

Animal Care and Use Committee and complied with National Research Council Guide for the Care and Use of
Laboratory Animals.

Animal Handling and Tissue Collection
Following one week of acclimation, all animals were handled for four days in the experimental room prior to
tissue collection, with at least 2 hours acclimation in the experimental room before handling. On day 1, mice
were handled by the experimenter until one of the two endpoints: (1) the mouse settled and started grooming, or
(2) 10 minutes passed. For all studies, only two mice reached the 10-minute time-out before grooming (total
44). For days 2-4, animals received daily intraperitoneal (IP) sterile water (H2O) injections, followed by
handling until mice groomed. On day 5, mice were brought to the experimental room and acclimated for 2
hours. One hour prior to tissue collection, animals were given IP treatments of either 0.32% lactic acid or H2O
and returned to their respective home cages, with a 30 minute between-subject window to account for perfusion
and tissue collection time. Subjects were deeply anesthetized with 0.07mL of phenytoin-pentobarbital (390
mg/mL pentobarbital sodium, 50mg/mL phenytoin sodium; Euthasol, Virbac Animal Health, Patterson,
Greeley, CO), followed by transcardial perfusion of ~5 mL 1x PBS and ~7 mL of 4% paraformaldehyde (PFA).
Brains and spinal cords were immediately collected and post-fixed in 4% PFA for 24 hours. Laminectomies
were performed to collect spinal cord tissue, with thoracic 10-13 (T10-13) and lumbar 1-5 (L1-5) collected
based on peritoneal innervation of the spinal cord(Gebhart, 2000) as separate sections and post-fixed in 4% PFA
for 24 hours. The iliac crest was used as the anchoring landmark for identification of spinal cord segments
starting at L5, and the first rib was used to check placement of T13. Following 24 hours post-fixation in 4%
PFA, brains and spinal cords were washed in cold PBS and placed in 30% sucrose for cryoprotection. Brains
were mounted directly to the chuck with Tissue Plus O.C.T compound (Fisher Health Care, 4585) for coronal
sectioning, and spinal cord sections embedded in O.C.T. in cryomolds (Peel-A-WayTM, Sigma-Aldrich, St.
Louis, MO). Tissue was then cryosectioned (Leica CM 1950) at 40m and placed into cold PBS with 0.02%
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sodium azide (ThermoFisher, AAJ2161022) at 4C for storage, with serial brain sections collected from the
nucleus accumbens to start of the cerebellum and every 4th spinal cord section collected.

Overview of Experimental Design
The goal of this study was to develop a comprehensive method for animal handling, tissue collection,
cryosectioning, immunohistochemical staining, and imaging for assessment of IP acid-related neuronal
activation, followed by identification and correction of issues preventing reliable assessment of cellular
biomarkers. Accordingly, the data from this study is presented in two parts. For the first study (Study 1),
methods are detailed for immunohistochemical staining and image analysis, followed by results and a brief
discussion evaluating the IHC protocol, with particular emphasis on necessary alterations that are detailed in
Table 1. For the second study (Study 2), full amended IHC staining and image analysis methods are described,
followed by results and a brief discussion on the effectiveness of the amended IHC protocol for reliable
assessment of cellular biomarkers in mouse brain and spinal cord.

Study I
Immunohistochemistry I
Free-floating immunohistochemical staining was performed on spinal cord sections and sections from brain
regions of interest (NAc, VTA and RMTg) identified through referencing the Mouse Brain Atlas (Paxinos,
2007). NAc sections were collected from +1.18mm AP to +0.74mm AP, VTA from -2.70 AP to -3.52, and
RMTg from -3.55 AP to -4.75 AP. Tissue processed for GAD67 staining first underwent an antigen retrieval,
with sections heated to 80C in 10mM Citrate Buffer (pH 6) for 30 min. After cooling to room temperature for
15 min, sections were washed 3 times in PBS, then placed in a blocking buffer of 3% normal goat serum (NGS)
(ThermoFisher, Waltham, MA, 10000C) and 0.25% Triton X-100 (Invitrogen, ThermoFisher, HFH10) in PBS
for 1 hour at room temperature. Sections were then incubated in primary antibodies in blocking buffer for 2
days on a rocker at 4C. Following 3 washes in cold 0.25% Triton solution, sections were light protected with
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foil and incubated in secondary antibodies in blocking solution at room temperature for 3 hours on a rocker,
followed by a final PBS wash. Sections were mounted on glass slides and cover slipped with VECTASHIELD
HardSet Antifade Mounting Medium with DAPI (Vector Laboratories, H-1500). The following antibodies were
used for each target: cFos: primary rabbit anti-cFos polyclonal antibody (1:1000, Synaptic Systems, 266 003)
and secondary goat anti-rabbit IgG Alexa Fluor 488 (1:500, Invitrogen, ThermoFisher, A-11008, green);
GAD67: primary mouse anti-GAD67 monoclonal antibody (1:1000, Abcam, ab26116) and secondary goat antimouse IgG Alexa Fluor 594 (1:500, Invitrogen, ThermoFisher, A-11005, red); TH: primary chicken anti-TH
polyclonal antibody (1:1000, Abcam, ab76442) and secondary goat anti-chicken IgY Alexa Fluor 594 (1:500,
Invitrogen, ThermoFisher, A-11042, red). For VTA and RMTg sections, every other section was split to form
two groups co-labeled with either TH + cFos or GAD67 + cFos, and NAc and spinal cord sections were colabeled with GAD67 + cFos.

Imaging and Analysis I
Images were obtained using an Olympus BX53 microscope with an X-Cite Series 120Q mercury short arc lamp
(Excelitas Technologies, Mississauga, Canada) and a Keyence BZ-X800 automated microscope (Keyence,
Osaka, Japan) with a halide lamp. Both instruments are equipped with GFP, Texas Red, and DAPI filters.
Images for validation of stains in brain sections were acquired first on the Keyence at 4x and 10x magnification
(Nikon objectives, Tokyo, Japan), with images stitched for whole-section observations, followed by 60x oil
immersion (Olympus objectives, Tokyo, Japan) on the Olympus microscope. Spinal cord sections were imaged
on the Keyence at 10x and 40x magnification. For all sections, the optimal plane for cFos observation was
selected for image acquisition. Only qualitative analysis was performed to evaluate correct co-labeling and
regional specificity of target stains.
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Results I
General Protocol
In Study I, the animal handling, perfusions, and tissue collection provided high-quality fixed brain and spinal
cord tissue for further sectioning and immunohistochemical processing. Figure A.I displays successful staining
and image acquisition for VTA and spinal cord sections. More specifically, Figure A.IA shows representative
images for the TH (red) and cFos (green) co-labeled VTA sections. In particular, inclusion of a laminectomy for
spinal cord dissection yielded excellent anatomical preservation (Figure A.IB), and utilization of the iliac crest
of the pelvis provided a reliable landmark for rapid lumbar vertebral segment identification. The free-floating
method provided robust staining with decreased IHC solution volumes per tissue section (1 mL/well, ~16
sections/well).

Characterization and co-localization of TH, cFos, and GAD67 in VTA and Spinal Cord
Figure A.IA shows the 10x stitched image demonstrates a robust and anatomically-selective TH signal for
identification of VTA and substantia nigra (SN) regions. The 60x oil immersion images demonstrate clear
identification of cFos + TH positive cells. Two different types of co-labeled cells were identified as cFos + TH
positive. Due to the nuclear localization of the cFos immunostain and cytosolic localization of the TH
immunostain, most co-labeled neurons were identified as TH+ cells with a distinct cFos+ nucleus (yellow
arrows). The clear TH signal also enabled identification of a second set of co-labeled cells that showed
overlapping TH and cFos fluorescence (orange arrow), likely due to the focal plane capturing the top or bottom
of the cell. Due to the thickness of sections, future quantification will focus on the first type for reliable
counting of cFos+ and TH+ neurons (yellow arrows). Importantly, white arrows denote distinction of cFos+
only cells. Figure A.IB shows representative images for lumbar spinal cord sections co-labeled with GAD67
(red) and cFos (green) at 10x and 40x. The 10x image demonstrates the higher expression of GAD67 staining in
the dorsal horn of the spinal cord, and the 40x images within the dorsal horn demonstrate a clear cFos signal
and a sharp boundary for the GAD67 stain between the white matter and laminae I.
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Protocol Issues
Table A.I provides an overview of issues encountered throughout the IHC protocol, with examples illustrated in
Figure A.II. The primary issue encountered during initial protocol development was bacterial contamination of
tissue sections during storage in PBS at 4C following cryosectioning, resulting in little tissue for further
immunohistochemical processing. The secondary issue was evaporation of mounting media, resulting in poor or
unattainable image acquisition (Figure A.IIA). The third issue was uneven illumination across sections (Figure
A.IIA), making stitched image acquisition or imaging of low signal-to-noise markers like GAD67 unreliable,
along with cFos quantification across images. The fourth issue was poor reliability of GAD67 staining for
identification of the RMTg, as shown in Figure A.IIB. Representative dashed white circles are placed where
previous studies have described the RMTg to be (example image from (Taylor et al., 2019) in Figure A.IIB).
The fifth issue during Study I was a low signal-to-noise ratio for cFos staining, creating difficult quantification
across sections dependent upon regional autofluorescence. The sixth and final issue was fragility of spinal cord
sections, which is especially important considering the peripheral location of the dorsal horn region of interest.

Discussion I
The protocol developed in Study I established a solid basis for immunohistochemical neuronal identification of
cFos and TH in brain and spinal cord; however, a variety of issues needed to be addressed before reliable image
analysis could be conducted. The necessary protocol amendments listed below in accordance to the issues
described above are listed in Table A.VI.

For the issue of bacterial contamination, 0.02% sodium azide was added to all PBS solutions used during IHC
processing, with exception of the final PBS wash before cover slipping. Evaporated media was initially
addressed by pairing the VECTASHIELD Hardset Antifade mounting media with a clear nail polish seal,
followed by transition to Fluoromount-GTM mounting medium with DAPI. The uneven illumination had a two146

fold cause. The first was due to tissue drying too long between mounting on slides and cover-slipping, which
was identified due to bright peripheral DAPI and dim central staining (Figure A.IIA). This was addressed by
ensuring slides did not dry longer than 10 min before cover slipping. The second cause was a light path issue
within the Keyence microscope, presenting as decreased illumination on the edges of images. Aside from
instrument maintenance, this was addressed by only capturing qualitative 10x images with high stitching
overlap on the Keyence for whole brain section observation, and quantitative images for spinal cord sections
and brain regions of interest were only acquired on the Olympus microscope (10x and 20x).

The poor reliability of GAD67 staining for RMTg identification presents a large problem as identification of
cFos-activated GABAergic neurons within the RMTg is key to address our hypothesis. Recent studies have
demonstrated FoxP1 as a remarkably reliable marker for RMTg GABAergic cells projecting to VTA
dopaminergic neurons (Smith et al., 2019; Jhou, 2021). Accordingly, the second portion of this study aimed to
characterize the expression of FoxP1 in VTA and RMTg sections for improved identification of GABAergic
RMTg neurons.

For the fifth issue of low signal-to-noise ratio of cFos staining, inclusion of sodium azide enabled cFos-stained
sections to be incubated overnight at room temperature following Synaptic Systems data sheet
recommendations, followed by a 4C for the remaining incubation. Finally, the sixth issue of peripheral damage
of spinal cord sections was addressed by keeping sections within the same 5mL glass vial, with additional wash
steps added to ensure minimal carryover.

Table A.I: Protocol Amendments
Protocol Section
Tissue storage

Issue
Bacterial contamination

Amendment
Sodium Azide in all PBS-based
solutions
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Section mounting

Evaporated mounting media

Fluoromount-GTM with DAPI

Imaging

Uneven illumination

Dry sections on slides <10 min

Imaging

Uneven illumination: light path

Olympus BX53: images for
quantification

Target identification

Poor RMTg identification via
GAD67 staining

FoxP1 antibody

IHC staining

Peripheral spinal cord damage

Decreased tissue transfers
(single glass vial)

Study II
Immunohistochemistry II
Free-floating immunohistochemical staining was performed on spinal cord sections and sections from brain
regions of interest (VTA and RMTg) identified through referencing the Mouse Brain Atlas (Paxinos, 2007).
VTA was sequentially collected from -2.70 AP to -3.52, and RMTg from -3.55 AP to -4.75 AP. All spinal cord
tissue was processed in the same 5 mL glass vial with additional wash for every PBS-based wash step to
decrease tissue handling. Tissue processed for GAD67 or FOXP1 staining first underwent an antigen retrieval,
with sections heated to 80C in 10mM Citrate Buffer (pH 6) for 30 min. After cooling to room temperature for
15 min, sections were washed 3 times in PBS, then placed in a blocking buffer of 3% normal goat serum (NGS)
(ThermoFisher, Waltham, MA, 10000C) and 0.25% Triton X-100 (Invitrogen, ThermoFisher, HFH10) in PBS
for 1 hour at room temperature. Sections were then incubated in primary antibodies in blocking buffer for 2
days on a rocker, with cFos-stained sections at room temperature overnight followed by 4C and all other
sections at 4C for the entire incubation.

Following 3 washes in cold 0.25% Triton solution, sections were light protected with foil and incubated in
secondary antibodies in blocking solution at room temperature for 3 hours on a rocker, followed by a final PBS
wash. Sections were mounted on glass slides (<10 min drying time) and cover slipped with Fluoromount-GTM
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mounting media with DAPI (ThermoFisher, 00-4959-52). The following antibodies were used for each target:
cFos: primary rabbit anti-cFos polyclonal antibody (1:1000, Synaptic Systems, 266 003) and either secondary
goat anti-rabbit IgG Alexa Fluor 488 or 594 (1:500, Invitrogen, ThermoFisher, A-11008, green or red,
respectively); GAD67: primary mouse anti-GAD67 monoclonal antibody (1:1000, Abcam, ab26116) and
secondary goat anti-mouse IgG Alexa Fluor 594 (1:500, Invitrogen, ThermoFisher, A-11005, red); TH: primary
chicken anti-TH polyclonal antibody (1:1000, Abcam, ab76442) and secondary goat anti-chicken IgY Alexa
Fluor 594 (1:500, Invitrogen, ThermoFisher, A-11042, red); FoxP1: primary mouse anti-FoxP1 monoclonal
antibody (1:1000, Abcam, ab32010) and secondary goat anti-mouse IgG2a Alexa Fluor 488 (1:500,
ThermoFisher, A-21131, green). For VTA and RMTg sections, every other section was split to form two groups
co-labeled with either TH + FoxP1 or cFos + FoxP1, and spinal cord sections were co-labeled with GAD67 +
cFos.

Imaging and Analysis II
Spinal cord and RMTg FoxP1 images were acquired using an Olympus BX53 microscope with X-Cite Series
120Q mercury short arc lamp using 10x, 20x, or 40x objectives (Olympus). Whole-section VTA and RMTg
stitched images were acquired with the Keyence BZ-X800 automated microscope using 10x objectives (Nikon).
For all sections, the optimal plane for either cFos observation or FoxP1 observation was selected for image
capture. Qualitative analysis was performed to evaluate correct co-labeling and regional specificity for VTA
and RMTg sections. ImageJ 1.53c software was used to manually count the number of cFos positive cells in
spinal cord sections using the cell counter plugin software, with all count-marked images saved alongside
original images.
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Results II
General Protocol Amendments
The addition of 0.02% sodium azide eliminated all issues of bacterial contamination within samples. Transition
to Fluoromount-GTM with DAPI provided durable tissue visualization for at least 3 weeks without need of a
clear nail polish seal. Decreasing the drying time of sections during tissue mounting resulted in even DAPI stain
across brain and spinal cord sections, and 10x stitching with ImageJ for generation of composite images
decreased shadowing issues in whole-section images (Figure A.IIIA). Additionally, processing spinal cord
sections in a single 5mL glass vial reduced both peripheral damage and tissue processing time. Finally, Figure
A.IIIA shows dorsal crystal-like green fluorescence. This was seen randomly distributed across VTA, RMTg,
and spinal cord sections and was identified as remaining PBS producing salts while drying before cover
slipping.

Characterization of FoxP1 as a marker for RMTg
Figure A.III shows representative images for the FoxP1 signal in mouse VTA at approximately -3.74 AP.
Figure A.IIIA demonstrates the well-defined TH signal (red) as seen in Study I, enabling visual identification of
various regions, including the SN, medial lemniscus (ml), paranigral nucleus (PN), parabrachial pigmented
nucleus (PBP), parainterfascicular nucleus (PIF), interfascicular nucleus (IF), the rostral linear nucleus (RLi),
and the interpeduncular nucleus (IPC). Surprisingly, the FoxP1 signal (green) lies dorsal to all TH + regions and
appears to be within the red nucleus (RMC) and oculomotor nucleus (OM). Figure A.IIIB shows this FoxP1
signal at 20x, highlighting the clear boundary between the TH and FoxP1 signals.

IP acid-induced cFos expression in mouse thoracic and lumbar spinal cord
Figure A.IV shows representative images for dorsal horn cFos quantification in mouse thoracic and lumbar
spinal cord sections, with the merged image including the exported ImageJ cell counter marks. Interestingly,
spinal cord sections from Study II possess high levels of autofluorescence in the white matter that was not
150

present in sections from Study I (see Figure A.IB). Figure A.IVB shows quantification results for cFos+ cells in
the lumbar (L1-5) and thoracic (T10-13) spinal cords of two IP acid and two H2O treated male mice. cFos+ cell
quantification was divided into two categories: dorsal horn (Figure A.IV, counted, pink markers) and rest of
grey matter (Figure A.IVA, counted, orange markers). There was a significant increase in cFos+ cells in T10T13 sections in the dorsal horn and rest of section, but no difference in cFos+ cells from L1-5 spinal cord
sections (Figure A.IVB). While data cannot be retroactively separated into smaller combinations of lumbar and
thoracic sections for analysis, these preliminary data indicate that future studies evaluating IP acid-induced
neuronal activation in mouse spinal cord can collect a smaller tissue section closer to where the lumbar and
thoracic spinal cord sections meet (e.g. L3-T13).

Discussion II
This appendix was broken into Study I and Study II, with the overarching goal to develop a comprehensive
method for assessment of IP acid-related neuronal activation. There were five main findings. First, the animal
handling, perfusions, tissue collection (particularly development of spinal cord laminectomy method),
cryosectioning, and free-floating IHC protocol yielded high-quality brain and spinal cord sections for imaging
and quantification. Second, TH provided a robust fluorescent signal with good anatomical selectivity and clear
axonal versus cell body profiles. Third, cFos produced a reliable nuclear signal that was enhanced following
overnight room temperature incubation, with TH and cFos co-labeled neurons easily identifiable. Fourth,
GAD67 provides valuable identification of dorsal horn laminae; however, identification of co-labeled cFos and
GAD67 + cells remain difficult due to GAD67’s expression in the cell body and synaptic terminals. This issue
is further highlighted by the inability to readily identify the RMTg due to diffuse GAD67 staining (Figure
VI.IIB). Finally, the FoxP1 antibody used in Study II for RMTg identification did not produce staining patterns
as described in the literature (Smith et al., 2019), with a very low signal to noise ratio and main detected signal
in the RMC and oculomotor nucleus. Overall, Studies I and II establish a strong foundation for cellular
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biomarkers in mouse brain and spinal cord, especially TH and cFos. Further validation needs to be conducted to
develop robust quantification methods and neuroanatomical characterization of the RMTg.

Implications for Appendix Studies
Neurochemical staining to identify GABAergic neurons
The above GAD67 IHC data shows poor resolution for cellular identification of GABAergic cell bodies due to
diffuse axonal and cytoplasmic staining. While some studies have shown good cell body resolution with the
anti-GAD67 ab26116 (Kasper et al., 2016; Li et al., 2017; Han et al., 2019; Ishiyama et al., 2019), our results
agree with a number of reports in the literature showing diffuse ab26116 staining, which they addressed through
pairing with high-magnification and Z-stack image acquisition (Kaufling et al., 2010; Wang et al., 2014; Ativie
et al., 2018; Bednarova et al., 2018; Fan et al., 2018; Ge et al., 2019) or pretreating animals with colchicine to
increase somatic antigen binding (Wang et al., 2014; Buhler et al., 2018). While reports suggest improved
clarification of GABAergic cells through fluorescent in situ hybridization (FISH) methods (Esclapez et al.,
1994; Takakura et al., 2007; Zhao et al., 2013; Chowdhury et al., 2019), communication with other research
groups and trends in the literature propose utility of genetic mouse lines paired with neurochemical staining as a
more robust method for GABAergic cell body identification (Wang et al., 2014; Gotts et al., 2016; Chowdhury
et al., 2019; Das Gupta et al., 2021). For example, Chowdhury et al. injected a Cre-inducible AAV virus
carrying GFP into the VTA of GAD67-Cre mice and used FISH to show clear somatic GFP staining that colabeled with GAD67 but not TH (Chowdhury et al., 2019). These GAD67-Cre mice can then be used for
development of chemogenetic studies to test necessity and sufficiency of neural circuits (also demonstrated in
Chowdhury et al. 2019). However, our specific research question is targeted to the VTA and RMTg, which will
likely be benefited most through staining with FoxP1.

While the GAD67 stain in the spinal cord dorsal horn produced slightly improved identification of individual
cell bodies, similar issues for individual cell identification exist due to the dense GABAergic interneuron
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population present throughout the laminae of the spinal cord dorsal horn (Todd and Koerber, 2013). If
quantification of GABAergic cells in the dorsal horn of the spinal cord is desired, data from this appendix
would suggest higher resolution acquisition methods (e.g. Z-stack, higher magnification), or transition to
another method for GABAergic cell identification, as described above.

FoxP1 staining for identification of RMTg GABAergic neurons
An emerging body of research demonstrates the transcription factor FoxP1 as a powerful tool for reliably
identifying GABAergic neurons in the RMTg (Lahti et al., 2016; Smith et al., 2019; Jhou, 2021). More
specifically, mRNA and protein characterization demonstrating robust labeling of GABAergic neurons with
direct projects to VTA DA neurons along with surprisingly distinct anatomical levels of expression showing
RMTg boundaries better than previous GABAergic markers that show high expression levels in adjacent
regions to the RMTg. Despite these promising reports, the mouse anti-FoxP1 antibody ab32010 did not produce
staining patterns as observed by other groups using the same antibody (Anderson et al., 2020) and a rabbit antiFoxP1 antibody (Smith et al., 2019; Jhou, 2021). It should be noted that a majority of the literature utilizes the
same rabbit anti-FoxP1 antibody ab16645 from Abcam, and a mouse anti-FoxP1 antibody was selected for this
study to provide compatible co-labeling with our validated rabbit anti-cFos antibody. Direct comparison of
ab32010 to ab16645 was kindly performed by Dr. Thomas Jhou’s lab, which confirmed the ab32010 antibody
to not produce standard FoxP1 staining, with no observable signal in the RMTg and higher levels of staining in
the RMC and oculomotor nucleus (data not shown). A pilot study with the rabbit anti-FoxP1 antibody ab16645
showed staining patterns in agreement with those reported in the literature (N=2 male ICR adult mice, data not
shown). As such, validation with the Abcam ab16645 antibody co-labeled with a cFos antibody from a nonrabbit host will need to be conducted before hypothesis testing of IP acid-induced effects can be conducted.
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Figures

Figure A.I: Characterization and co-localization of TH, cFos, and GAD67 in mouse VTA and spinal cord.
(A) The left column shows a representative coronal mouse section imaged at 10x (stitched) stained with TH
(red) and counterstained with DAPI (blue), with labels denoting major regions of interest and reference image
from Paxinos 3rd edition. The right column shows representative 60x oil immersion images for cFos + cells,
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TH+ cells, and co-localization, with arrows denoting the following: yellow = cFos+TH non-overlapping colocalization (most common), white = cFos+, orange = cFos+TH overlapping co-localization (least common).
(B) Examples of lumbar spinal cord sections stained with cFos (green), GAD67 (red), and counterstained with
DAPI (blue). Region abbreviations: VTA = ventral tegmentum area; SN = substantia nigra; PAG =
periaqueductal grey, DH = dorsal horn.
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Figure A.II: Image illumination and target quality issues. (A) The left image demonstrates how mounting
media evaporation produced high levels of autofluorescence preventing identification of cFos signal. The right
image shows uneven DAPI illumination across a coronal brain section due to prolonged drying time before
cover slipping. (B) Representative coronal brain sections at approximately -4.04 AP (10x) demonstrating the
diffuse GAD67 stain with poor RMTg regional identification. White dashed circles illustrate the suggested
location of RMTg per the literature, as shown in the reference example from Taylor et al. 2019. For all above
images, cFos = green, GAD67 = red, and DAPI = blue.
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Figure A.III. Characterization of FoxP1 as a marker for RMTg. (A) Representative coronal mouse section
at approximately -3.74 AP (10x stitch) stained with TH (red), FoxP1 (green), and DAPI (blue). Identification of
157

VTA regions, SN, and additional landmarks are denoted in white. (B) Representative 20x images of FoxP1
(green) and TH (red) staining, with the merged image showing clear delineation between the two markers.
Abbreviated regions: IF = interfascicular nucleus; IPC = interpeduncular nucleus; ml = medial lemniscus; OM =
oculomotor nucleus; periaqueductal gray (PAG); PBP = parabrachial pigmented nucleus, PN = paranigral
nucleus, RLi = rostral linear nucleus; the red nucleus (RMC), and SN = substantia nigra.
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Figure A.IV. IP acid-induced cFos expression in mouse thoracic and lumbar spinal cord. (A)
Representative images (10x) from mouse lumbar spinal cord for cFos (green) and GAD67 (red) staining. The
right “counted” image shows the merged channels (DAPI = blue) with ImageJ CellCounter Markers inlaid on
the image. Pink markers denote cFos+ cells in the dorsal horn and orange markers denote cFos+ cells in the
remaining gray matter. (B) Quantified cFos+ cells in lumbar vs thoracic sections in male ICR mice (N =
2/treatment) that received either IP acid or IP veh 1 hr before tissue collection. Abscissae: treatment with IP
H2O or IP acid. Ordinates: number of cFos+ cells. Asterisks (*) indicate significant difference by Welch’s twotailed t-test, p<0.05.
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